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Abstract 
 
Background 
The role of aromatase inhibitors (AIs) in breast cancer has expanded since their introduction in 
the mid-1990s. They are superior to tamoxifen in the treatment of postmenopausal women with 
oestrogen dependant tumours in the metastatic, neoadjuvant, and adjuvant settings and are 
currently been explored as a chemopreventive agents. When compared to tamoxifen they are 
known to reduce bone mineral density (BMD), increase fracture rate, increase joint symptoms, 
and may also increase the risk of cardiovascular disease. The International Breast Cancer 
Intervention Study-II (IBIS-II) is the only breast cancer prevention randomised trial studying 
the role of anastrozole versus placebo in preventing breast cancer in postmenopausal women 
with a high risk of breast cancer. 
Methods 
This thesis focus on four main areas:  (a) Analysis of data from the bone sub-study of the IBIS-
II study, exploring the effects of anastrozole on bone mineral density at 12 and 36-months, and 
the ability of bisphosphonates treatment to reduce bone loss in women with low mineral density 
(BMD) at baseline. (b) Analysis of data from the prevention stratum of the IBIS-II study, 
exploring the effect of anastrozole on cholesterol fractions. (c) Analysis of the data from the 
Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, exploring different risk factors 
for fractures in women with breast cancer who received either anastrozole or tamoxifen for five 
years (d) Analysis of data from the prevention stratum of the IBIS-II study, exploring if baseline 
25(OH) vitamin D levels predicted arthralgia within one year of study. 
Results 
Women with normal BMD at baseline had a significant BMD loss at lumbar spine and total hip 
for both anastrozole and placebo. However, the BMD loss at lumbar spine was significantly 
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greater with anastrozole. Osteopenic women, who received anastrozole plus risedronate, after 
12-months of treatment gained significant bone density at lumbar spine compared to women 
receiving anastrozole without risedronate, but not at total hip. At 36 months, there was no 
significant gain in bone density either at lumbar spine or total hip. In osteoporotic women, 
risedronate abrogated the detrimental effect of anastrozole, after 12 months of treatment, 
significantly at lumbar spine, but not at total hip. After 36 months of treatment, risedronate still 
abrogated the effect of anastrozole at lumbar spine, but not significantly. These 12 and 36-
months data suggest that bone loss associated with anastrozole may be manageable with DXA 
monitoring and bisphosphonate use. 
 
Use of anastrozole did not lead to any significant changes in total cholesterol and high-density 
lipoprotein cholesterol levels when compared with placebo, except that anastrozole marginally 
decreased TC levels. These data support the lack of cardiovascular toxicity with anastrozole 
seen in the adjuvant trials.  
 
Using a model containing the following risk factors; age, weight/height/BMI, geographical 
regions, smoking, use of statins and other medication at baseline, previous chemotherapy, 
previous radiotherapy and trial therapy, only treatment, age and geographical regions were 
found to be significantly associated with fracture risk.  
 
No significant effect of baseline vitamin D levels were seen on the risk of musculoskeletal 
symptoms in healthy postmenopausal women at a high risk of breast cancer. The serum 25 (OH) 
vitamin D levels significantly increased in the anastrozole group from baseline to 12 months, 
when compared with placebo.  
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and VERT-MN) 
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North American Menopausal Society (NAMS) 
National Osteoporosis Foundation (NOF) 
N-telopeptide of collagen crosslinks (NTx) 
National Health and Nutrition Examination Survey (NHANES) 
Oestrogen receptor status (ER) 
 
Ovarian ablation (OA) 
  
Ovarian suppression (OS) 
 
Ovarian function suppression (OFS) 
 
Osteoprotegerin (OPG) 
Osteocalcin (OC) 
Osteonecrosis of the jaw (ONJ) 
Pyridinolines (Pyr) 
Progesterone receptors (PR) 
 
Parathyroid hormone (PTH) 
Quantitative computed Tomography (QCT) 
Raloxifene Use for the Heart (RUTH) 
 
Risedronate Effect on Bone loss in Breast Cancer trial (REBBeCa) 
Relative risk (RR) 
Study of Anastrozole with the Bisphosphonate Risedronate (SABRE) 
Standard deviation (SD) 
Study of Tamoxifen and Raloxifene (STAR) 
 
Selective ER modulators (SERMs) 
 
Suppression of Ovarian Function Trial (BIG SOFT) 
 
Tartrate- resistant acid phosphatase (TRAP) 
The International Breast Cancer Intervention Study-II (IBIS-II) 
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Triglycerides (TG)  
Total Cholesterol (TC) 
Tamoxifene and Exemestane Adjuvant Multicentre (TEAM) 
Total hip (TH) 
 
Femoral neck (FN) 
 
Zoladex in Premenopausal Patients (ZIPP) 
 
Zometa-Femara Adjuvant Synergy Trials (ZO-FAST & Z-FAST) 
World Health Organisation (WHO) 
 
Women’s  Health  Initiative  (WHI) 
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Chapter 1: Introduction 
 
This thesis investigates the effect of anastrozole, a third generation aromatase inhibitor (AI), on 
bone mineral density and lipid fractions when used to prevent breast cancer in high risk 
postmenopausal women. It also examines the concomitant risk factors for fracture in women 
with breast cancer. 
 
This thesis will present results from four studies: 
1. Results from the bone sub-study of the International Breast Cancer Intervention Study-II 
(IBIS-II), exploring the effects of anastrozole on bone mineral density (BMD) and to confirm the 
ability of bisphosphonate treatment to prevent BMD loss in women with low BMD at baseline. 
 
2. Results from the Prevention part of IBIS-II, exploring the effects of anastrozole on lipid 
profiles. 
 
3. Some results from the main Arimidex, Tamoxifen, Alone or in Combination study (ATAC), 
exploring different risk factors for fractures in women with breast cancer receiving anastrozole 
or tamoxifen. 
 
4. Results from the Prevention part of IBIS-II, exploring if baseline 25(OH) vitamin D levels 
predicted arthralgia within one year of study, and mean change in 25 (OH) vitamin D levels after 
one year of treatment. 
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1.1 Breast cancer and Oestrogen  
Breast cancer is the most common cancer and the second leading cause of cancer death in 
women (Parkin, DM 2005; Gralow, JR 2006). According to the World Health Organisation 
(WHO), more than 1.2 million women are diagnosed with breast cancer every year worldwide, 
accounting for a tenth of all new cancers and 23% of all female cancer cases (Parkin, DM 2005). 
The proportion of new breast cancer cases diagnosed each year varies greatly around the world.  
In Europe, breast cancer is the most common cancer among women. In 2006, it accounted for 
429,900 cases (Ferlay, J 2007). In most developed countries, breast cancer accounts for 27% -
30% of all new cancer cases and causes between 15% and 18% of all cancer deaths, (Osuch, JR 
2002; Tyczynski, JE 2004; Jemal, A 2006). In the UK, breast cancer is the most common cancer. 
In the UK, each year more than 44,000 women are diagnosed with breast cancer and more than 
12,300 deaths are reported each year (http://info.cancerresearchuk.org/cancerstats/types/breast/).  
 
Change in breast cancer incidence over the last 50 years and projected incidence 
Between 1940-1993, there was a steady annual rate of increase in breast cancer of about 1% per 
year (Garfinkel, L 1994). Between 1982 and 1987, the increase was about 4% per year 
(Garfinkel, L 1994), but between 1990 and 1994, the incidence of developing breast cancer 
appeared to stabilize at approximately 110 cases per 100,000 women (Ries, LAG 1997). In the 
UK and Europe, over the thirty year period (1979-2008), the age-standardised incidence rate 
(EASR) for women increased by more than half (65%) from 75 per 100,000 in 1979 to 124 per 
100,000 in 2008. Over the same time the annual number of new cases of breast cancer in women 
almost doubled from 23,876 to 46,537 in Britain (Office for National Statistics, 2010). The 
numbers of breast cancer cases in the UK are expected to increase from 119 per 100,000 in 
2000-04 to 124 per 100,000 in 2020-24 (Statistical Information Team UK, 2008).  
Oestrogen plays a significant role in the development and growth of hormone-dependent breast 
cancer (Bernstein, L 1993; Hulka, BS 1996). The link between oestrogen and breast cancer 
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growth and development was recognised more than a century ago (Jensen, EV 2003). The 
concept that oestrogen plays a critical role in the development and progression of breast cancers 
first emerged in 1896, with the observation by Sir George Beatson that elimination of ovarian 
function, by means of oophorectomy, could benefit women with inoperable disease (Beatson, 
GT 1896). Oestrogen stimulates normal breast epithelium and breast cancer cell proliferation 
(Hulka, BS 1996). Several risk factors for breast cancer, including early menarche, late 
menopause, and postmenopausal obesity, reflect an increased cumulative lifetime exposure to 
oestrogen (Dhingra, K 2001).  
 
 
In premenopausal women, ovaries are the primary source of oestrogen. However, in 
postmenopausal women, when ovaries are no longer functional, oestrogens are produced mainly 
in the adipose tissue and adrenals, by the conversion of androgens to oestrogens via 
aromatisation. In postmenopausal women, the female breast has also been recognised as an 
important site of oestrogen production. It is observed that oestrogen concentrations in the healthy 
breasts of postmenopausal women are unexpectedly higher (four- to six- fold) than in serum, and 
similar to those in premenopausal women. Oestrogen action at breast cancer and other target 
sites around the body is mediated through oestrogen receptors. Oestrogen deprivation, either by 
reducing the oestrogen synthesis or by blocking oestrogen receptors, is the basis for the 
endocrine treatment of breast cancer (Angelopoulos, N 2004).  
 
The most important predictor of response to hormonal/endocrine therapy is the oestrogen 
receptor status (ER) of the original tumour. It is estimated that 60-70% of breast cancers are ER 
positive, and the proportion increases with age, ranging from 60% in premenopausal women to 
80% in postmenopausal women (Hulka, BS 1996; Rabaglio, M 2007). The oestrogen stimulation 
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of these receptors is a significant factor in the development and growth of breast cancer. Most 
hormonal/endocrine therapies either block the binding of oestrogen to its receptor, or reduce 
serum and tumour concentrations of oestrogen. In metastatic breast cancer these therapies are 
mainly used for palliation and increased survival, while in early stage breast cancer, they reduce 
recurrence rate and increase the survival rate. In women with early breast cancer, hormonal 
therapy is recommended as an adjuvant treatment in nearly all women with a breast tumour that 
expresses oestrogen receptors (ER) or progesterone receptors (PR). Early detection and wider 
use of chemotherapy and hormone therapy in the past two decades have led to a reduction in 
breast cancer mortality of 25-30% (Peto, R 2000).Adjuvant endocrine therapy is recommended 
for nearly all women with a breast tumour that expresses ERs or progesterone receptors 
(Angelopoulos, N 2004). 
 
1.2 Hormonal therapies  
Endocrine therapies remove the influence of oestrogen from breast cancer cells, preventing the 
cancer cells from growing and spreading, and have been proven to improve survival in breast 
cancer patients. They act by interrupting the oestrogen receptor (ER) alpha signalling pathway 
by either interfering with ER-ligand interaction through the use of selective ER modulators 
(SERMs) like tamoxifen, or by decreasing production of the ligand, oestrogen, via ovarian 
ablation, (OA) ovarian suppression (OS), or aromatase inhibitors (AI). The hormonal therapy 
used for women with breast cancer varies depending on their menopausal status. 
 
1.2.1 Hormonal therapy in premenopausal women 
In premenopausal women, 60% of breast tumours are hormone sensitive (Pujol, P 1998)  and 
therefore treated by a hormonal therapy. This is mainly achieved by blocking oestrogen 
receptors with drugs such as tamoxifen, suppressing oestrogen synthesis with luteinizing 
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hormone-releasing hormone (LHRH) analogues, or by ovarian ablation either surgically or using 
radiotherapy (Aebi, S 2007).   
 
LHRH, Ovarian ablation Tamoxifen and Aromatase Inhibitor 
In 1896, Sir George Beatson was the first to successfully treat metastatic breast cancer in young 
women with bilateral oophorectomy and established the role of endocrine therapy in the form of 
OA in managing women with breast cancer (Beatson, GT 1896). Fifty years later, investigators 
from the Christie Hospital in England conducted the first randomized controlled trial of ovarian 
irradiation in breast cancer patients, which along with five succeeding randomized trials, further 
confirmed a role of OA in managing premenopausal women with operable breast cancer (Clarke, 
MJ 2008).   In   the   1990s,   the   early   Breast   Cancer   Trialists’   Collaborative   Group   (EBCTCG)  
meta-analysis reaffirmed the efficacy of OA/OS in women younger than 50 years of age by 
demonstrating that OA/OS reduced the incidence of breast cancer recurrence and mortality by 
30% (EBCTCG 1996). An update of the meta-analysis of the EBCTCG published in 2005 
showed that ovarian ablation (surgery or radiotherapy) and ovarian suppression (LHRH 
analogues) in premenospausal women produced significant benefits in terms of reduction of the 
risk of recurrence and death (EBCTCG 2005; Cuzick, J 2007). On the other hand, the same 
meta-analysis also showed that the use of adjuvant tamoxifen produced benefits in disease-free 
survival (DFS) and overall survival very similar to those observed in postmenopausal women 
(EBCTCG 2005). For many years now, 5 years of tamoxifen has been shown to reduce the 
annual odds of recurrence by 34% and death by 24% in premenopausal women under 50 years 
with HR-positive breast cancer (EBCTCG 2005). Tamoxifen is likely to remain the backbone of 
endocrine therapy for young women.  
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Ovarian suppression in general by oophrectomy, radiotherapy or with LHRH analogues has been 
studied in several ways; alone compared with chemotherapy, in addition to other 
 endocrine therapy (mostly tamoxifen), and in addition to chemotherapy (Jakesz, R 2002; 
Kaufmann, M 2003; Baum, M 2006; Jakesz, R 2007; Rabaglio, M 2007; Regan, MM 2008). The 
list of a few of trials that used LHRH analogues along with or without chemotherapy or/and 
radiotherapy is listed in table 1.1 (Cuzick, J 2008 (c)). LHRH agonists have proven to be as 
effective as oophorectomy in metastatic breast cancer (Rutqvist, LE 1999; Jakesz, R 2002). In 
premenopausal women with ER-positive advanced breast cancer, a meta-analysis of four clinical 
trials showed that the combined treatment of LHRH agonist plus tamoxifen confers a significant 
benefit in survival, progression-free survival, and overall response rate over tamoxifen alone 
(Klijn, JG 2001; Cuzick, J 2007) (Utsumi, T 2007).  
 
Combination therapies of an LHRH agonist plus aromatase inhibitor (AI) have also appeared as 
a safe and beneficial therapy in premenopausal women with metastatic breast cancer (Forward, 
DP 2004). AI’s   are   unsuitable   as   stand-alone hormonal therapy in premenopausal women. A 
major concern in using AI therapy in premenopausal women is their potential in causing ovarian 
hyperstimulation. A reduction in oestrogen levels due to AI therapy can lead to refractory 
increase in gonadotropin production (Winer, EP 2005; Hubalek, M 2010). Currently, the LHRH 
analogue/AI combination is being evaluated as adjuvant therapy in the ABCSG 12 trial (Gnant, 
MF 2007; Hadji, P, N. Bundred, 2007) and in the SOFT, TEXT and PERCHE trials (Regan, MM 
2008).  
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1.2.2 Hormonal therapies in postmenopausal women 
1.2.2.1 Tamoxifen - Selective oestrogen receptor modulator (SERM) 
80% of breast cancer tumours in postmenopausal women are hormonal receptor positive 
(Wittliff, JL 1984; Rabaglio, M 2007) and therefore sensitive to hormone deprivation therapy. 
Since the early 1980s, when tamoxifen was first introduced as a breast cancer treatment and until 
recently, it was the gold standard adjuvant treatment after primary surgery for women with early 
breast cancer in postmenopausal women (EBCTCG 2005). Tamoxifen is a SERM that acts as an 
antiestrogen in certain tissues, including the breast, while acting like a partial oestrogen in other 
tissues such as bone and the uterus (Diel, P 2002). Most of the unique pharmacology of SERMs 
works by three interactive mechanisms: differential oestrogen-receptor expression in a given 
target tissues, differential oestrogen-receptor conformation on ligand binding, and differential 
expression and binding to the receptor of co-regulator protein. There are two type of receptors- α  
and  β.  Tamoxifen  functions  as  pure  antagonists  when  it  act  through  β  receptor  but  also  works as 
partial   agonist   through   oestrogen   receptor   α.   Tamoxifen   binds   to   the   nuclear   ER   and   exerts  
oestrogen-antagonist activity in breast tissue thus inhibiting tumour growth (Choueiri, TK 
2004).The overview of 37,000 women with breast cancer from 55 trials of adjuvant therapy 
showed a 47% reduction in recurrence of breast cancer after 5 years of tamoxifen, and 26% 
reduction in mortality after 10 years of tamoxifen use (EBCTCG 1996; EBCTCG 2005). In the 
ATAC trial, the 100-months median follow-up report showed that even after completion of 5–
yrs tamoxifen continued to show carryover benefit for recurrence in the hormone-receptor 
positive breast cancers (Forbes, JF 2008) Despite its proven efficacy, there are some limitations 
to the use of adjuvant tamoxifen therapy. It is associated with potentially serious adverse effects, 
including thromboembolic events, ischemic cerebrovascular events and endometrial cancer, as 
well as menopausal symptoms such as hot flushes and vaginal discharge that affect quality of 
life (Cuzick, J 2003; Howell, A 2005; Lewis, S 2007).   
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 In the last two decades, the third generation aromatase inhibitors, which were introduced in the 
late 1990s, have expanded the adjuvant endocrine therapy options for postmenopausal women. 
Now AIs have developed as alternative anti-oestrogenic therapeutic agents to further improve 
outcomes for ER–positive, early, and metastatic breast cancer, and have largely replaced 
tamoxifen as the standard first-line treatment in ER-positive early breast cancer for 
postmenopausal women (Pennery, E 2008). 
 
1.2.2.2 Aromatase inhibitors  
In premenopausal women, the ovaries are the primary source of oestrogen, but ovarian oestrogen 
biosynthesis ceases after menopause, although androgen production continues. In 
postmenopausal women, androgen is used as substrate of oestrogen synthesis by the aromatase 
enzyme in peripheral tissues such as skin, muscle and fat.  Aromatase enzyme is responsible for 
the final step of oestrogen synthesis, in which the androgens androstenedione and testosterone 
undergo aromatisation to form the oestrogens estrone (E1) and oestradiol (E2) (Mokbel, K 2003) 
(Figure 1.1). The aromatase enzyme complex in such tissues converts androgens into oestrogen 
(Grodin, JM 1973; Sitteri, PK, P. C. MacDonald, 1973; Reed, MJ 1979). In patients with breast 
cancer, another potentially important source of oestrogen is the tumour cell itself. Aromatase 
inhibitors (AIs) are developed to prevent oestrogen biosynthesis in the tumours and other 
oestrogen producing tissues by inhibiting the enzyme aromatase.  
 
They have been developed through three generations, with each succeeding generation showing 
improved potency and selectivity (Table 1.2). They are classified into first-generation (e.g. 
aminoglutethimide), second-generation (e.g. formestane and fadrazole) and third-generation (e.g. 
anastrozole, letrozole and exemestane) agents. They are classified into different types depending 
on their mechanism of action. Type 1 inhibitors bind irreversibly to the steroid binding site on 
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the aromatase enzymes and are androstenedione steroidal analog. Type 2 inhibitors bind 
reversibly to the heme group on the aromatase molecule and are non-steroidal.  
 
The first generation aromatase inhibitor, aminoglutethimide, became available in the late 1970s, 
but its widespread use was limited because of its overall toxicity and lack of selectivity for the 
aromatase enzyme that needed concomitant corticosteroid supplementation. This was improved 
by second generation AIs (formestane and fadrozole), but they still lacked selectivity. 
Anastrozole, letrozole, and vorozole, are type 2 non-steroidal third generation AIs, and 
exemestane, is a steroidal third generation AI. Each of the third generation aromatase inhibitors 
reduces oestrogen synthesis by over 98% (Geisler, J 2002). All these third generation AIs, 
anastrozole, letrozole, and exemestane have been tested in phase III randomised trials of 
postmenopausal patients with receptor-positive breast cancer, and have replaced second 
generation AIs, based on their increased effectiveness and superior safety profile in advanced 
disease. Table 1.3 shows the clinical developmental milestones of aromatase inhibitors in 
postmenopausal patients with hormone receptor-positive breast cancer. 
 
Third-generation aromatase inhibitors are now considered the gold standard endocrine therapy in 
the first-line and second-line settings for oestrogen receptor (ER) and or/progesterone receptor 
(PgR) positive advanced breast cancer in postmenopausal women (Mokbel, K 2003) . Based on 
their superiority in metastatic disease, the efficacy of all three AIs has been proven in large, 
randomized controlled clinical trials in the adjuvant endocrine treatment options for 
postmenopausal women with hormone receptor positive early breast cancer (Baum, M 2002; 
Goss, PE 2003; Coombes, RC 2004; Boccardo, F 2005; Howell, A 2005; Jakesz, R 2005; 
Thurlimann, B 2005; Coombes, RC 2007; Eisen, A 2008).  
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Trials used different strategies to integrate the use of AIs with tamoxifen as an adjuvant therapy: 
(1) as an alternative to tamoxifen in the initial (upfront) adjuvant setting (ATAC; BIG 1-98), (2) 
as   a   sequencing  or   “switching”  approach,  whereby   the  patients   receives   2-3 years of adjuvant 
tamoxifen prior to receiving 2-3 years of an AI (IES, ITA, ABCSG-8 and ARNO-95), and (3) as 
an extension of adjuvant therapy, whereby the patients receive AI therapy following completion 
of the recommended 5-year course of tamoxifen (MA-17, NSABP B-33 ABCSG-6a trials). 
Table 1.4 shows the efficacy of aromatase inhibitors (AIs) in the adjuvant setting. In all these 
trials, aromatase inhibitor showed consistently longer disease-free survival rates, with a relative 
risk reduction of 17% to 44% when compared either to tamoxifen alone or placebo/no treatment 
(Pennery, E 2008).  
 
The ideal timing (upfront, switch, or extended), sequencing, and duration (2-3 years, 5 years or 
longer) of AIs is not yet established. However, the model created by Cuzick et al suggested that 
for PgR-positive tumours the initial use of AIs for 3 years is better than sequencing AIs after 2 
years of tamoxifen, as this is the period with highest recurrence rates (Cuzick, J 2006).  In most 
of the above settings, AIs given for 5 years appeared to be less toxic than tamoxifen when the 
global rate of serious adverse events is taken into consideration. When the side effects from all 
the trials are reviewed together, a trend seemed to emerge (table 1.5). A first series of side 
effects appears to be specific and favourable to AIs (hot flushes, gynaecological side effects and 
cardiovascular events including thromboembolism), a second series were specific to AIs but 
favourable to tamoxifen (bone fractures/osteoporosis and arthralgia), and a third series of side 
effects were more specific to given AIs (lipid metabolism, cardiac and cardiovascular events) 
(Nabholtz, JM 2008).  Overall, AIs were associated with a decreased incidence of endometrial 
cancer, cerebrovascular events, thromboembolic events, and vasomotor symptoms (Howell, A 
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2005; Thurlimann, B 2005), but were associated with reduced BMD, increased risk of fractures, 
hypercholesterolemia and joint pain.  
 
Several trials (ABCSG, BIG-SOFT, BIG-TEXT) are currently investigating the potential role of 
AIs in treating premenopausal women with breast cancer (Table 1.6). These trials are exploring 
the use of AIs in combination with LHRH (Goserelin) with or without zoledronic acid (Gnant, 
MF 2007; Regan, MM 2008).       
 
1.2.2.2.1 Anastrozole 
Anastrozole is an orally active, highly selective, well-tolerated, non-steroidal aromatase inhibitor 
(Wiseman, LR 1998). It is the most extensively investigated third-generation aromatase inhibitor 
in the treatment of breast cancer (Mokbel, K 2003). For clinical use the drug is administered 
orally (1mg) once daily, and the plasma steady state (Jonat, W 1996) is reached in 41- 48 hrs. In 
1995, anastrozole was the first of the newer-generation aromatase inhibitors to become clinically 
available for postmenopausal women with advanced breast cancer (Plourde, PV 1995; Buzdar, 
AU 1997; Buzdar, AU 1997; Nabholtz, JM 2000). Anastrozole can suppress circulating 
oestrogen levels to a similar extent as letrozole, vorozole, and exemestane, but to a greater extent 
than formestane. Anastrozole has shown superior efficacy as a second line therapy in 
postmenopausal women with oestrogen receptor and/or progesterone positive advanced breast 
cancer. Phase III clinical trials have demonstrated that anastrozole significantly prolongs the 
time for tumour progression when compared to tamoxifen as a first line therapy for ER and/or 
PR-positive advanced breast cancer in postmenopausal women (Bonneterre, J 2000; Vergote, I 
2000; Nabholtz, JM 2000).  
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Following these encouraging results achieved in the treatment of advanced disease, the efficacy 
of anastrozole has been investigated in the adjuvant setting as an alternative to tamoxifen, 
combined with tamoxifen, or a switch after a few years of tamoxifen as post-adjuvant treatment. 
The latest results of the ATAC study have shown superior efficacy of anastrozole over 
tamoxifen at 100 months follow-up in terms of disease-free survival (DFS), non-musculoskeletal 
adverse effects and prevention of contralateral breast cancer in postmenopausal women. The 
results indicated that anastrozole can decrease recurrence by 50% in the post-treatment period 
compared with no treatment (Forbes, JF 2008).  
 
Currently anatrozole has also been tried as an alternative to chemotherapy in premenopausal 
women with hormone-responsive breast cancer (Gnant, MF 2007). The potential role of 
anastrozole in a neoadjuvant setting (Smith, IE 2004) , the management of Ductal Carcinoma in 
Situ (DCIS) (IBIS-II trial), and prevention of breast cancer is currently under trial (IBIS-II trial).                                
 
1.3 Chemoprevention of Breast Cancer 
1.3.1 Tamoxifen  
Over the past 25 years, more than 10 million woman-years of clinical experience with tamoxifen 
has been accumulated in the prevention of the recurrence of breast cancer in both pre- and 
postmenopausal women with endocrine-responsive early breast cancer. The success of 
tamoxifen in preventing recurrence and reducing mortality in established breast cancer 
(EBCTCG 1992; EBCTCG 1996), its ability to prevent or delay a substantial number of new 
contralateral tumours (Cuzick, J 1985) and its very low toxicity made it an attractive agent to 
consider in a preventive setting. Tamoxifen was first shown to prevent new contralateral tumours 
in women with breast cancer in 1985 (Cuzick, J 1985).   Tamoxifen’s   ability   to   prevent   new  
primary and secondary cancers in the contralateral breast, together with its oestrogen-directed 
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mechanism of action provided the rationale for its evaluation as a chemoprevention agent in 
women at risk of breast cancer and led to the initiation of the NSABP P-1, Royal Marsden and 
Italian chemoprevention trials (Powles, T 1998; Veronesi, U 1998; Cuzick, J 2001) (table 1.7). 
The NSABP P-1 trial, Breast Cancer Prevention Trial (BCPT), was conducted by the National 
Cancer Institute from June 1992 to September 1997, during which time 13,388 women of 35 
years of age or older were randomized to either 5 years of tamoxifen (20mg/day) or placebo. A 
49% reduction in invasive breast cancers was observed with tamoxifen, which led to the US 
Food   and  Drug  Administration   (FDA)’s   approval   of   tamoxifen   for   breast   cancer   reduction   in  
high-risk women (Dunn, BK 2007).  
 
The benefit of tamoxifen was also seen in the reduction of non-invasive breast cancer, with 50% 
overall reduction owing to tamoxifen (Chlebowski, RT 2002). The IBIS-I trial showed that after 
a median of 49.6 months of follow-up, tamoxifen reduced the incidence of breast cancer 
(invasive and ductal carcinoma in situ combined) by 32 % (Cuzick, J 2002). Although the small 
Royal Marsden and Italian trials did not show a significant reduction of breast cancer incidence, 
but both the large NSABP-P1 and IBIS-I trials clearly showed that tamoxifen may indeed 
prevent breast cancer incidence (Fisher, B 2005; Cuzick, J 2006; Cuzick, J 2007). A meta-
analysis of all the above studies reported that half of oestrogen receptor positive tumours can be 
prevented with 5 years of prophylactic tamoxifen (Cuzick, J 2003) but this agent has no impact 
on oestrogen negative tumours. Overall 38% reduction in the risk of breast cancer was reported 
at about five years of follow-up. Recent reports (Cuzick, J 2007; Powles, TJ 2007) have shown 
that the benefits with tamoxifen were seen beyond the 5-year treatment. In particular in years 5-
10, after 5 years of tamoxifen in the IBIS-I trial, the risk of new ER-positive breast cancer was 
reduced by 44%. In addition endometrial and thromboembolic events reported with tamoxifen in 
other trials were not seen in excess in the IBIS-I trial after completion of treatment. 
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1.3.2 Raloxifene 
Raloxifene is a second generation SERM. It was developed initially for breast cancer treatment 
but its use was abandoned later. Raloxifene has been extensively studied for its effects on bone. 
Four trials have reported on the use of raloxifene for breast cancer prevention (Table 1.8). Data 
on   raloxifene’s   influence   on   breast   cancer   comes   almost   exclusively   from   the   Multiple  
Outcomes of Raloxifene (MORE) and the Continuing Outcomes Relevant to Evista (CORE) 
studies. In the MORE study, 7,705 postmenopausal women with osteoporosis were randomized 
to raloxifene at 60 or 120 mg/day or placebo for 4 years and monitored for breast cancer 
development from the safety database (Ettinger B 1999). After 4 years of treatment a 65% 
reduction in all breast cancer was found in the MORE trial (Cummings, SR 1999). The CORE 
trial was an extension to the MORE trial, and women were given raloxifene for an additional 4 
years. 50% reduction in breast cancer was reported in the CORE trial (Martino, S 2004). The 
overall incidence of breast cancer after 8 years of the MORE and CORE trials, regardless of 
invasiveness, reported 58% reduction in breast cancer in the raloxifene group compared with 
placebo. Some increase of thrombo-embolic complications, as seen with tamoxifen, were 
reported in these trials but no excess of endometrial cancers or other gynaecological problems 
were seen with raloxifene use. 
 
 Similar results were observed in the Raloxifene Use for the Heart (RUTH) trial, where the effect 
of raloxifene on the coronary events and invasive breast cancer were compared with placebo 
(Barrett-Connor, E 2006). Use of raloxifene for five years when compared with placebo showed 
a risk reduction of breast cancer by 44%. The efficacy of raloxifene was compared with 
tamoxifene in a 20,000 woman head-to-head trial for prevention of breast cancer in the National 
Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) trial. 
When compared, both raloxifene and tamoxifen were equally effective (50% risk reduction) in 
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preventing the development of invasive breast cancer, and raloxifene showed reductions in 
thromboembolic disorders, endometrial cancers and other side effects (Vogel, VG 2006).  
 
1.3.3 Aromatase Inhibitor 
The rationale for the potential use of AIs in preventing breast cancer in healthy postmenopausal 
women has mainly come from adjuvant studies in women with early breast cancer where AIs 
lead to significant reduction in the development of tumours in contralateral breast (Cuzick, J 
2005; Cuzick, J 2006; Cuzick, J 2007; Cuzick, J 2008 (b)). Eight major trials comparing AIs 
with tamoxifen as adjuvant treatment for invasive breast cancer reported significant reductions 
(42%) in the risk of contralateral breast cancer favouring AIs (Goss, PE 2003; Howell, A 2005; 
Thurlimann, B 2005; Coombes, RC 2007) and similar results were reported by two other trials 
(Boccardo, F 2005; Jakesz, R 2005). These trials have shown a further 50% reduction in new 
contralateral tumours above and beyond the 50% achieved by tamoxifen. This suggests that in 
future 70-80% of all oestrogen-receptor positive breast cancer might be prevented with these 
drugs. AIs are also associated with fewer, albeit different, side-effects than tamoxifen and 
raloxifene (Goss, PE 2003; Cuzick, J 2007).  
 
Currently two primary prevention trials using AIs as a chemopreventive drug are currently in 
progress in postmenopausal women with a high risk of breast cancer. These are IBIS-II and 
MAP.3 trials. The IBIS-II trial is an on-going large randomized trial comparing anastrozole 
versus tamoxifen for 5 years in 6,000 women with a high risk of breast cancer. In the MAP.3 
trial, exemestane is compared to placebo in 3,000 postmenopausal women at increased risk 
(Cuzick, J 2008 (b)). The value of AIs for prevention of breast cancer could be limited by 
potential adverse effects including bone loss, increased risk of fractures, and arthralgia. 
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However, these side effects could be manageable with regular BMD measurements through 
DXA scanning and using bisphosphonates in women with medium or high risk of fractures. 
 
1.4 Osteoporosis in postmenopausal women 
Osteoporosis is a disease that causes significant morbidity and mortality in postmenopausal 
women. Osteoporosis is a metabolic bone disease characterised by low bone mineral density 
(BMD), micro architectural deterioration of bone structure, with an increased bone turnover that 
leads to increased bone fragility and an increased risk of fracture (Sayegh, RA 2002; Siris, ES 
2004; Cole, Z 2008). It is becoming one of the leading health problems for postmenopausal 
women today (Waltman, NL 2008). It is estimated that one in two American women and one in 
three European women over the age of 50 will develop an osteoporosis-related fracture 
(primarily spine, wrist or hip) in their lifetime. Recently, the annual number of hip fractures in 
15 countries of the EU was estimated to be 500,000, with a total case cost of $4.8 billion per 
year (Minnie, H 1999). Osteoporosis causes more than 1.5 million fractures annually, impairs 
quality of life, and accounts for annual healthcare expenditure of more than $17 billion (Brown, 
JP, Josse, R. 2002; NIH 2003; Hajjar, RR 2004).   
 
Oestrogen plays an important role on bone health in postmenopausal women (Leslie, WD 1995). 
Oestrogen acts directly on osteoblasts and osteoclasts to maintain the balance between bone 
formation and resorption; the loss of this balance due to oestrogen deprivation is the major factor 
in the development of postmenopausal osteoporosis (Eastell, R 2008). Bone mass peaks at 
approximately 30 years in both men and women (Hodgson, SF 2003). From this point, 
approximately 0.4% of bone mass is lost per year in women until menopause occurs. Bone loss 
in postmenopausal women occurs in two phases. In the first 5 years after menopause, there is a 
rapid phase of bone turnover/loss (about ~1.5% per year) followed by a phase of slower rate of 
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bone loss (about 0.2 to 1.4 % per year) (Dennison, E 1999; Recker, R 2000; Ramaswamy, B 
2003) that starts at around 55 years of age (Twiss, JJ 2001; Ramaswamy, B 2003). In 
postmenopausal women, low oestradiol levels are associated with increased bone turnover 
(Chapurlat, RD 2001; Rogers, A 2002), low BMD (Ettinger, B 1998)and increased fracture risk 
(Cummings, SR 1998; Chapurlat, RD 2000; Rogers, A 2002). The low level of oestrogen that 
remains in circulation during menopause has a protective effect that can be negated in 
postmenopausal women with breast cancer who are treated with third generation aromatase 
inhibitors (Eastell, R 2008). Even though breast cancer is the disease women fear most, 
osteoporosis and osteoporotic-related fractures cause more deaths in postmenopausal women 
than breast cancer (Jones, LW 2005).   
 
1.5 Fracture rate in postmenopausal women 
Osteoporosis and associated fragility fracture is a far more common problem than breast cancer 
for postmenopausal women. The lifetime risk of hip fracture in women is higher than the sum of 
the lifetime risks of having breast, endometrial and ovarian cancer combined (IOF 2003 & 
2005). In 2005 in the US, Osteoporosis was responsible for more than 2 million fractures 
annually, including more than 300,000 hip fractures, 700,000 vertebral fractures, 250,000 wrist 
fractures, and 300,000 fractures at other sites (Lewiecki, EM 2005). The annual number of 
osteoporosis hip fractures in the European community is 485,000 (I O Foundation. 2003). 30-
50% of women suffer a fracture related to osteoporosis in their lifetime (van Staa, TP 2001) . In 
the UK, the lifetime incidence of any fracture in a 50 year old is 40% for women and 13% for 
men (Cole, Z 2008). It is predicted that the estimated number of hip fractures worldwide will rise 
from 1.7million in 1990 to 6.3 million in 2050 (Sambrook, P 2006). 
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Vertebral fractures cause severe, chronic pain, disfigurement, loss of pulmonary functions, and 
loss of ability for self-care (Kamel, HK 2006; Lewiecki, EM 2008). The human cost of 
osteoporotic fractures is immense. Quality of life gets affected because of limited mobility, 
coping with deformity, and anxiety about additional fractures. Osteoporotic hip fractures require 
hospitalisation and surgery. In general, the risk of vertebral fractures approximately doubles for 
each SD decrease in the lumbar spine or femoral neck BMD. Also, the risk of any type of 
fracture increases 1.5 fold for each SD decline in BMD measured at any site. Approximately 
25% of patients with osteoporotic hip fractures die within in a year (Kamel, HK 2005). Of those 
who survive, only 50% to 60% recover their prefracture walking ability and their ability to 
perform all necessary activities for daily life (Chrischilles, EA 1991). These patients frequently 
require placement in extended care facilities (Magaziner, J 1990). A meta-analysis of trials 
relating fracture incidence to prevalent fracture suggests than once a vertebral fracture has 
occurred, the risk for further fractures increases 4.4 fold and the risk for hip fracture increases 
2.3 fold, independent of BMD (Riggs, BL 1986).  
 
Although BMD is widely used to predict fracture risk, other behavioural (e.g. smoking, 
glucocorticoid use) and clinical factors (e.g. bone turnover and microarchitecture) contribute to 
fracture risk. Some recent studies showed that up to fifty percent of patients with incident 
fractures had baseline bone mineral density higher than the WHO diagnostic threshold of 
osteoporosis  (T  score  ≤  -2.5) (Kanis, JA 2005).  
 
1.6 Hormonal therapy and its effects on bone 
1.6.1 Tamoxifen and its effects on bone health 
Tamoxifen is a non-steroidal anti-oestrogen, with tissue selective oestrogen agonist and 
antagonist activity. It acts primarily as an oestrogen antagonist in breast tissues and a partial 
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oestrogen agonist in uterine and bone tissues. Though tamoxifen has a number of side effects, it 
exerts a beneficial effect on bone density in postmenopausal women due to its oestrogen-agonist 
activity.  The  skeletal  effect  of  tamoxifen  appears  to  vary  depending  on  the  patient’s  menopausal  
status. Premenopausal women have been seen to experience bone loss in placebo controlled 
tamoxifen chemoprevention studies (Gotfredsen, A 1984; Powles, TJ 1996; Vehmanen, L 2006). 
In a sub-population of 33 women who remained premenopausal through the observation period 
of 3 years, a loss of BMD in the lumbar spine was noted, compared with a modest gain of BMD 
for women on placebo (Powles, TJ 1996). Similar findings were observed in the Zoladex in 
Premenopausal Patients (ZIPP) trial that compared different endocrine approaches in early breast 
cancer. After 2 years of tamoxifen treatment, a significant decline of total bone density was seen 
in premenopausal women (Sverrisdottir, A 2004). 
 
 
Postmenopausal women receiving tamoxifen, due to its mild oestrogen agonist action, have been 
reported with a reduction in biochemical markers of bone turnover, a gain in BMD, fewer cases 
of new osteoporosis and fragility fractures. The beneficial effects of tamoxifen on BMD are 
most apparent at sites of trabecular bone, such as the lumbar spine. The protective effects of 
tamoxifen are associated with a decreased bone turnover, leading to a decreased bone resorption 
and bone formation. However, 80% of the total skeleton is comprised of cortical bone where the 
bone preservative effects of tamoxifen are less obvious (Grey, AB 1995). 
 
Several clinical trials have studied the effects of tamoxifen on bone health. The National 
Surgical Adjuvant Breast and Bowel Project P-1 study (Saarto, T 1997) (NSABP-P1) evaluated 
the use of tamoxifen versus placebo for the primary prevention of breast cancer and reported an 
overall decrease in the risk of fracture of the spine, hip and forearm (Vogel, VG 2006). A few 
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other studies also found that tamoxifen preserved bone mineral density when used in 
postmenopausal women (Love, RR 1992; Grey, AB 1995; Marttunen, MB 1998). When 
tamoxifen is compared with AIs in an upfront or a switch setting in postmenopausal women with 
early breast cancer patients, they showed significant increase in BMD and a decrease in fracture 
rate in most of the trials. These will be discussed in details in the chapter 2, section I and II.  
 
 
1.6.2 Aromatase inhibitors and their effects on BMD and osteoporosis 
In postmenopausal women, AIs reduce oestrogen levels to near zero by blocking the activity of 
the aromatase enzyme, which is expressed in peripheral tissues including fat, muscle, liver and 
bone (Douglas, D 2006). Moreover, osteoblasts also express the aromatase enzyme and regulate 
oestrogen production in the bone microenvironment, and therefore AIs could have a detrimental 
effect on bone health due to combined effects on the suppression of systemic oestrogen levels 
and local oestrogen production.  
 
To date, five on-going trials have reported the use of different AIs on bone mineral density in 
postmenopausal women with breast cancer (Table 1.9) (Eisen, A 2008). In all these adjuvant 
trials, significant BMD losses either at lumbar spine (LS) or at total hip (TH) or at both the sites 
were reported with AIs when compared with tamoxifen or placebo in an upfront, or a switch-
over setting. In the bone sub-protocol of the ATAC study with a primary analysis population of 
197 patients, anastrozole was associated with a significantly higher BMD loss in spine and hip 
bone at 2 and 5 years when compared with tamoxifen, although the loss in the lumbar spine (LS) 
slowed down after year 2. Interestingly, no patients with normal BMD at baseline developed 
osteoporosis and only a few women developed osteopenia at 5 years with anastrozole (Eastell, R 
2006; Eastell, R 2008). Similar BMD losses have been reported with letrozole and exemestane. 
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In the IES study, where exemestane was given after 2-3 years of tamoxifen therapy, in the bone 
sub-study of 206 patients, significant decreases in BMD at LS and TH were reported when 
compared to tamoxifen. The decreases started at 6 months after treatment and were sustained at 
24 months after randomisation (Coombes, RC 2004; Coleman, RE 2007; Coombes, RC 2007). 
Although the BMD decreased significantly in the first 6 months after switching to exemestane, 
thereafter the rate of bone loss decreased. These results suggest that the bone loss associated 
with AI therapy might slow down over time. Also, women in the exemestane group showed a 
significantly higher incidence of osteoporosis when compared to tamoxifen.  
 
In the NCIC-CTG MA.17 trial, after a median interval of 54 months, patients in the letrozole 
group had developed new osteoporosis more frequently than those who received placebo (Perez, 
EA 2006). In the (Perez, EA 2006), a relatively modest decrease in BMD at LS and TH was 
observed after 2 years of letrozole therapy (Perez, EA 2006).  
 
All the trials described so far investigated the effects of AIs on BMD when compared with 
tamoxifen, which itself has a protective effect on bone through its oestrogen-agonist activity. It 
is therefore difficult to know whether differences in BMD observed between AIs and tamoxifen 
were due to oestrogen suppression by the AIs, the bone sparing effects of tamoxifen, or a 
combination of these factors. Lonning et al evaluated the skeletal effect of exemestane in a 
placebo controlled trial of 147 patients who had not been previously treated with tamoxifen and 
who   did   not   receive   any   other   cancer   therapy.   The   results   showed   that   2   years’   treatment   of  
exemestane was associated with a modest but significant bone loss in the femoral neck (FN) but 
not in LS (Mincey, BA 2004; Lonning, PE 2005). In a large retrospective study where the 
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skeletal effects in 1354 patients on AIs were compared with 11,014 control patients, a significant 
increase in bone loss was observed in the AI group (Mincey and Tan 2004). 
 
 
A recent study of anastrozole versus tamoxifen as an adjuvant therapy in patients with breast 
cancer who received goserelin (LHRH) demonstrated that the overall bone loss was significantly 
greater after 3 years of anastrozole treatment (Gnant, MF 2007). 
 
The true skeletal effects of AIs can only be obtained from placebo-controlled trials in healthy 
postmenopausal women. Three such small trials have looked at the effect of AI versus placebo 
on skeletal health, but only on bone markers and not on BMD (Harper-Wynne, C 2002; 
Heshmati, HM 2002; McCloskey, EV 2007). 
 
Finally, results from all the studies mentioned above have provided good evidence that AI 
treatment in women with breast cancer can have a negative effect on bone mineral density. 
Future trials which will compare the classes of AIs will provide more information regarding their 
bone-sparing effects, including the MA.27 and Femara versus Anastrozole, Clinical Evaluation 
(FACE) trials that are currently comparing 5 years of anastrozole versus exemestane or letrozole, 
respectively, in patients with HR-positive early breast cancer (O'Shaughnessy, J 2007). In a 
chemoprevention setting, other than IBIS-II, another randomized placebo-controlled trial, the 
NCIC-CTG MAP3, is currently on-going and will evaluate the effect of AIs on skeletal health 
(MAP3). 
 
The latest ASCO guidelines have identified bone mineral density as a valid tool in treatment 
decision making. It is recommended that early treatment with bisphosphonate in women with 
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early breast cancer receiving AIs may preserve skeletal integrity by preventing bone loss and 
decreasing fracture risk (Hillner, GE 2003).  
 
1.6.3 Aromatase inhibitors and their effects on fracture rate 
The incidence of fractures was significantly higher with all the AIs compared with tamoxifen in 
most of the randomised, controlled clinical trials (Howell, A 2005; Baum, M 2006; Forbes, JF 
2008, Jakesz, R 2007; Boccardo, F 2005; Coates, AS 2007; Perez, E A 2006; Bundred, N J 
2006; Gnant, MF 2007; Coombes, RC 2007; Mamounas, EP 2008)  (table 1.9). Out of these 7 
trials, 2 trials used AIs as an upfront adjuvant treatment, 3 trials used AIs following 2-3 years of 
tamoxifen use and in one trial an AI was prescribed after 5 years of tamoxifen use. All the trials 
showed a significant increase in fracture incidence with AIs when compared with tamoxifen. 
The most detailed data on fracture risk comes from the ATAC trial. After 5 years of upfront 
treatment in the ATAC trial (at 68 months), anastrozole was associated with a significant 3.3% 
higher incidence of bone fractures (Eastell, R 2006) compared to tamoxifen (5.9 vs. 3.7). 
However, the incidence of hip fractures, which can be life threatening, was low and did not 
differ between the groups. In addition, the analysis done at 100-months showed that increased 
yearly fracture rate observed during the five year treatment continued into the post-treatment 
follow-up period  (11v 7.7%) (Forbes, JF 2008).  
 
Similar increases in fracture rate were also seen in the BIG 1-98 trial (Coates, AS 2007). After 2 
years of upfront treatment, fractures were significantly more frequent in the letrozole group 
when compared to tamoxifen. In the combined Arimidex-Nolvadex/Austrian Breast and 
Colorectal Cancer Study (ARNO 95/ABCSG 8) trial and the IES trial, women who had received 
2-3 years of adjuvant tamoxifen therapy and then switched to AIs (anastrozole in the ARNO trial 
and exemestane in the IES trial) had significantly more fractures than women who continued on 
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tamoxifen for 5 years (Coleman, RE 2007; Coombes, RC 2007). Interestingly, in the placebo-
controlled MA.17 trial, after 5 years of adjuvant tamoxifen, patients were randomized to an 
additional 5 years of letrozole or placebo. The development of osteoporosis was significantly 
different between the treatment arms, but the fracture rates did not differ significantly between 
the letrozole and placebo group (Perez, EA 2006). 
 
 
All these trials clearly confirmed that all three AIs significantly increase the risk of fractures 
compared with tamoxifen by about 50%, though this effect may be smaller when they are 
compared with the placebo. Further randomised trials, with longer follow-up durations, 
comparing AIs with placebo will reveal the real effect of AIs on fracture risk. 
 
 
1.7 Effect of hormonal therapy on lipid profiles  
1.7.1 Cardiovascular disease in women 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among 
postmenopausal women worldwide (Clearfield, M 2004). In the USA, one in four people aged 
20 years or over, have some form of CVD (high blood pressure, coronary heart disease, 
congestive heart failure, stroke or congenital cardiovascular defects). It is the main cause of 
death in women in the United States (accounting for 40% of all deaths) and in all countries of 
Europe (accounting for 44% of deaths in those aged 75 or older) (Peterson, S, V. Peto, M. 
Rayner 2005). The risk of CVD increases with age, and in women the risk increases 
substantially and progressively at or after the age of 55 years (American Heart Association 
Report, 2005). Although the incidence is low in premenopausal women, it increases after the 
onset of menopause (Kannel, WB 1976; Pritchard, KI 2006). Although breast cancer is a 
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common cause of death up to the age of 55 years, women overall experience greater mortality 
from CVD than from breast cancer (American  Heart Association, 2005). CVD is also the most 
frequent cause of death in women. The role of oestrogen on the cardiovascular health of 
postmenopausal women is not very clear. The rapid increase in CVD after spontaneous or 
medically induced menopause is believed to be due in part to the loss of endogenous oestrogen 
(Monnier, A 2007). Reduced oestrogen levels during menopause have shown negative effect on 
lipid metabolism causing increase in total cholesterol (Stevenson, JC 1993; Tremollieres, FA 
1999; Kuh, D 2005), low-density lipoprotein cholesterol (LDL) (Matthews, KA 1989) and 
triglycerides (TG) (Kuh, D 2005) and decreases in high-density lipoprotein cholesterol (HDL) 
levels (Matthews, KA 1989).  
 
Initial observational studies have suggested that postmenopausal women who received hormone 
replacement therapy (HRT) (oestrogen either with or without progesterone) had fewer CVD 
events than those who did not receive the treatment (Rosano, GM 2003). This led to the belief 
that HRT played a role in the prevention of CVD. However, randomised clinical trials have 
disagreed   with   these   initial   reports.   A   trial   conducted   by   Women’s   Health   Initiative   group  
concluded that among healthy postmenopausal women, the combined use of oestrogen and 
progestin actually resulted in an increase of incidence in coronary heart disease (Manson, GE 
2003).  
 
Other than age/menopausal status, there are many other risk factors for CVD. These are a diet 
rich in saturated fats, diabetes, obesity, a family history of CVD, smoking, lack of exercise, 
excessive alcohol intake drinking etc (American Heart Association. 2005). Breast cancer and 
CVD share several risk factors, including age, obesity and inactivity (Pritchard, KI 2006). Any 
combination of two or more risk factors increases the overall risk for the occurrence of a 
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cardiovascular event. The most preventable and detectable risk factor for CVD is the detection 
of lipid profile. Abnormal blood lipid levels, like high total cholesterol, high levels of LDL, high 
levels of TG and low levels of HDL are associated with a high risk of CVD.  
 
  Postmenopausal women have increased levels of LDL and a decreased HDL compared with 
premenopausal women of the same age, so these unfavourable changes are considered to be a 
risk factor for the development of coronary heart disease in these women (Grundy, SM 2004; 
Davies, GM 2005). Deaths resulting from cardiovascular disease rather than from malignancy 
are not uncommon in breast cancer patients. Therefore much attention has been focussed on the 
effect of hormonal therapies on changes in lipid profile. In a chemoprevention setting, it is 
important to confirm that healthy women are not put at greater risk of CVD. 
 
 
1.7.2 Effect of hormonal therapy on lipid profiles 
Current evidence gained from the clinical trials in breast cancer patients has demonstrated that 
tamoxifen has a favourable effect on lipid profiles. Most trials have shown a modest LDL 
lowering effect (6-28% reduction), although the effects on HDL have been more variable 
(Mannucci, PM 1996; Herrington, DM 2001). Unlike tamoxifen, AIs lack partial oestrogen 
agonist activity and therefore lack the positive lipid-lowering effects seen with tamoxifen 
(Elisaf, MS 2001; Bundred, NJ 2005; Sawada, S 2005; Esteva, FJ 2006; Mouridsen, HT 2006; 
Conte, P 2007; Lewis, S 2007; Perez, EA 2007). Preclinical studies conducted in ovariectomised 
rats have not shown any adverse impact of any AI on serum lipids (Goss, PE 2004).  
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A better evaluation of the impact of AIs on lipid profiles comes from studies in an earlier stage 
of breast cancer (table1.11). In the ATAC trial, a higher incidence of hypercholesterolemia was 
reported in the anastrozole treated patients when compared to the tamoxifen group (Buzdar, A 
2006). In the BIG 1-98 study, more patients in the letrozole arm experienced 
hypercholesterolemia at least once during treatment, but the majority of cases in both arms were 
grade I (The grading of the adverse events was done according to the common toxicity criteria of 
the National Cancer Institute). Also, the median total cholesterol did not change significantly in 
the letrozole arm (Thurlimann, B 2005).  
 
 The same increases were seen with AIs when they were given in the switch setting in the ITA 
trial and IES study (Boccardo, F 2005; Coombes, RC 2007). Similar results were also seen with 
exemestane in the TEAM trial, where neutral effects on TC and HDL-C were observed, although 
the levels of LDL had increased at 24 months. When compared with placebo, increased 
hypercholesterolemia was not reported with letrozole in the MA-17 trial (Wasan, KM 2005; 
Goss, PE 2007; Waltman, NL 2009). Likewise, another study found that exemestane had no 
major effects on lipids, with the exception of a small decrease from baseline HDL and 
apolipoprotein (Lonning, PE 2005), which showed a marginally significant percent increase in 
LDL at 12 months. In the Tamoxifen and Exemestane Adjuvant Multicentre (TEAM) sub-study, 
the lipid profiles remained unchanged in the anastrozole group after one year of treatment 
(Markopoulos, C 2005). In the Adjuvant post-Tamoxifen Exemestane versus Nothing Applied 
(ATENA) study, when compared with placebo, no significant differences were observed for any 
lipid parameters (Markopoulos, C 2005 (a)).  
 
In a neoadjuvant setting, after 3 months of treatment in the Immediate Preoperative Arimidex, 
Tamoxifen, or combination with Tamoxifen (IMPACT) trial, anastrozole resulted in a significant 
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increase in HDL levels but with no significant increase in LDL and TC levels (Banerjee, S 
2005). In conclusion, longitudinal and placebo-controlled studies of the three AIs have found no 
evidence of a detrimental effect on serum lipids, in contrast to tamoxifen-controlled studies 
(Monnier, A 2007). The LEAP trial directly compared safety parameters between the steroidal 
AI exemestane and the non-steroidal AIs anastrozole and letrozole in 90 healthy postmenopausal 
women (McCloskey, E 2007). Initial results from the trial showed that there were no significant 
differences between anastrozole and letrozole in effects on LDL: HDL ratios, triglyceride 
concentrations, and non-HDL concentrations. Exemestane was associated with an increase in 
LDL: HDL ratio (+17) (p= 0.047) compared with anastrozole. There was no median change 
from baseline in total serum cholesterol for letrozole, a slight increase for anastrozole (+0.4), and 
a non-significant  decrease  for  exemestane  (−3.9)  (p= 0.164 vs. anastrozole). 
 
1.8 Bone  
1.8.1 Bone Tissue 
Bone is a specialised connective tissue composed of both mineral and organic phases that are 
exquisitely designed for its role as the load-bearing structure of the body. Bone is formed of 
combination of dense compact bone (cortical bone) and cancellous (trabecular) bone. Cortical 
bone, which comprises approximately 70-80%  of   the  body’s  bone  mass,   is   the  site   for  20%  of  
bone turnover; whereas trabecular bone, which comprises only 20-30%  of  the  body’s  bone,  is  the  
site for 80% of bone turnover (Ray, NF 1997; Dempster, DW 2006) (table 1.12). The trabecular 
bone is predominant in the axial skeleton and near the joints of long bones. Due to high surface 
area of trabecular bone compared to cortical bone, most of the bone turnover takes place in the 
trabecular bone (Lenora, J 2007). It consists of a network of interconnected plates and struts 
fused to and encased by a thin cortex. In the human skeletal trabeculae are typically 100-150 µm 
thick, whereas the thickness of cortical bone varies between 1 and 5 mm (Wehrli, FW 2007). 
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The  ability  of   a  bone   to   resist   fractures   (or   “whole  bone   strength”)  depends  on   the  amount  of  
bone (i.e. mass), the spatial distribution of the bone mass (i.e. shape and microarchitecture), and 
the intrinsic properties of the materials that comprise the bone (Bouxsein, ML 2009). 
 
1.8.2 Bone Remodelling 
Throughout life, bone undergoes constant remodelling by an orderly process of bone formation 
and resorption, which happens in discrete foci throughout the skeleton called remodelling units 
(Blake, MG 1999). The process of bone resorption followed by formation is a delicate balance 
between two different cell types, osteoclasts and osteoblasts. Osteoclasts are cells of myeloid 
origin, which adhere to bone and initiate matrix degradation and resorption. The process of bone 
resorption causes a release of growth factors that attract osteoblasts to the site of bone 
degradation. The osteoblasts participate in slower processes that promote new bone formation 
and hence normal bone integrity is maintained. The cycle of bone resorption followed by 
formation takes place over a 3 - 4 month period, leading to complete remodelling of the adult 
skeleton over approximately 10 years (Dempster, DW 2006). Resorption and formation are 
tightly coupled in young adulthood, so that the net balance of change in bone mass is zero.  
 
Control of this complex process is regulated by a combination of systemic hormones and local 
factors. The systemic hormones involved in this process include parathyroid hormone (PTH), 
calcitonin, insulin and growth hormone (GH), while local factors include growth factors, 
cytokines and prostaglandins. Any disruption in this balance can lead to the formation of 
abnormal bone (Hillard, CT, C. J. Stevenson, 1991). For example, oestrogen suppresses the 
ability of osteoblasts to produce cytokines that stimulate osteoclastogenesis. This causes 
increased resorption of bone. Oestrogen is also associated with increased production of 
osteoprotegerin (OPG) from osteoblasts, which is a potent inhibitor of osteoclastogenesis. A 
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deficiency of oestrogen is therefore likely to increase osteoclast survival and activity, and lead to 
bone density loss (Manolagas, SC 2000).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
1.8.3 Impact of menopause on bone metabolism 
Oestrogen plays a critical role in maintaining skeletal structure integrity and is a major 
determinant of bone turnover (Leslie, WD 1995). Early in the menopause, oestrogen deficiency 
leads to increased bone remodelling, but a differential effect favours resorption over formation, 
resulting in large resorption cavities that cannot be refilled with new bone (Stepan, JJ 1987). In 
late postmenopausal women, bone loss is predominantly caused by the reduced numbers of 
osteoblasts (Manolagas, SC 2000), and women are thus unable to replace bone lost by 
resorption. Therefore, declining oestrogen levels in healthy postmenopausal women causes 
weakened bone micro-architecture, low bone mineral density (BMD) (Chapurlat, RD 2000; 
Rogers, A 2002)  and increased fracture risk (Lacy, MQ 2006). 
 
Reductions in the circulating oestrogen levels at menopause are associated with 
rapid reduction in bone mineral density, averaging 2% per year over the subsequent 5 to 10 years 
(Stepan, JJ 1987). Oestrogen maintains bone mass, especially in the trabecular bone of the spine. 
In healthy women, endogenous oestrogen concentrations decrease approximately 90% between 
the last 2 years of premenopause and the first years of postmenopause (Burger, HG 1999). These 
reduced oestrogen levels during menopause tend to affect trabecular bone more than cortical 
bone. As a result, bone loss is first apparent in the vertebrae, then in the femoral neck, and last in 
the total hip and radius shaft (Josse, RG 2007).  It has been suggested that some 20-30% of 
trabecular bone and 5-10% of cortical bone can be lost during the menopause, depending upon 
the extent and duration of resorption (Pfeilschifter, J 2000). This represents the rapid phase of 
bone loss during the perimenopause. In bone, aromatase is expressed in osteoblasts and 
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chondrocytes (Sasano, H 1997), and aromatase activity in cultured osteoblasts is comparable to 
that present in adipose stromal cells (Shozu, M 1998). Thus, it appears that in bone also, local 
aromatase expression is the major source of oestrogen responsible for the maintenance of 
mineralization. There is a little data available to demonstrate the direct effects of aromatase 
inhibitors on bone cells. Human osteoblast-like cells have been demonstrated to express the 
aromatase gene (Shimodaria K, 1996). Only a single study is available regarding the effect of 
aromatase inhibitors on osteoblast-like cells. Miki Y et al studied the effects of AIs including the 
steroidal AI, exemestane (EXE), and non-steroidal AIs, Aromatase Inhibitor I (AI-I) and 
aminoglutethimide (AGM), on a human osteoblast (Miki Y, 2006). In this study, aromatase were 
detected in osteoblasts-like cells lines and it also demonstrated that exemestane stimulates 
osteoblastic activity via both androgen receptor (AR) dependent and independent pathways. No 
other studies are available of the effect of aromatase inhibitors on osteoclasts, or osteocytes in 
vitro.  
 
In overiectomized rats, exemestane treatment has shown to increase trabecular 
bone volume, trabecular number, trabecular thickness and decrease of trabecular separation. 
However, the mechanical strength of the femur remained constant. No animal data on bone 
structure are available regarding other aromatase inhibitors (Folkestadl L, 2008). 
 
The effects of aromatase inhibitor on osteoblasts and osteoclasts are mainly 
observed via their action on oestrogen levels amongst postmenopausal breast cancer patients. It  
is observed that in postmenopausal women, anastrozole, letrozole and exemestane, lower the 
serum levels of oestrogen by almost 98% (Buzdar A. U, 2006). At the cellular level, oestrogen 
has profound effects on both osteoblasts and osteoclasts. Oestrogen decreases the osteoblastic 
production of resorptive cytokines [receptor activator of nuclear factor kappa B ligand (RANK-
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L), colony-stimulating factor-1, interleukin-1 and tumour necrosis factor] and at the same time 
increases the production of antireceptive cytokines (mainly osteoprotegerin) (Folkesda1 l, 2008). 
As a result this leads to increased osteoclastic apoptosis and increased osteoblastic activity 
(Pfeilschifter, J 2003 and Lindberg M K, 2005).   
 
In postmenopausal women with breast cancer, aromatase inhibitors have been reported to reduce 
oestrogen levels by 95% (Geisler, J 1996; Geisler, J 2002) or almost zero by blocking the 
activity of the aromatase enzyme (Douglas, D 2006) . Therefore they may place postmenopausal 
women at an even greater risk of skeletal damage by further reducing the residual oestrogen 
levels.  
 
Hormone replacement therapy (HRT) is known to reduce bone loss in early, late, and elderly 
postmenopausal women by the inhibition of bone resorption. Findings of several case-control 
and cohort studies on postmenopausal women suggest that HRT decreases the risk of fracture 
(Corrao, G 2008).  However,  results  from  the  Women’s  Health  Initiative  (WHI)  study  showed  an  
increase in the risk of breast cancer after 10 years of HRT use, especially for combined 
oestrogen/progesterone formulations. The increase and risk associated with oestrogen were 
found to exceed the benefits, even in women at high risk of fractures (Cauley, JA 2003)  
 
1.9 Osteoporosis  
1.9.1 Definition and diagnosis of Osteoporosis  
The criteria for defining osteoporosis are recommended by World Health Organisation (WHO) 
study group. The definition is based on the on the reference value for BMD in young adults. 
Osteoporosis is diagnosed by measuring BMD and defined by the WHO study group as a bone 
mineral density (BMD) measurement at femoral neck, LS or forearm sites of 2.5 standard 
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deviations (SD) or more below the young adult mean value, commonly expressed as a T score (< 
-2.5 SD. Osteopenia is defined as a T-score between -1 and -2.5 (WHO 1994). 
 
1.9.2 Recommendations of the WHO study group 
The WHO recommends the following diagnostic categories for assessments using DXA  
1. Normal bone mass: Hip BMD at or greater than 1 standard deviation (SD) below young 
adult reference mean (T-score -1.0 or above). 
2. Osteopenia or low bone mass: Hip BMD at or between 1 and 2.5 SD below adult 
reference mean (T-score below -1.0 and above -2.5) 
3. Osteoporosis: Hip BMD 2.5 SD or more below adult reference mean (T-score -2.5 or 
below) 
4. Severe osteoporosis: Hip BMD 2.5 SD or more below adult reference mean with 
presence of one or more fragility fractures. 
Bone quality or strength is comprised of trabecular bone, macro- and microarchitecture, bone 
turnover, cortical bone thickness, and mineralization. Approximately 60-70% of bone strength 
variation can be measured by BMD (Majumdar, S 2003) . In clinical practice, measurement of 
BMD is the accepted gold standard for diagnosis of osteoporosis. Other than BMD there are 
several risk factors that may predict fracture risk independent of BMD (Table 1.13) (Kanis, JA 
2005; Keen, R 2007). The risk factors identified by the WHO study group are as follows: 
a. History of fragility fracture 
b. Use of glucocorticoids 
c. Parental history of fracture 
d. Associated medical disease (i.e. rheumatoid arthritis) 
e. Cigarette smoking 
f. Excessive alcohol intake 
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g. Low body weight. 
 
1.9.3 Techniques for assessing Bone Mass 
A number of technologies can be used to assess mineral density. These are: 
1. Dual-Energy X-ray Absorption (DXA), only two types: 
a. Hologic Discovery 
b. Lunar Prodigy 
2. Quantitative computed Tomography (QCT) (Spine and Hip) 
3. pDXA (Peripheral measurement of forearm, hand and heel) 
 
1.9.4 Dual energy x-ray absorptiometry (DXA) Scan 
DXA is recognised as the reference method to measure BMD (Blake GM 2007). DXA machines 
have been available since 1987 and are the most widely researched method of investigation for 
the diagnosis of osteoporosis. Most researchers agree that DXA is the preferred method to 
measure BMD due to its safety, ease of use, short scan times, easy availability, low radiation 
exposure, and stable calibration (Fogelman, I 2000; Sayegh, RA 2002; Khan, AA 2004). The 
WHO study group has established DXA as the best densitometry technique for assessing BMD 
in postmenopausal women, and has based the definitions of osteopenia and osteoporosis on its 
results (Kanis, JA 1994; Kanis, JA 2005). DXA allows the diagnosis of osteoporosis, estimation 
of fracture risk and monitoring of patients undergoing treatment. Modern machines are precise 
and can rapidly scan patients using very low levels of radiation exposure. A DXA measurement 
can be obtained in about 10 seconds with minimal radiation exposure. Radiation dose used for 
hip and spine is very low varying from 1-10 µSv, which is about one-tenth that of a standard 
chest X-ray for a quick hip and spine exam, or at worst is similar to a chest radiograph (Baim, S 
2005).   
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The DXA technique uses the X-ray transmission factors. The transmission factor is the fraction 
of the energy carried in the X-ray  beam  that  is  transmitted  all  the  way  through  the  patient’s  body  
and emerges the other side. DXA scanners work by measuring the transmission factors of X-ray 
beams with two different photon energies. One beam consists of high energy X-rays and the 
other of low energy X-rays. Because the high and low energy beams are absorbed differently by 
bone and soft tissue (high energy X-rays are absorbed equally by bone and soft tissue, while low 
energy X-rays are preferentially absorbed by bone), by measuring the transmission factor of each 
beam and knowing the attenuation coefficients of bone and soft tissue it is possible to calculate 
the areal density of bone.   
 
BMD is the measured parameter, and it allows the calculation of the bone mineral content 
(BMC) in grams and the two-dimensional projected area in cm2 of the bone (s) being measured. 
Thus the units of BMD are g/cm2  (Kanis, JA 1994). In practice, the BMD values are themselves 
not used for diagnosing osteoporosis as there are differences in the BMD values between 
Hologic and Lunar machines. Instead, osteoporosis is defined on the basis of a T-score, which is 
the difference between the measured BMD and the mean value of young adults, expressed in 
standard deviations (SD) for a normal population of the same gender and ethnicity. In addition to 
diagnosing osteoporosis, DXA is also used in treatment decisions and monitoring response to 
different therapies. In addition to the T-scores, DXA also provides Z-scores, which are 
calculated in a similar way to the T-scores,  except  that  the  patient’s  BMD  is  compared  with  an  
age-matched (and race- and gender-matched) mean. The results of the Z-score are expressed as a 
standard deviation score (Watts, NB 2004).  
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There is evidence to suggest that the optimum site for predicting the risk of hip fracture is the 
femur (neck or total hip), and for monitoring the response to treatment is the spine. Thus, many 
authors have recommended measuring hip alone for assessing the hip fracture risk (Kanis, JA 
2002; Johnell, O 2005; Kanis, JA 2005) and LS measurements for assessing the spinal fracture 
risk and for follow-up. In spine, the preferred site of doing DXA scanning is L1 through L4 or 
L2-L4 vertebrae. It is suggested that the DXA image at spine should be evaluated for artefacts 
(e.g. surgical clips, navel rings, coin, clip, or other metallic objects) or local structural changes 
(e.g. osteophytes, compression fractures etc.) as almost all artefacts can elevate BMD levels 
(Watts, NB 2004) This is especially true for spinal degenerative changes, which can elevate 
spine BMD by 2, 3, or more T-score points. If an artefact is observed, the affected vertebrae 
should be deleted from the test, and only the remaining vertebrae should be used for the analysis.  
Differences between BMD values from Hologic and Lunar devices 
Lunar devices produce BMD values that are about 15% higher than Hologic devices. This is 
because the two types of scanners are calibrated differently. Lunar machines are calibrated based 
on excised vertebrae and allow for the average fat content in bone marrow, while Hologic 
machines are calibrated using the Hologic spine phantom, which consists of plastics that 
simulate bone and soft tissue and do not allow for marrow fat. Despite this difference in 
calibration, when the BMD values are converted into T-scores there is hardly any difference 
between the two machines provided that T-scores are calculated using either the Lunar (DPX 
Series  Operators  manual  1998)  or  Hologic  (Kelly  1990)  manufacturer’s  reference  range  for  the  
lumbar spine (L1-L4) and the NHANES III reference range for the hip region (Looker, AC 
1998). 
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1.9.4.1 Limitations of current DXA use 
Despite its clinical utility, DXA technology has limitations. There is a limitation in measurement 
of BMD due to error caused by variation in composition of soft tissue. Other limitation of DXA 
is that it is a 2D rather than a 3D technique therefore it is sensitive to differences in bone size 
(Burghardt, AJ 2009).  
 
Variability 
There is an approximate 15% difference in BMD values between Lunar and Hologic machines. 
A discrepancy in Lunar and Hologic hip T-scores led to replacement of manufactures reference 
range by NHANES. The Third National Health and Nutrition Examination Survey (NHANES 
III) (1988 to 1994) was the first comprehensive U.S. survey that used DXA to assess 
osteoporosis prevalence based on proximal femur BMD from a reference multigraphic 
population of white women and men from 20 to 29 years of age. The International Committee 
for Standards in Bone Measurement recommends the NHANES III database to be used to 
standardize the hip T-score (Binkley, N 2005). 
 
Accuracy 
Accuracy is most important for diagnosis and assessment of fracture risk, but is less important 
for monitoring BMD changes over time (precision error). Accuracy can be assessed by cadaver 
studies or CT/MRI imagining.  
 
Precision  
DXA precision, or reproducibility, is the ability to obtain serial BMD values of the same patient 
over a short time with the same numerical results (Baim S 2005 & 2006). The long-term 
precision of DXA is 1.5% for the spine and total hip, and 2.5% at the femoral neck (Patel, R 
 
 
54 
2000). It is recommended that baseline and follow-up scans should be done on the same 
instruments, using the same procedure (Lewiecki, EM 2006) .  
 
Difference between accuracy and precision and how accuracy is assessed by 
CT/MRI  
The accuracy error specifies how closely the measured value agrees with the actual (true) value. 
The precision error measures the reproducibility of the measurements. If every measurement has 
the same accuracy error the precision error will appear to be much smaller than the accuracy 
error. This is the situation with DXA. Spine and hip BMD measurements have a precision error 
of 1.0 to 1.5%, but accuracy errors of 5 to 7%. Accuracy errors arise because DXA scans use 
transmission measurements at two different X-ray energies to measure two types of tissue, bone 
and soft tissue. But the human body is composed of three types of tissue, bone, lean tissue 
(muscle), and adipose tissue (fat). Accuracy errors in DXA are caused by the varying content 
and distribution of the adipose tissue. Accuracy errors can be studied in cadaver studies in which 
bones are excised and ashed to measure the true BMC. Accuracy errors can also be estimated 
using CT and MRI imaging to measure the amount and distribution of extraosseous fat (CT or 
MRI) and marrow fat (MRI) and performing calculations to simulate the DXA measurement 
process.  
 
The reason why DXA scanning is clinically relevant for assessing outcomes and change in BMD 
after a minimum of 1 or 2 years of treatment is because the accuracy of DXA measurements for 
monitoring purposes is limited by the precision error (this assumes there is no change in the 
accuracy error due says to weight change). Both the baseline and follow-up measurements are 
affected by precision errors, so if the precision is 1% then the error in the difference of two 
measurements will be 1.4% (square root of 2 times larger). A BMD change at least 1.96 times 
the total error is required for a result to be statistically significant with 95% confidence. This is 
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called the least significant change (LSC). For a precision error of 1% the LSC is 1% x 1.4 x 1.96 
= 2.8%. In practice for measurements made on different days the true long-term precision error 
is larger (about 1.5%) than the figure of 1% usually quoted for the short-term precision errors 
measured by repeated measurements on the same day. Hence the LSC for DXA is really around 
4 to 5%. The minimum monitoring interval is the time it takes for the BMD to change by the 
LSC, e.g. if the rate of BMD loss on an AI is 5% per year the minimum monitoring interval will 
be 1 year, but if the rate of loss is 2.5% per year it will be 2 years. 
Measures to correct BMD for body size 
DXA scans are not three-dimensional like CT scans, but two-dimensional, like a plain X-ray. 
Areal BMD is calculated by dividing the total bone mineral content (BMC) of the bone by the 
projected area A to give BMD in units of g/cm2. The measurements are therefore sensitive to 
differences in bone size (for example when comparing children with adults, women with men, 
black subjects with white subjects) as well as differences in the true (volumetric) bone density. 
This can be corrected by using BMAD (Bone Mineral Apparent Density) (Leonard, MB 2006). 
BMAD is calculated on the assumption that the volume of the bone is equal to the area raised to 
the power 1.5 (volume = A3/2), which is equivalent to assuming that the thickness of the bone is 
equal to the square root of A. Hence BMAD is found by dividing the BMC by A3/2 to give an 
estimated volumetric BMD in units of g/cm3. 
1.9.5 Bone markers 
Although osteoporosis is one of the strongest risk factors for fractures, only about half of the 
fractures occur in women who have BMD below the diagnostic threshold of osteoporosis 
(Bergink, AP 2005; Sanders, KM 2006). Therefore, other methods are used to identify individual 
who are at high risk for fractures. Bone turnover or biochemical markers of bone turnover are 
bone tissue proteins or their fragments, or enzymes released from bone cells during bone 
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turnover (Lenora, J 2007). Bone remodelling rate can be assessed by measuring bone turnover 
markers in serum or urine.  
Types of Bone Markers   
There are several bone markers to assess   the rate of bone turnover. These can be categorised 
into two groups; bone formation and bone resorption markers. The formation markers include 
bone protein incorporated into the bone matrix (osteocalcin or collagen) or the enzyme involved 
in mineralization, alkaline phosphatase (ALP). All resorption markers are fragments of bone 
specific collagen released by osteoclasts. 
 
Bone specific ALP is secreted by osteoblasts, and although its exact function is unknown, it is 
known to cause increased bone calcification and bone formation. As a result, bone specific 
alkaline phosphatase (BSAP) levels are raised during a period of bone growth and high turnover. 
Type I collagen, the major component of bone, is broken down into many different substrates. 
These can be measured as highly specific markers of bone resorption.  
Bone markers are divided as follows; 
1. Bone formation markers (Serum) 
a. Bone specific alkaline phosphatase (BSAP) 
b. Osteocalcin (OC) 
c. Carboxy-terminal propeptide of type I collagen (PICP) 
d. Amino-terminal propeptide of type I collagen (PINP) 
2. Bone resorption markers 
I – Urine 
a. N-telopeptide of collagen crosslinks (uNTx) 
b. C-telopeptide of collagen cross-links (uCTX) 
c. Deoxypyridinolines, free and total (Dpd) 
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d. Pyridinolines, free and total (Pyr) 
II- Serum   
a. N-telopeptide of collagen cross-links (sNTx) 
b. C-telopeptide of collagen cross-links (sCTX) 
c. Cross-linked C-telopeptide of type I collagen (ICTP) 
d. Tartrate resistant acid phosphatase (TRAP) 
 
 
1.9.6 Guidelines for management of osteoporosis 
The American Association of Clinical Endocrinologists (AACE), North American Menopausal 
Society (NAMS), and National Osteoporosis Foundation (NOF) have provided 
recommendations for the identification of women who should be assessed for osteoporosis and 
should be provided with treatment (Hodgson, SF 2003).  
 
New NOF Guidelines and the WHO Fracture Assessment Tool or FRAX  
The National Osteoporosis Foundation has released a 2008 update to the NOF guidelines last 
published in 1999. The guidelines provide recommendations for screening, counselling and 
treatment of osteoporosis. This update was prompted by the publication of the FRAX, a new 
fracture risk assessment tool (Kanis, JA 2008). 
FRAX  
World Health Organization has developed this new fracture risk assessment tool to identify 
individuals at high risk of osteoporotic fracture. The current standard, which bases treatment 
decisions largely on bone mineral density measurement, has proven to be specific, but not 
sensitive, for the identification of patients at high risk of fracture.  Because nearly 50% of 
postmenopausal women in the community over the age of 50 years who suffer an osteoporotic 
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fracture do not have osteoporosis defined by a BMD test (Siris, ES 2001; Siris, ES 2004), and 
because of the limited availability of BMD in many countries, clinical risk factors were added to 
BMD to improve the identification of patients at high risk for osteoporotic fractures.   
A task force from the WHO evaluated the clinical risk factors that predict increased risk of 
fracture in nearly all of the 12 population cohorts evaluated worldwide.  These are: age, sex, 
prior fragility fracture after age 50, history of corticosteroid use (5 mg or more for three months 
or more), parental history of hip fracture, rheumatoid arthritis, secondary osteoporosis (e.g., type 
1 diabetes, osteogenesis imperfecta in adults, longstanding hyperthyroidism, hypogonadism, 
premature menopause, chronic malabsorption and chronic liver disease), current smoker, alcohol 
use of greater than 2 units daily (a unit is one medium glass of wine or a glass of beer) and BMI.   
FRAX integrated the future osteoporotic fracture risk associated with clinical risk factors with 
that associated with femoral neck BMD. The incident rates of fractures are country specific and 
provide the clinician with the 10 year probability of hip fracture and the 10 year probability of 
major osteoporotic fracture (clinical vertebral, forearm, hip and shoulder).  FRAX is currently 
being validated in additional longitudinal cohort databases. It is anticipated that in the latter half 
of 2008, the FRAX is available as a software update for DXA equipment. FRAX is now 
available to clinicians online at www.shef.ac.uk/FRAX/ (Dawson-Hughes, B 2008). 
The FRAX provides an estimated fracture risk in a given individual but does not identify the 
level of fracture risk at which treatment should be started  (“Intervention  threshold”).  
Limitations 
FRAX model is a model in progress. It does not include spinal BMD data or bone turnover 
markers, as bone marker data is not available from many of the countries that contributed 
longitudinal cohorts to generate the FRAX.  Also, FRAX does not include data on BMD 
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measured at the peripheral skeletal sites.  Most patients studied for fracture risk were women, 
and data on ethnic groups in the US are limited.  The FRAX cannot be used in patients who have 
been treated with osteoporosis medications since the probability of fracture may be 
overestimated. 
ASCO Guidelines for prevention of AIs Induced bone loss 
Any patient initiating or receiving an AI with a T-score  ≤-2.0 and no other fracture risk factors 
should be monitored every 1-2 years for change in risk status or BMD loss. If these patients 
experience  an  annual  BMD  decrease  ≥5%  (using  the  same  machine),  secondary  causes  of  bone  
loss such as vitamin D deficiency should be evaluated and bisphosphonate therapy considered 
(zoledronic acid 4mg IV every 6 months). Any patient initiating or receiving AI therapy with 
any 2 of the following risk factors should receive bisphosphonate therapy; T-score <-1.5, age 
>65 years, low BMI (<20 kg/m2), family history of hip fractures, personal history of fragility 
fracture after age 50, use of oral corticosteroids > 6 months, and current or history of smoking. 
Any patient initiating or receiving AI therapy with a T-score <-2.0 should receive 
bisphosphonate therapy, BMD should be monitored every 2 years, and treatment should continue 
for at least 2 years, and possibly for as long as AI therapy is continued (Hillner, BE 2003) .   
Recommended management strategy for preventing and treating bone loss in women with 
breast cancer receiving AI therapy (Hadji, P 2008; Reid, DM 2008 (a)). 
For Post-menopausal women: 
 
a. All women beginning at therapy should receive calcium and vitamin D 
supplements as recommended by previous ASCO guidelines for bone health in 
women with breast cancer.  
b. Patient with a T-score  ≥-2.0 and no other risk factors should be monitored every 
1-2 years for change in risk status or BMD loss. If these patients experience an 
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annual   BMD   decrease   ≥5%,   secondary   causes   of   bone   loss   such   as   vitamin D 
deficiency should be evaluated and bisphosphonate therapy should be considered. 
c. Any patient initiating or receiving AI with any 2 of the following risk factors 
should receive bisphosphonate therapy; T-score <-1.5, age >65 years, low BMI 
(<20 kg/m2), family history of hip fracture, personal history of fragility fracture 
after age 50, oral corticosteroid use of >6 months, and current or history of 
smoking.  
d. Any patient initiating or receiving AI therapy with a T-score <2.0 should receive 
bisphosphonate therapy. 
e. In all patients receiving bisphosphonates, BMD should be monitored every 2 
years, and treatment should continue for at least 2 years and possible for as long 
as AI therapy is continued. 
f. In patients receiving oral bisphosphonates, biochemical markers of bone may be 
measured at 3 months and annually thereafter to monitor patient compliance with 
oral bisphosphonate therapy. 
g. In patients with premature menopause receiving a concomitant aromatase 
inhibitor it is recommended that patients with a T-score of <1 should receive bone 
therapy with a bisphosphonate and follow-up with a DXA scan after 24 months 
intervals and/or measurement of a bone resorption marker, and in patients with a 
T-score of >1 to have a regular follow-up DXSA scan at 24 months intervals 
(Epstein, S 2006) 
1.10 Treatment of osteoporosis 
There are 4 major goals in the treatment of osteoporosis: prevention of fracture: prevention of 
fracture/stabilization or achievement of increased bone mass; relieving symptoms of fracture and 
skeletal deformity; and maximizing physical function (Hodgson, SF 2003; Gass, M 2006). These 
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goals can be achieved by making life style changes (physical activity, fall prevention and taking 
adequate calcium and vitamin D doses), and through pharmacotherepeutic interventions to 
improve bone mineral density. Various drugs are available for the prevention and treatment of 
osteoporosis and for reduction of fracture risk. These are strontium ranalate, bisphosphonates, 
SERMs, calcitonin, teriparatide, oestrogen preparations and denosumab).  
 
Table 1.14 shows the comparison of effect of current treatments licensed for use in UK on 
vertebral, non-vertebral and hip fractures (Cole, Z 2008) and table 1.15 shows the results of 
meta-analysis on anti-fracture risk efficacy of major drugs in postmenopausal women with 
osteoporosis. 
 
1.11 Bisphosphonates 
The main aim of treatment of osteoporosis is to prevent and reduce the frequency of both 
vertebral and non-vertebral fractures especially hip fractures, which are responsible for the high 
morbidity associated with the disease (Boonen S 2005, Cole Z 2008). In last two decades several 
bisphosphonates have been investigated for a wide variety of clinical applications including the 
treatment of osteoporosis, bone metastasis,   Paget’s   disease   and   hypercalcemia   of  malignancy  
etc. (Fleisch, HA 1997; Lacy, MQ 2006; Reginster, JY 2007; Ruggiero, SL 2008). 
Bisphosphonates were first discovered as anti-resorptive agents in 1960 by Fleisch (Watts, NB 
1998). Several clinical trials have proved the efficacy of bisphosphonates for prevention of bone 
loss caused by aging, oestrogen deficiency and glucocorticoid usage, and are licensed for 
prevention and treatment of osteoporosis and fractures in postmenopausal women and 
glucocorticoid-induced osteoporosis. Bisphosphonates reduce bone resorption by reducing the 
activity of osteoclasts and increasing the bone apoptosis (Fleisch, H 1998; Riggs, BL 2002; 
Anastasilakis, AD 2008).  
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They are categorized into 2 major structural classes, based on the presence of a nitrogen 
molecule in the variable side chain; non-nitrogen- and nitrogen-containing bisphosphonates 
(Marcus, R 1999). The nitrogen-containing bisphosphonates (alendronate, ibandronate, 
pamidronate, risedronate, zoledronic acid) are generally more potent than the non-nitrogen-
containing bisphosphonates (clodronate, etidronate, and tiludronate). They are also classified 
according to the first-generation (etidronate), second-generation (alendronate and pamidronate) 
and the third generation bisphosphonate (risedronate) (table 1.16). The antiresorptive properties 
of bisphosphonates have increased approximately ten fold between different drug generations 
(Empana, JP 2004). Alendronate, risedronate and ibandronate are mostly used for the prevention 
and treatment of osteoporosis (Gass, M 2006), while pamidronate and zoledronic acid are 
essentially used for prevention of bone complications and the treatment of severe hypercalcemia 
associated with multiple myeloma or bone metastasis from breast and prostate cancers (Hillner, 
BE 2000; Berenson, JR 2002). Recently zoledronic acid has been extensively studied and has 
proven efficacy in cancer treatment induced bone loss (CTIBL) and AI-associated bone loss 
(Bundred, NJ 2006; Brufsky, A 2007; De Boer, R 2007; Gnant, MF 2007; Logman, F, B. Heeg, 
M. F. Botteman MF 2007; Schenk, N, A. Lombart, A. Frassoladti , et al. 2007). 
 
Alendronate and risedronate are currently the preferred therapy for the treatment of osteoporosis. 
They increase the bone mass and decrease the risk of both vertebral and non-vertebral fractures 
by reducing bone turnover, increasing bone mass, and improving the bone strength. Both the 
drugs have shown reduction in new vertebral fractures by 40% to 50% after 3 years of treatment 
in postmenopausal women with osteoporosis, including those with radiologically verified 
vertebral fractures at baseline (Miller, PD 2005). 
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Increase adherence to the treatment with bisphosphonates was achieved by prolonging the 
administration of the drugs from once daily to once weekly (alendronate and risedronate) and 
then later to once monthly (ibandronate) (Empana, JP 2004). 
 
Table 1.17 shows the names, doses and route of established drugs used for the treatment of 
osteoporosis (Rachner, TD 2011).  
 
1.11.1 Risedronate 
Risedronate is a potent, third-generation bisphosphonate currently used for the treatment of 
diseases characterized by increased bone resorption. Risedronate inhibits osteoclast-mediated 
bone resportion and modulates bone metabolism. It acts on bone metabolism by binding and 
blocking the enzyme farnesyl diphosphate synthase in the mevalonate pathway, which prevents 
the formation of two metabolites (farnesol and geranylgeraniol) that are essential for connecting 
small proteins to the cell membrane. This phenomenon is known as prenylation, and inhibition 
of this process affects many proteins found in osteoclasts. Risedronate is FDA-approved for the 
prevention and treatment of postmenopausal osteoporosis, and prevention and treatment of 
glucocorticoid-induced osteoporosis (Morgan, SL 2008). The efficacy of risedronate in reducing 
the risk of fracture in postmenopausal women with osteoporosis has been demonstrated in many 
clinical trials (Harris, ST 1999; Hooper, M, P. Ebeling, A. Roberts, M. D'Emden, G. Nicholson 
C. Crusan, D Wenderoth, D. Ethgen 1999; Miller, PD 1999; Fogelman, I 2000; McClung, MR 
2001; Harrington, JT 2004; Boonen, S 2005; Rosen, CJ 2005). In the North American and 
Multinational Vertebral Efficacy with Risedonate Therapy trials (VERT-NA and VERT-MN), 
the relative risk of new vertebral fractures was reduced by 49% at 0 to 3 years, and by 59% at 4 
to 5 years when risedronate was compared with placebo (Harrington, JT 2004; Roux, C 2004). In 
the VERT-NA trial, 2458 women with postmenopausal osteoporosis and pre-existing vertebral 
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fracture were treated for 3 years with risedronate (5mg/d). In this trial, the risk of non-vertebral 
fracture was reduced by 39% when compared with placebo. In clinical trials, risedronate reduced 
the risk of both clinical vertebral and non-vertebral fractures as early as 6 months after the start 
of therapy (Harrington, JT 2004; Roux, C 2004). The FDA-approved 5mg/day or 35mg/weekly 
dose of risedronate is the same for either the prevention or treatment of postmenopausal 
osteoporosis (Epstein, S 2006). Oral once weekly risedronate has shown beneficial results in 
preventing bone loss or improved bone mass, decreased bone turnover. It is well tolerated both 
in postmenopausal women without breast cancer (Rosen, CJ 2005; Reid, DM 2008), and in 
postmenopausal women with breast cancer receiving AI therapy (Greenspan, SL 2008). 
 
The bone sub-study of the IBIS-II is aimed at investigating the effect of risedronate in 
preventing bone loss associated with anastrozole in women who were osteopenic or osteoporotic 
at baseline. Therefore the effect of risedronate in postmenopausal women with osteopenia and 
osteoporosis are discussed below. 
 
1.11.1.1 Effect of Risedronate in postmenopausal women with osteopenia 
According to the new National Osteoporosis Foundation (NOF) guidelines, osteopenic women 
with a T-score less than -2.0 by central DXA with no risk factors, and those with T-scores less 
than -1.5 with one or more risk factors for fractures should be treated with bisphosphonates. 
However, there is limited clinical data to support therapeutic intervention in this group. 
Osteopenic patients were identified from four controlled trials (BMD Multinational, BMD North 
America, VERT-MN and VERT-NA), who had received 5mg risedronate daily for 1.5 to 3 years 
compared to placebo. Results in 620 postmenopausal women showed that risedronate 
significantly reduced the risk of fragility fracture by 73% over 3 years (Siris, ES 2008). In two 
other studies on postmenopausal women with osteopenia, at 24-months, 5mg/day of risedronate 
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was associated with the prevention of bone loss at the spine and hip (Fogelman, I 2000; 
Valimaki, MJ 2007). 
 
1.11.1.2 Effect of risedronate and other bisphosphonates on breast cancer 
patients with or without AI therapy 
In the last decade, the efficacy of bisphosphonates for the prevention of bone loss during 
adjuvant therapy for early stage breast cancer has been examined. However, there are currently 
no approved treatment or prevention therapies for Cancer-Treatment Induced Bone Loss 
(CTIBL) or Aromatase Inhibitor-associated bone loss (AIBL). Two small studies on 
postmenopausal women with breast cancer receiving oral clodronate, and premenopausal women 
with chemotherapy-induced menopause receiving oral risedronate, showed increases in BMD 
after 2 years of bisphosphonate treatment (Delmas, PD 1997; Saarto, T 1997 (a & b)). However, 
the 10-year follow-up of women receiving oral clodronate found that BMD loss was slowed but 
not prevented (Saarto, T,2006). Various randomized trials are currently on going to determine 
whether oral and IV bisphosphonate can prevent bone loss during AI therapy. In the Risedronate 
Effect on Bone loss in Breast Cancer trial (REBBeCa), postmenopausal women who received 
anastrozole and risedronate had a significant bone loss at spine and no loss at hip after 24 
months of treatment (Greenspan, SL 2007; Greenspan, SL 2008).  
 
The on-going Study of Anastrozole with the Bisphosphonate Risedronate (SABRE) is a phase 
III/IV trial which is evaluating the benefit of including risedronate with anastrozole in 
preventing bone loss in postmenopausal women with HR-positive early-stage breast cancer (Van 
Poznak, C 2010). Risedronate was administered to patients based on their risk of fragility 
fracture. At 12 months, risedronate reduced bone marker levels and prevented bone loss in 
osteopenic patients receiving anastrozole (Van Poznak, C 2010). A 1-year analysis from the 
Arimidex-Bondronat study (ARIBON), found that monthly ibandronate prevented bone loss in 
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osteopenic women (n=25) compared with placebo with pre-existing osteoporosis (Lester, JE 
2008). In a prospective open cohort study, osteoporotic postmenopausal women with early breast 
cancer were treated with anastrozole and risedronate. The 1-year results showed that bone loss 
was prevented at hip, and increased at the spine (Confavreux, CB 2007). Another study 
conducted among Japanese women with breast cancer reported that bone resorption markers 
were reduced in patients who received anastrozole and alendronate (Yamada, K, N. Kohno, K. 
Endoh K, et al. 2006). The primary limitation of the above mentioned studies using oral 
bisphosphonates is that they were inadequately powered, and the duration was too short to 
provide sufficient evidence to make firm recommendations. However, this data does suggest that 
oral bisphosphonate can prevent bone loss in breast cancer patients receiving AI therapy.  
 
To date, the largest concentrations of data in support of bisphosphonate therapy to prevent AI-
induced bone loss (AIBL) comes from 4 independent stage IV bisphosphonate studies (ABCSG-
12, Z-FAST, ZO-FAST, E-ZO-FAST) (Brufsky, A 2007; Gnant, MF 2007; Schenk, N, A. 
Lombart, A. Frassoladti , et al. 2007; Bundred, NJ 2008), which included 2600 pre- and 
postmenopausal women with early breast cancer. Results from all the 4 studies showed that 
breast cancer patients who received up-front zoledronic acid experienced an increase in lumbar 
spine and total hip BMD (Brufsky, A 2006; Brufsky, A 2007; De Boer, R 2007). Evidence from 
all these randomized controlled trials indicates that 4 mg zoledronic acid when administered 6 
monthly can prevent AIBL in both pre- and postmenopausal women. 
 
There is a hope that bisphosphonate therapy in combination with an AI will offer the potential to 
prevent AI-induced bone loss in patients with early breast cancer, and also in postmenopausal 
women in a chemoprevention setting. 
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1.11.2 Adverse effects of bisphosphonates  
1.11.2.1 Gastrointestinal side-effects 
Bisphosphonates are usually well tolerated, with the most common adverse effects being 
gastrointestinal disturbance such as nausea, heartburn, oesophageal irritation, oesophagitis, 
abdominal pain and diarrhoea. Oesophagitis is a potentially serious side effect reported in a 
small percentage of patients (de Groen, PC 1996; Perkins, AC 2001). The gastrointestinal 
disturbance associated with bisphosphonates can be best avoided if the drug is taken in the 
morning with a glass of water and if the patient remains upright for 30 minutes until breakfast is 
taken (Cole, Z 2008) . 
 
Recently, osteonecrosis of the jaw (ONJ), characterized by the presence of exposed bone in the 
oral cavity, has been reported as an uncommon event in patients with cancer who are receiving 
treatment regimens that include IV bisphosphonates, and in a very small number of patients 
receiving oral bisphosphonates for indications other than cancer (Weitzman, R 2007).  
 
1.11.2.2 Osteonecrosis of the jaw  
Osteonecrosis of the jaw (ONJ) is defined as exposed bone in the maxillary area that occurs in 
association with dental surgery or occurs spontaneously, with no evidence of healing (Pendrys, 
DG 2008). ONJ is an extremely painful condition that presents with exposure of the mandibular 
or maxillary bones and results in vulnerability to bone loss, tooth loss and oral infection (Woo, 
SB 2006). There is increasing awareness of the risk of osteonecrosis of the jaw developing in 
patients taking bisphosphonates. Approximately 94% of cases of osteonecrosis of the jaw among 
bisphosphonate users have been reported among cancer patients who received the most potent 
intravenous bisphosphonate formulations (Shoback, D 2007; Hess, LM 2008) .  
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The exact mechanism for the development of ONJ is unclear. Recent oral surgery, tooth 
extraction, denture use, and poor oral hygiene are factors, which have been implicated in 
osteonecrosis of the jaw among patients taking bisphosphonates (Kademani, D 2006; Ruggiero, 
SL 2006; Ruggiero, SL 2008). The incidence of ONJ in oral bisphosphonate therapy users for 
the treatment of osteoporosis is low (1 in 10,000 to 1 in 100,000), but this figure is expected to 
rise as awareness of the complication grows, and as more data is collected (Arrain, Y 2008). The 
prevalence of ONJ in patients with cancer receiving intravenous bisphosphonate varies from as 
low as 1.2% to as high as 28.0%, depending on the study design, the type and duration of 
bisphosphonate therapy, the cancer population, and the clinical parameters assessed (Nicolatou-
Galitis, O 2011). 
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Figure 1.1:Metabolic pathways for converting of androgens to estrogens by the aromatase enzyme 
complex (Cuzick, J 2005) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Name of some of the trials that used LHRH analogues in addition to endocrine and/or 
chemotherapy (Cuzick, J 2008). 
 
 
Name of the trial Number of 
patients 
ECOG E5188 (Eastern Cooperative Oncology Group 1536 
ZEBRA (Zoladex Early Breast Cancer Research Association) 1640 
ABCSG (Austrian Breast and Colorectal Cancer Study Groups) 1037 
IBCSG VIII (International Breast Cancer Study Group)  1109 
GABG IV-A-93 (German Adjuvant Breast Cancer Study Group) 771 
ZIPP Stockholm (Zoladex in Premenopausal Patients) 926 
TABLE (Takeda Adjuvant Breast Cancer Study with Leuprorelin) 589 
ZXBC (Zoladex Breast Cancer Study Group) 207 
FASG 06 (French Adjuvant Study Group)  331 
 
 
 
 
 
 
 
 
Androstenedione
Estrone
Estrone sulphate
Testosterone
Estradiol
Proliferation of breast 
cancer cells
Aromatase inhibitor
Aromatase enzyme complex
17 ß-HSDH
17 ß-HSDH
Fat 
Liver
Muscle
Breast cancer cells
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Table 1.2: Aromatase Inhibitors by Class and type 
Class Type I (Steroidal) 
 
Type 2 (Non-steroidal) 
First generation 
 
None Aminoglutethimide 
Second generation 
 
Formestane Fadrozole 
Third generation Exemestane Anastrozole 
Letrozole 
Vorozole 
 
 
 
 
Table 1.3: Clinical developmental milestones of aromatase inhibitors in postmenopausal patients 
with hormone receptor-positive breast cancer (Sulkes, A 2005) 
Year Treatment 
Late 1970s Aminoglutethimide 
 
1990s Second- and third generation AIs 
 
1996 AIs superior to megestrol acetate as second-line hormone therapy in 
metastatic breast cancer 
 
2000 AIs better than tamoxifen as first-line therapy on advanced breast 
cancer 
2002 Anastrozole better than tamoxifen in adjuvant setting 
 
2003-2004 Sequential use of tamoxifen and either letrozole or exemestane 
more effective than tamoxifen alone as adjuvant therapy 
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Table 1.4: Efficacy of aromatase inhibitors (AIs) in the adjuvant setting: disease survival (Ponzone, 
R 2008) 
Treatment 
strategy 
Protocol FU (months) Relative risk 
reduction (%) 
Absolute risk 
reduction (%) 
Upfront 
ATAC A vs. T 68 
 
17 3.7 
BIG 1-98 L vs. T 51 
 
18 2.9 
Sequential 
IES  T          E vs. T 
 
55.7 26 3.4 
ARNO T          A vs. T 
 
30.1 34 4.2 
ABCSG/ARNO T          A vs. T 
 
28 40 3.1 
ITA T          A vs. T 
 
64 44 7.9 
Extended adjuvant 
MA .17 T          L vs. P 
 
30 42 4.6 
 
FU, follow-up; ATAC, anastrozole, tamoxifen alone or in combination (ATAC Trialists' Group 
2005); BIG, breast International Group (Coates et al. 2007); IES, Intergroup Exemestane Study 
(Coombes et al. 2007); ARNO, ARimidex–NOlvadex (Kaufmann et al. 2007); ABCSG, Austrian 
Breast Cancer Study Group (Jakesz et al. 2005); ITA, Italian tamoxifen anastrozole (Boccardo et al. 
2006); (Jonat et al. 2006); MA 17, (Goss et al. 2005); Ana, anastrozole; Tam, tamoxifen; Let, 
letrozole; Exe, exemestane. 
 
Table 1.5: Summary of adverse events with AI class effect 
 
Favourable to AIs 
1. Hot flushes and night sweats 
2. Gynaecological events 
3. Thromboembolic disease 
Unfavourable to AIs (Favourable to tamoxifen) 
1. Skeletal complications 
2. Arthralgia and musculoskelatal pain 
3. Sexual dysfunction 
Adverse events without Ai class effects, specific to given AIs 
1. Lipid metabolism 
2. Cardiac events 
3. Cerebrovascular events 
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Table 1.6: Ongoing clinical trials testing the role of aromatase inhibitors for premenopausal patients 
with endocrine-responsive breast cancer 
 
Study Design 
ABCSG 12    Tamoxifen + GnRH ± bisphosphonate 
Anastrozole + GnRH ± bisphosphonate 
 
BIG SOFT Tamoxifen x 5 years 
OFS + tamoxifen x 5 years 
OFS + exemestane x 5 years 
 
BIG TEXT GnRH (± CT) + tamoxifen x 5 years 
GnRH (± CT) + exemestane x 5 years 
 
ABCSG =Austrian Breast and Colorectal Cancer Study Group (Gnant, MF 2007); BIG TEXT= Breast 
International Group Tamoxifen and Exemestane; CT=chemotherapy; IBCSG=International Breast Cancer 
Study; GnRH= gonodotropin-releasing hormone; OFS=ovarian function suppression with oophorectomy or 
ovarian radiation or LHRH analogue; BIG SOFT= Suppression of Ovarian Function Trial (Regan, MM 
2008). 
 
 
 
 
 
Table 1.7: Breast cancer prevention trials using tamoxifen 
 
Trial (Entry dates) Population Number 
randomized 
Agents (vs. placebo) 
and daily dose (mg) 
Intended 
duration of 
treatment 
(years) 
Royal Marsden 
(1986-1996) 
High-risk 
Family history 
2,470 Tamoxifen 20 5-8 
NSABP-PI  
(1992-1997) 
High-risk women 
>1.6% 5 year risk 
13,388 Tamoxifen 20 5 
Italian  
(1992-1997) 
Normal risk 
Hysterectomy 
5,408 Tamoxifen 20 5 
IBIS-I 
(1992-2001 
>2-fold relative risk 7,139 Tamoxifen 20 5 
Adjuvant overview 
(1976-1995) 
Women with ER+ 
operable breast 
cancer in 11 trials 
~ 15,000 Tamoxifen 20-40 
with or without 
chemotherapy in both 
arms 
3 or more 
(average ~5) 
Royal Marsden (Powles, T 1998); NSABP-PI (Fisher, B 2005); Italian (Veronesi, U 1998); IBIS-I 
(Cuzick, J 2002); Adjuvant overview (Cuzick, J 2003) 
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Table 1.8: Prevention trials using raloxifene 
 
Trial (Entry 
dates) 
Population Number 
randomised 
Agents (vs. placebo) 
and daily dose (mg) 
Intended 
duration of 
treatment 
(years) 
MORE 
(1994-1999) 
 
Normal risk 
 
Postmenopausal 
women with 
osteoporosis 
7,705 Raloxifene 60 or 120 
(3 arms) 
4 
CORE 
(2000-2004) 
 
Normal risk 
 
Postmenopausal 
women with 
osteoporosis 
4011 Raloxifene 60 Additional 
4 
RUTH 
(1998-2000) 
 
Normal risk 
 
Postmenopausal 
women with 
osteoporosis 
10,101 Raloxifene 60 5 
STAR 
|(2001-2005) 
 
High-risk post-
menopausal women 
>1.6% 5 years breast 
cancer risk 
19,747 Raloxifene 60 vs. 
tamoxifen 20 
5 
MORE (Ettinger, B 1999); CORE (Martino, S 2004) ; RUTH (Mosca, L 2001) ; STAR (Bevers, TB 
2007) 
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Table 1.9: Effect of AIs on bone mineral density  
Trial Treatment arms F-up BMD 
(% change) 
 
LS TH FN 
ANASTROZOLE 
ATAC 
 
(308 EBCP) 
 
 
A vs. T 1 yr 
 
-2.6 vs. 1.2 
P<0.001 
-1.7 vs. 0.8 
P<0.001 
 
2yr 
 
-3.2 vs. 1.9 
P<0.001 
-4.0 vs. 1.2 
P<0.001 
- 
5 yr -6.1 vs. 2.8 
 P<0.001 
-7.24 vs. 0.7 
P<0.001  
 
- 
LETROZOLE 
MA.17 
 
 (122 EBCP ) 
 
T   
T  T 5yrs         
 
L vs. T for 5 yrs 
 
 
12 months 
 
 
   24 months 
-3.3 vs. -2.5 
(P=0.64) 
 
-5.4 vs. -0.7 
(P=0.008) 
-1.4 vs. -2.4 
(P=0.68) 
 
-3.6 vs. -0.7 
(P=0.044) 
- 
EXEMESTANE  
IES 
 
 (206 EBCP) 
T   T 2-3yrs         
E vs. T for 5 yrs 
 
24 months -3.2 vs. -0.2 
 
(P<0.0001) 
-2.2 vs. -0.6 
 
(P<0.0001) 
NR 
TEAM 
 
(538 EBCP) 
 E vs. T for 5 yrs 12 months 
 
 
24 months 
-2.8 vs. 1.2 
(P=0.008) 
 
-3 vs. -0.4 
(P=0.02) 
-1.1 vs. 1.6 
(P=0.09) 
 
-2.5 vs. -0.7 
(P=0.46) 
NR 
 
 
NR 
Lonning et al  
 
 (128 EBCP) 
E vs. P for 2 yrs 12 months -2.17 vs. 1.84 
(P=0.658) 
- -2.72 vs. 1.48 
(P=0.24) 
Gonnelli et al  
 
 (70 EBCP) 
 
T  T 2-3yrs         
E vs. T for 5 yrs 
 
12 months 
 
 
24 months 
-2.37 
(P<0.05) 
 
-2.99 
(P<0.01) 
 
NR 
 
 
-2 
(P<0.05) 
 
-1.2 
(P<0.05) 
 
-1.9 
(P <0.1) 
 
LEAP 
 
  (90 HPMW) 
 
A vs. L vs. E 24 weeks T-score 
values 
 
-0.1 
 
 
T-score values 
 
-0.1 
 
A=anastrozole; L=letrozole; E=exemestane; P=placebo; P=placebo; LS =lumbar Spine; TH= Total Hip; 
FN=Femoral neck; EBCP = early breast cancer patients; HPMW=healthy postmenopausal women; NR= not reported. 
ATAC (Eastell, R 2006; Eastell, R 2008); MA.17(Perez, EA 2006); IES (Coombes, RC 2007); TEAM 
(Hadji, P 2009); (Lonning, PE 2005); (Gonnelli, S 2007); LEAP (McCloskey, EV 2007) 
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Table 1.10: Effect of AIs on fracture rate 
Trial Treatment arms F-up 
 
Clinical fracture rate (%) 
ANASTROZOLE 
ATAC 
 
 
 
A vs. T 33 months 11.0 vs. 7.7 
             P <0.0001 
 
68 months 5.9 vs. 3.7 
P<.0001 
 
100 months  12 vs. 7.7 
               P<.0001 
ARNO 95/ ABCSG 
8 
T  T   2yrs         
A vs. T for 3 yrs 
 
28 2 vs. 1 
P=0.015 
ITA  
 
 
T   T 2-3 yrs         
A vs. T for 2-3 yrs 
 
36 1.0 s. 1.3 
 
P=0.06 
LETROZOLE 
BIG 1-98 
 
L vs. T (5 yrs) 4.25 yr 8.6 vs. 5.8 
 
(P<0.001) 
 
MA.17  
 
T  T   5yrs         
L vs. P for 5 yrs 
 
24 5.3 vs. 4.6 
 
(P=0.25) 
 
Z-FAST  
 
 
L L + upfront ZA vs.  
 L + delayed ZA 
 
12 month 
Low-trauma 
fracture 
 
Traumatic fractures 
 
1 vs. 0.7 
 
2.3 vs. 2 
 
ZO-FAST  
L  L + upfront ZA vs.  
  L + delayed ZA 
12 month 
 
8 vs. 9 
EXEMESTANE 
IES T T 2-3yrs         
E vs. T for 5 yrs 
 
30 months 7.0 vs. 4.9 
 
(P=0.003) 
NSABP B-33 T  T   5yrs         
E vs. P for 2 yrs 
 
24 months 28 fractures vs. 20 fractures 
 
(P=0.33) 
E=exemestane; A=anastrozole; L=letrozole; T=tamoxifen; ZA=zoledronic acid; P=placebo; ATAC 
(Howell, A 2005; Baum, M 2006; Forbes, JF 2008); ARNO 95/ ABCSG 8 (Jakesz, R 2007); ITA (Boccardo, 
F 2005); BIG 1-98 (Coates, AS 2007); MA.17 (Perez, EA 2006); Z-FAST (Bundred, NJ 2006); ZO-
FAST (Gnant, MF 2007); IES (Coombes, RC 2007); NSABP B-33 (Mamounas, EP 2008) 
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Table 1.11: Effect of anastrozole on lipid profiles 
Study/Authors Treatment  N Duration                         Results 
TC LDL-C HDL-C TG 
Anastrozole 
ITA trial T 2-3yrs  
A vs. T for 2-3 yrs 
 
448  Hypercholesterolemia 
18 vs. 6 
(P= 0.04) 
 
 Japanese study  
 
 
A  vs. T 
Upfront 
44 12 weeks  NC NC +10.2 
 
P<0.001 
Reduced 
P=0.003 
vs. 
baseline 
 IMPACT trial A vs. T 
 
Neoadjuvant  
Upfront 
176 12 weeks + 2.9  (NS) + 3.4  
(NS) 
+ 11.2 
 
P<0.05 
NR 
ATAC trial 
 
A vs. T 
 
Adjuvant  
Upfront 
9366 
 
 
 Hypercholesterolemia 
 
9.0 vs. 3.5 
 
 LEAP trial  
Healthy women 
A vs. L vs. E 90 12 weeks  
24 weeks 
36 weeks 
-2.4 
+0.3 
-0.6 
-2.8 
+1.3 
-0.6 
-1.8 
-0.3 
0.5 
-2.9 
+0.2 
-6.7 
Letrozole 
BIG 1-98 trial L vs. T 
 
Adjuvant 
Upfront 
 
2463 
 
5 yrs +43.6 vs. 
+9.2  
ND ND ND 
Hypercholesterolemia 
51 vs. 25 
P<0.001 
MA.17 trial T  T 5yrs         
 
L vs. P for 5 yrs 
 
347 5 yrs Hypercholesterolemia 
16 vs. 16 
(P= 0.79) 
 
LEAP trial A vs. L vs. E 90 12 weeks  
24 weeks 
36 weeks 
-3.7 
0.0 
    +2.3 
   -4.1 
+1.2 
  +2.3 
-3.5 
-2.9 
1.8 
9.6 
5.3 
10.7 
Exemestane 
 Harper-Wynne et al 
2002 
HPMW 29 3 months NC NR 
 
TEAM Greek  
 
E   vs. T 
 
Adjuvant  
Upfront 
176 6 months 
 
 
12 months 
NC 
 
 
NC 
Decreased 
 
 
Decreased 
(P=0.034) 
Decreased  
P= 0.018 
 
Decreas
ed 
(P=0.00
8) 
 
NC 
 
ATENA study E vs. 
Observation 
 
Switch trial 
340 12months NS increase 
 
Increased 
(P= 0.01) 
NS 
decrease 
 
 
NS 
decrease 
 
 
Lonning et al 
2005 
E vs. T 64 24 months NC NC decreased 
P<0.0001 
NC 
 
 LEAP  A vs. L vs. E 90 12 weeks 
24 weeks 
36 weeks 
-5.5 
-3.9 
1.8 
-3.5 
-0.5 
3.3 
-10.4 
-13.9 
-1.7 
 
-7.7 
2.3 
10.7 
NC=no change; NS=not significant; NR= not reported; E=exemestane; A=anastrozole; L=letrozole; ITA trial 
(Boccardo, F 2005); Japanese study (Sawada, S 2005); IMPACT trial (Banerjee, S 2005) ; ATAC (Buzdar, A 2006); LEAP trial 
(McCloskey, EV 2007); BIG 1-98 trial (Thurlimann, B 2005); MA.17 trial (Wasan, KM 2005); TEAM Greek (Markopoulos, C 
2005); ATENA (Markopoulos, C 2005); (Lonning, PE 2005) 
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Table 1.12: Distribution of cortical and trabecular bone 
 
Distribution of bone Trabecular Cortical 
 
Thoracic spine 
 
75% 25% 
Mid radius 5% 
 
95% 
Distal radius 25% 
 
75% 
Femoral neck 25% 
 
75% 
Hip intertrochanteric 
region 
50% 50% 
 
 
       Table 1.13: Risk factors for osteoporosis  
1. Personal medical history of non-traumatic fracture (such as a fall from a 
standing height or less) 
 
2. Low peak BMD 
 
3. Body weight of <127 lbs 
 
4. Unexplained cessation of menstruation 
 
5. Anorexia nervosa 
 
6. Low lifetime calcium intake 
 
7. Vitamin D deficiency 
 
8. Lifestyle lacking weight-bearing exercise 
 
9. Alcohol consumption >2 drinks per day 
 
10. Cigarette smoking 
 
11. Family medical history of non-traumatic fracture) primary relative) and/or 
osteoporosis 
 
12. Chronic diseases related to secondary osteoporosis 
 
13. Long-term use (>6months) of some medications (such as corticosteroids, 
medroxyprogesterone (Depo Provera), thyroid hormones, anticonvulsants, 
aluminium-containing antacids, methotrexate sodium, cholestyramine) 
 
14. White or Asian race 
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Table 1.14: Comparison of effect of current treatment licensed for use in UK on vertebral, non-
vertebral and hip fractures (Cole, Z 2008) 
 
Drug Fracture reduction (%) 
Vertebral Hip Non-vertebral 
Alendronate ++ ++ ++ 
Risedronate ++ ++ ++ 
Ibandronate ++ NS NS 
Zolendronic acid ++ ++ ++ 
Teriparatide ++ NS ++ 
Strontium renalate ++ ++ ++ 
Raloxifene ++ NS NS 
NS=not significant 
 
 
 
 
 
 
 
 
Table 1.15: Anti-fracture risk efficacy of major drugs in postmenopausal women with osteoporosis: 
results of meta-analysis (Iwamoto, J 2006)  
 
Drugs Vertebral fractures Non-vertebral fractures 
RR (95% CI) P value RR (95% CI) P value 
Calcium 0.77 (0.54,1.09) 0.14 0.86 (0.43, 1.72) 0.66 
Vitamin D 0.63 (0.45, 0.88) <0.01 0.77 (0.57, 1.04) 0.09 
Etidronate 0.63 (0.44, 0.92) 0.02 0.99 (0.69, 1.42) 0.97 
Alendronate 0.52 (0.43, 0.65) <0.01 0.51 (0.38, 0.69) <0.01 
Risedronate 0.64 (0.54, 0.77) <0.01 0.73 (0.61, 0.87) <0.01 
Raloxifene 0.60 (0.50, 0.70) 0.01 0.91 (0.79, 1.06) 0.24 
Calcitonin 0.79 (0.62,1.00) 0.05 0.80 (0.59, 1.09) 0.16 
HRT 0.66 (0.41, 1.07) 0.12 0.87 (0.71, 1.08) 0.10 
Fluoride 0.67 (0.38, 1.19) 0.17 1.46 (0.92, 2.32) 0.11 
HRT=hormone replacement therapy; RR=relative risk; CI=confident interval 
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Table 1.16 Classifications of Bisphosphonates 
 
Nitrogen-containing compounds 
1. Pamidronate 
2. Alendronate 
3. Risedronate 
4. Zoledronate 
5. Ibandronate 
Non-nitrogen containing compounds 
1. Etidronate 
2. Clodronate 
3. Tiludronate 
 
 
 
Table 1.17: Established Treatment for osteoporosis (Rachner, TD 2011) 
 
Drug Dose Interval Route 
Alendronate 70mg Weekly Oral 
Risedronate 35 or 50 mg Weekly or monthly Oral 
Ibandronate 150 mg Monthly Oral 
Ibandronate 3mg Every 3 months IV 
Zoledronic acid 5 mg Yearly IV 
Raloxifene 60 mg Daily Oral 
Strontium ranelate*  2 g Daily Oral 
Teriparatide 20μg Daily SC 
PTH (1-84) ++ Μg Daily SC 
 
IV=intravenous; SC=subcutaneous; *approved in more than 70 countries; ++ Approved in Europe 
but not in USA. 
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                                     Chapter 2: Review of literature 
 
Section-I: Effect of Anastrozole on bone mineral density and fracture rate 
 
2.1.1 Introduction 
The purpose of this section is to review all the studies on the effect of anastrozole on bone 
mineral density and fracture rate in postmenopausal women when compared with placebo or 
other endocrine therapy; and with or without concomitant bisphosphonate therapy. The review 
was last updated in June 2008. 
 
IBIS-II prevention study is currently the only trial recruiting healthy postmenopausal women 
with high risk of breast cancer to study the benefit of anastrozole in a chemoprevention setting. 
The bone sub-study will study the effect of anastrozole on BMD, and the effect of oral 
bisphosphonate (risedronate) treatment on BMD among given concomitantly to women who had 
an osteopenic or osteoporotic T-scores at the time of joining the trial. 
 
There is a hope that bisphosphonate therapy in combination with anastrozole will offer the 
potential to prevent bone loss in postmenopausal women in a chemoprevention setting.                                                                                                                                                                    
 
2.1.2 Criteria for considering studies for this review 
2.1.2.1 Type of studies/participants 
Randomised and non-randomised trials that recruited a minimum of 50 pre- or postmenopausal 
women and who received anastrozole in an adjuvant, neo adjuvant or a chemoprevention setting 
were considered for the review.  
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2.1.2.2 Type of Intervention 
Intervention included all doses of anastrozole for the duration of at least 3 months.  
  
2.1.2.3 Type of outcome measures 
1. Changes in bone mineral density levels by DXA. 
2. Fracture rate  
 
2.1.3 Search strategy for identification of studies 
The data was searched between Jan 2008-March 2008, and last updates in June 2008. Searches 
of databases including Web of Science, Pub Med and Embase were used to identify publications. 
The electronic search strategy through MEDLINE consisted of the following key text words 
#1 anastrozole 
# 2 aromatase inhibitors 
#3 (#1 AND # 2) 
#4 postmenopausal women 
#5 (#3 AND #4) 
# 6 premenopausal women  
#7 (#5 AND #6) 
#8 early breast cancer or chemoprevention 
#9 bone mineral density 
#10 (#7 AND #8 AND #9)  
#11 Fracture rate 
#12 (#10 AND #11)  
#13 bone loss 
#14 (#12 AND #13)  
Also searched: 
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(Anastrozole or aromatase inhibitors) AND (postmenopausal women) AND (early breast 
cancer), (chemoprevention) AND (bone mineral density) or (bone metabolism) 
 Relevant review articles or related other articles located in the reference lists were 
searched for relevant trials.  
 Data from abstracts accepted at major conferences in the last two years are also included 
in the review as limited data is available from the published data in the journals. 
    
2.1.4 Review of randomised and non-randomised trials (Anastrozole) 
2.1.4.1 Description of studies 
A total of six studies were chosen for the review (table 2.1.1). 
One trial reported the effect of anastrozole on bone mineral density at 1, 2 and 5 years, and 
fracture rate when used without bisphosphonate therapy. Two other smaller studies reported the 
effect on bone mineral density when anastrozole was given along with oral bisphosphonates. 
Two studies reported the effect of anastrozole on fracture risk at 2 and 3 years as a severe 
adverse event but did not measure BMD. One study reported the effect of anastrozole on bone 
mineral density and fracture rate after 3 years of anastrozole use when taken concomitantly with 
IV bisphosphonate in premenopausal women.  
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Table 2.1.1: List of trials that investigated the effect of anastrozole on bone mineral density and 
fracture rate 
Trial Treatment Clinical 
fracture 
rate  
BMD change 
 
ATAC  
 
 
No Bisp R R 
ARNO 95/ 
ABCSG 8 
No Bisp 
 
R NR 
ITA  No Bisp 
 
R NR 
SABRE 
 
A with or 
without 
Bisp 
 
NR R 
ARIBON  
 
 
A with or 
without 
Bisp 
NR R 
ABCSG-12 
 
 
A with or 
without 
Bisp 
NR R 
                   A=anastrozole R=reported; NR=not reported or investigated;    
Bisp=bisphosphonates; ATAC (Eastell, R 2006; Eastell, R 2008); ARNO 95/ ABCSG 8 (Jakesz, 
R 2007); ITA (Boccardo, F 2005); SABRE (Van Poznak, C 2010); ARIBON (Lester, JE 2008); 
ABCSG-12 (Gnant, MF 2007) 
 
 
 
 
(Eastell, R 2006; Eastell, R 2008) studied a large randomized, double blind trial, the Armidex, 
Tamoxifen, alone or in Combination (ATAC) trial to evaluate the efficacy and tolerability of 
anastrozole 1mg/ day, tamoxifen 20mg/day or a combination of both agents as adjuvant therapy 
in 9366 postmenopausal women with early breast cancer. The combination therapy of the study 
was discontinued following analysis of the main trial at a median follow-up of 33 months. 
Patients with osteoporosis (T-score < -2.5) were excluded from the primary analysis population, 
and those with osteopenia (T-score between -1 and -2.5) were included at the   investigators’  
discretion. An additional 46 postmenopausal women with invasive breast cancer, who were part 
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of normal clinical practise were not receiving any hormonal treatment following primary 
surgery, were recruited as a control group.  
 
A bone sub-protocol was prospectively designed on 308 postmenopausal women. The data 
available for anastrozole (A) and tamoxifen (T) was (A=81; T=86 at year 1), (A=65; T=65 at 
year 2), and (A=57; T=51 at year 5). Patients who entered the bone sub-study had their BMD 
measured through DXA scans of the lumbar spine (LS) and total hip (TH) at baseline, which was 
repeated at 1, 2 and 5 years.  
 
For the lumbar spine, DXA measurement was derived by taking an average of the L1, L2, L3, 
and L4 values. The exclusion criteria included were use of hormone replacement therapy or 
bisphosphonates within the last 12 months of randomisation or during the study; bone fracture 
within 6 months before randomisation; use of anticonvulsant or corticosteroid therapy. A history 
of chronic renal/hepatic impairment, malabsorption syndrome, or endocrine disorders was also 
not allowed. Participants were not routinely supplemented with vitamin D or calcium tablets.  
 
 
(Jakesz, R 2005)  reported the effect of anastrozole on fracture rate in the Australian Breast and 
Colorectal Study Group / Arimidex-Nolvadex study (ABCSG-8 / ARNO-95) study. The 
ABCSG-8 / ARNO 95 trial was a prospective planned, multicentre, randomized, open labels 
trial. Postmenopausal women aged 80 years or younger with invasive HR-positive breast cancer, 
who had completed 2 years of tamoxifen, were randomised to receive either anastrozole for 3 
years or continued on tamoxifen for a further 3 years. No bone sub-protocol was planned, and 
women did not receive any BMD measurements at any point in the study. Fractures were 
reported as a serious adverse event at 28 months of follow-up. 
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(Boccardo, F 2005)  reported the results of the Italian Tamoxifen Anastrozole (ITA) trial, which 
was a prospective randomized trial comparing crossover to anastrozole (1mg daily) after 2 to 3 
years of tamoxifen to 5 years of tamoxifen. This was a small study of 448 postmenopausal 
women with HR-positive early breast cancer. No BMD data was collected in this study. 
Fractures were reported as a serious adverse event at 36 months of follow-up. 
 
(Van Poznak, C 2010) reported one year results from the SABRE (Study of Anastrozole with 
the Bisphosphonate Risedronate). This is a Phase III/IV trial that is currently on-going and is 
evaluating the benefit of including risedronate with anstrozole in preventing bone loss in 
postmenopausal women with HR-positive early breast cancer. Risedronate was administered to 
patients based on their risk of fragility fracture. A total of 234 women were randomised. 42 
classified   as   lower   risk   (T   score   ≥   -1) were treated with anastrozole alone. 38 patients in the 
higher risk group (T score  ≤  -2 and/or history of fracture), received anastrozole and risedronate, 
whereas   the   154   patients   in   the   moderate   risk   group   (T   score   between   ≤-1   and   ≥-2) were 
randomized to receive anastrozole with or without risedronate. All patients were recommended 
to take vitamin D and calcium supplementation. 
 
(Lester, JE 2008) reported one year results from the ARIBON (Arimidex Bondronat) trial. The 
trial recruited 131 postmenopausal women with surgically treated breast cancer to receive 
anastrozole plus 150 mg oral ibandronate or placebo every month for 1 year. All patients were 
treated with anastrozole 1 mg once a day and calcium and vitamin D supplementation. In 
addition osteopenic patients were randomized to receive either treatment with ibandronate 150 
mg every month or placebo. BMD were measured at baseline, 1 and 2 year. 
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(Gnant, MF 2007) reported 3 years results from the Austrian Breast and Colorectal Cancer 
Study Group (ABCSG-12) trial. This study is a randomized, open label, phase III, four arm trial 
comparing tamoxifen (20mg/day orally) and goserelin (3.6 mg every day subcutaneously). 
Premenopausal women who had undergone primary surgery for early stage HR-positive breast 
cancer were assigned to receive either goserelin plus tamoxifen ± zoledronic acid or goserelin 
plus anastrozole ± zoledronic acid for 3 years. In the ABCSG-12 bone sub-protocol, BMD 
measurements of 401 patients were evaluated for BMD loss. Patients underwent DXA of LS and 
TH at baseline and at 6, 12, 36, and 60 months. The exclusion criteria included bisphosphonate 
treatment within 1 year before study entry, current or prior bone disease, or chronic 
corticosteroid therapy.  
 
2.1.5 Results  
2.1.5.1 Effect of anastrozole on bone mineral density (table 2.1.2) 
In the ATAC trial, patients on anastrozole had a loss of BMD at LS and TH at 1, 2 and 5 years, 
whereas the tamoxifen group had slight gains in BMD at LS and no change in BMD at TH from 
baseline. For anastrozole, there were significant losses (P<0.001) in median BMD at the LS and 
TH at 1 year (-2.26% and -1.51%, respectively), 2 years (-3.97% and -3.92 %, respectively) and 
5 years (-6.08% and -7.24% respectively). For tamoxifen there were significant gains (P=0.005) 
at the LS and TH at year 1 (+1.42 % and +0.86 %, respectively) at year 2 (+2.12 % and +1.21%, 
respectively) at year 5 (+2.77% and +0.74%, respectively). The increase in median BMD with 
tamoxifen occurred only during the first 2 years, and no additional increase in BMD was seen in 
years 2 to 5 (Eastell, R 2006; Eastell, R 2008).  
 
In the ATAC trial, there was a lower rate of BMD loss at the LS in the anastrozole-treated group 
from 2-5 years compared with baseline to 2 years (mean difference in annual rate of change 
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0.0113; 95% CI 0.006, 0.017; P=0.0002). There was no evidence of slowing down in BMD loss 
at TH. Interestingly, none of the patients who had a normal BMD at baseline developed 
osteoporosis at 5 years. No patients with a baseline T-score above -1.5 developed a BMD T-
score of < -2.5 on treatment. Also, more patients in the anastrozole group were within 1 year of 
menopause compared with the tamoxifen group (11 vs. 2), and at all time points (1, 2 and 5 
years), the rate of BMD loss among women treated with anastrozole was greatest for women 
within 1 year of menopause at randomisation. Furthermore, in the anastrozole treated-group, the 
percentage change in median LS BMD from baseline to 5 years was -6.08% overall and -11.32% 
in patients within 4 years of their last menstrual period (LMP).  
 
In two other smaller studies, women were randomized to receive anastrozole with or without 
bisphosphonates depending upon their baseline T-scores. In the ARIBON study, in the 
anastrozole and placebo group (women with normal BMD), mean declines in BMD were 
observed at 1 and 2 years, both at the LS (-2.35% and -3.22%; CI -16.0, +4.3, respectively) and 
TH (-2.27% and -3.90; CI -12.3, +7.2 respectively). Patients who were osteopenic at baseline 
(N=50), and received ibandronate plus anastrozole, had a significant gain in LS BMD of +3.11 
after 1 year and +2.98% after 2 years. At TH, BMD increased by +0.98% after 1 year, and 
stabilised to +0.60% after 2 years. In the anastrozole plus placebo group, the mean BMD values 
reduced at 1 and 2 years at LS (-2.35% and -3.22%) (Lester, JE 2008). In the SABRE trial at 24 
months, women with a low risk T-score   (≥   -1.0) at baseline (N= 35), who did not receive 
risedronate, had a BMD loss of (-2.1% and -0.4%, respectively) at LS and TH. However, in the 
moderate   risk   group   (T   score   ≤   -1.0   but   ≥   -2.0), among patients (N=73) who received 
anastrozole and risedronate, the BMD gains were (+2.2% and +1.8 %, respectively) compared 
with non-risedronate group (-1.8% and -1.1% respectively) at LS and TH (Van Poznak, C 2010). 
The percentage gain in BMD at TH in the osteopenic group here was similar to 50 patients in the 
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ARIBON study. In the high risk (osteoporotic)  group  (T  score  ≤  -2.0 and/or history of fracture), 
where all the women received risedronate, there was a BMD gain of (+3.0% and +2.0 %, 
respectively) at LS and TH. The BMD losses observed here are lower compared to the results 
from the ARIBON study. It should be noted that in this study all the patients were provided with 
vitamin D and calcium. 
 
In the ABCSG-12 trial (Gnant, MF 2007), among premenopausal women, treatment with 
zoledronic acid overall had a significant bone loss of -14% at 36 months (P<0.001). The bone 
loss in the anastrozole/goserelin therapy was greater (-17.3%; P<0.0001) than observed with 
tamoxifen/goserelin therapy (-11.6 %; P<0.0001). Interestingly, when concomitant zoledronic 
acid was administered to these patients, no significant BMD loss was observed at LS and 
trochanter (P<0.0001), regardless of the type of endocrine therapy administered. In the 
anastrozole/goserelin group, 54% of patients were reported to have osteopenia, and 25% of 
patients were reported to have osteoporosis at 36 months. In the ananstrozole/goserelin group 
with concomitant zoledronic acid use, however, 44% of cases reported osteopenia and none of 
the patients developed sufficiently severe BMD losses to become osteoporotic. 
 
 
2.1.5.2 Effects on fracture rates (table 2.1.3) 
 (Buzdar, A 2006) (ATAC study) observed that the overall, fracture rate was higher in the 
anastrozole group than in the tamoxifen group (5.9% vs. 3.7%, respectively; relative risk (RR), 
1.59; P<0.0001) but there was no difference in the hip fracture rate (0.4% for both groups) (The 
ATAC   Trialists’   Group,   2002). A tolerability update (median treatment duration: 37months), 
showed that the risk of fractures was similar to that reported at 33 months (fracture incidence 
7.1% vs. 4.4% for anastrozole vs. tamoxifen, respectively: RR, 1.60; 95 % confidence interval 
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1.30 to1.97; P<0.0001). The difference in fracture rates observed between the anastrozole and 
tamoxifen group could have been due to either profound oestrogen suppression by anastrozole or 
the partial oestrogen-agonist effect of tamoxifen. AT 68 months, fractures occurred more 
frequently in the anastrozole group than in the tamoxifen group (11% versus 7.7%; p < 0.0001). 
The 100-month analysis results showed that the increased yearly fracture rate noted at 33 and 
68-month treatment did not continue into the post-treatment follow-up period, which shows that 
the increase in fracture rates with anastrozole is associated only with the active treatment period 
and does not continue after its completion (Forbes, JF 2009). In the ARNO 95/ ABCSG 8 study 
by (Jakesz, R 2005) after a median interval of 28 months, there were significantly more clinical 
fractures in patients who switched to anastrozole than in those who received only tamoxifen (1% 
vs. 2%, p=0.015). In another study by (Boccardo, F 2005), at a median interval of 36 months, 
non-significant difference in fracture rates were reported between the anastrozole and tamoxifen 
group (1.0% vs. 1.3% p=0.6). Interestingly, in both the trials mentioned above, the clinical 
fracture rate in the anastrozole group was lower than that seen at a similar point in the ATAC 
trial, suggesting that the prior 2-3 years of tamoxifen use must have reduced the fracture risk 
caused by subsequent anastrozole use.  
 
In the ABCSG-12 trial (Gnant, MF 2007), in premenopausal women who received 
anastrozole/goserelin treatment with or without zoledronic acid, no fracture cases were reported 
at 36 months follow-up.  
 
2.1.6 Conclusion 
Results from the ATAC trial have indicated that anastrozole is associated with increased rate of 
bone loss when compared with tamoxifen alone, in postmenopausal women with HR-positive 
breast cancer, at LS and TH at 1, 2 and 5 years. Anastrozole also showed increased bone losses 
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at LS and TH when given along with goserelin. Results from two smaller studies have confirmed 
these findings on the effect of anastrozole on BMD. Mature results from the SABRE and 
ARIBON trials will provide more evidence on the percentage of bone loss with anastrozole use 
in osteopenic and osteoporotic women. 
 
All the major trials (ATAC, ABCSG-8/ARNO-95 and ITA) reported significant increases in the 
risk of clinical fractures with anastrozole when compared to tamoxifen. However, none of these 
trials were designed to address this question adequately. 100-month analysis results from the 
ATAC trial showed that the increased yearly fracture rate observed during the five-year 
treatment did not continue into the post-treatment follow-up period. Furthermore, all the three 
trials that reported fracture rate compared it with tamoxifen, which itself has a bone-protective 
effect through its oestrogen-agonist activity in bone. It is therefore difficult to know whether the 
differing effects on bone health observed between anastrozole and tamoxifen were due to 
oestrogen suppression by the AIs, the bone sparing effects of tamoxifen, or a combination of 
these factors.  
 
Recent data from the SABRE, ARIBON and ABCSG-12 trials indicates that antiresorptive 
therapy using bisphosphonates is effective in preventing bone loss caused by anastrozole in 
premenopausal and postmenopausal women with early-stage HR-positive breast cancer. 
Nevertheless, several questions regarding the use of bisphosphonates in women taking 
anastrozole remain unanswered:  
1) Will all patients receiving anastrozole therapy benefit from bisphosphonate therapy?  
2) How long should bisphosphonate therapy be administered?  
3) Will the increase in BMD observed in the above trials with oral and IV bisphosphonate 
therapy lead to a decrease in fracture rate?  
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4) What is the ideal mode of bisphosphonate delivery (oral vs. IV bisphosphonates) to be used 
in women who will receive anastrozole in future? 
To fully assess the effects of anastrozole on BMD, this study will examine the effects of 
anastrozole vs. placebo on healthy postmenopausal women who are at high risk of breast cancer. 
The study will also assess the ability of bisphosphonate treatment to reduce bone mineral loss in 
women with osteopenic and osteoporotic T-scores at baseline. Other aromatase inhibitors, 
letrozole and exemestane, have also reported similar results on bone mineral density and fracture 
rate in a variety of settings. These will be discussed in the next section to confirm the findings of 
the effects of anastrozole on bone mineral density and fracture rate. 
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Table 2.1.2: Effect of anastrozole on bone mineral density  
Trial F-up Treatment 
arms 
BMD 
(% change) 
LS TH FN 
ATAC 
 
 
 
1 yr 
 
A vs. T -2.26 vs. +1.42 
 
-1.51 vs. +0.86  
2yr 
 
A vs. T -3.97 vs.+2.12 
 
-3.92 vs. +1.21 - 
5 yr A vs. T -6.08 vs. 2.77 
 
-7.24 vs. +0.74 
 
- 
SABRE 
(Upfront 
anastrozole with 
or without 
Risedronate  (R) 
depending upon 
the fracture risk) 
2 yr 
 
 
 
 
 
 
 
 
 
 
High-risk  =  
A + R 
 
Moderate risk = 
 A + R 
 
Moderate risk = 
A + P 
 
Low-risk = 
 A only 
 3.0 
 
 
 
+2.2 
 
 
-1.8 
 
-2.1 
 
+2.0 
 
 
 
+1.8 
 
 
-1.1 
 
-0.4 
- 
ARIBON  
 
(Upfront 
anastrozole with 
or without 
ibandronate  (I)  
1 yr 
 
 
 
 
2 yr 
A+ I 
 
A+Placebo 
A+ I 
 
A+Placebo 
+3.11 
 
-2.35 
 
 
+2.98 
 
-3.22 
         +0.98 
 
-2.27 
 
 
+0.60 
 
-3.90 
- 
ABCSG-12 
 
[upfront 
anastrozole or 
tamoxifen with 
to without 
zoledronic acid 
(ZA)] 
 
36 
month
s 
 
 
A+ LHRH +ZA 
 
 
A + LHRH 
 
 
 
T + LHRH+ ZA 
 
 
 
T + LHRH 
-2.6 
(P=0.316) 
 
-17.4 
(P<0.0001) 
 
1.4 
(P=0.601) 
 
-11.6 
(P<0.0001) 
 
- Trochanter 
 
-0.6 
(P=0.865) 
 
-11.3 
(P=0.0006) 
 
 -1.7 
(P=0.476) 
 
-5.1  
(P<0.132) 
A=anastrozole; T=tamoxifen; ZA=zoledronic acid; I=Ibandronate; P=placebo; LHRH= luteinizing 
hormone-releasing hormone; R=risedronate ATAC (Eastell, R 2006; Eastell, R 2008); SABRE 
(Van Poznak, C 2010); ARIBON (Lester, JE 2008); ABCSG-12 (Gnant, MF 2007) 
 
 
93 
Table 2.1.3: Effect of anastrozole on fracture rate 
Trial F-up 
 
Treatment arms Clinical fracture rate (%) 
ATAC  
 
 
 
33 months A vs. T 5.9 vs. 3.7 
 
P <0.0001 
 
68 months A vs. T 11 vs. 7.7 
 
P<.0001 
 
 
100-month A vs. T 
 
12 vs. 7.7 
 
P<.0001 
 
ARNO 95/ ABCSG 8 
 
 
 
28 T  T   2yrs         
A vs. T for 3 yrs 
 
2  vs. 1 
 
P=0.015 
 
ITA  
 
 
36 T   T 2-3 yrs         
A vs. T for 2-3 
yrs 
 
1.0 s. 1.3 
 
P=0.06 
 
ATAC (Eastell, R 2006; Eastell, R 2008, The  ATAC  Trialists’  Group,  2002); ARNO 95/ ABCSG 8 
(Jakesz, R 2007); ITA (Boccardo, F 2005) 
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Section-II: The effect of letrozole and exemestane on bone mineral 
density and fracture rate 
 
2.2.1 Introduction 
The purpose of this section is to review all the studies on the effect of letrozole and exemestane on 
bone mineral density and fracture rate in postmenopausal women when compared with placebo or 
other endocrine therapy, and with or without concomitant bisphosphonate therapy. 
 
2.2.2 Criteria for considering studies for this review 
2.2.2.1 Type of studies/participants 
Randomised and non-randomised trials that recruited a minimum of 50 pre- or postmenopausal 
women who received letrozole or exemestane in an adjuvant or a neo adjuvant or a chemo-
prevention setting, have been considered for the review.  
 
2.2.2.2 Type of Intervention 
Intervention included all doses of letrozole or exemestane for duration of at least 3 months. 
 
2.2.2.3 Type of outcome measures 
1. Changes in bone mineral density levels by DXA. 
2. Fracture rate  
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2.2.3 Search strategy for the identification of studies 
The data was last updates in June 2008. Search databases including Web of Science, Pub Med and 
Embase were used to identify publications. The electronic search strategy through MEDLINE 
consisted of the following key text words 
#1 letrozole  
# 2 aromatase inhibitors 
#3 (#1 AND # 2) 
#4 postmenopausal women 
#5 (#3 AND #4) 
# 6 exemestane 
#7 (#5 AND #6) 
#8 early breast cancer or chemoprevention 
# 9 (#7 and #8) 
#10 bone mineral density 
# 11 fracture rate 
#12 (#9 AND #10 AND #11)  
 Also searched  
(letrozole or exemestane or aromatase inhibitors) AND (postmenopausal women) AND (early 
breast cancer) (chemoprevention) AND (bone mineral density) or (bone metabolism). 
 Relevant review articles or other related articles located in the reference lists were searched 
for relevant trials.  
 Data from abstracts accepted at major conferences in the last two years are also included in 
the review as limited data is available from the published studies in the journals.                           
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2.2.4 Review of randomised and non-randomised trials (Letrozole and exemestane) 
2.2.4.1 Description of studies 
A total of ten studies were chosen for the review. Three studies reported the effect of letrozole on 
BMD. Five studies reported the effect of exemestane on BMD (IES, TEAM, Geisler et al, Gonnelli 
et al, LEAP trial, out of which two studies provided concomitant bisphosphonate along with 
exemestane treatment. One small study looked at the effect of letrozole and exemestane on T-scores 
but the sample size was very small (LEAP trial). Four studies reported the fracture rate with 
letrozole and two studies reported the fracture rate with exemestane (BIG 1-98 and MA.17, IES, 
NSABP B-33). 
Table 2.2.1: List of trials that investigated the effect of letrozole or exemestane on bone mineral 
density and fracture rate 
 
                   E=exemestane; L=letrozole, R=reported; NR= not reported or investigated; 
Bisp=bisphosphonates; MA.17 (Perez, EA 2006); BIG 1-98 (Coates, AS 2007) ; Z-FAST (Bundred, NJ 
2006); ZO-FAST (Gnant, MF 2007); IES (Coleman, RE 2007); TEAM (Hadji, P 2009); (Geisler, J 2006); 
(Gonnelli, S 2007); NSABP B-33 (Mamounas, EP 2008); LEAP (McCloskey, EV 2007) 
 
Trial Treatment Clinical 
fracture rate  
BMD change 
 
Letrozole 
MA.17 
 
No Bisp R R 
BIG 1-98 No Bisp 
 
R NR 
Z-FAST 
 
L with Bisp R R 
ZO-FAST L with Bisp R R 
Exemestane 
IES 
 
No Bisp 
 
R R 
TEAM No Bisp 
 
NR R 
Geisler et al No Bisp 
 
NR R 
Gonnelli et al 
 
No Bisp 
 
NR R 
NSABP B-33 No Bisp 
 
R NR 
LEAP 
 
No Bisp 
 
NR R 
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(Coates, AS 2007), reported results from the Breast Cancer Collaborative Group (BIG 1-98), a 
large randomised, Phase III trial to compare 5 years of tamoxifen use to 5 years of letrozole as an 
adjuvant treatment on 8010 postmenopausal women with operable invasive breast cancer. Women 
were assigned to receive monotherapy with letrozole or tamoxifen for five years, letrozole for 2 
years followed by tamoxifen for 3 years, or tamoxifen for 2 years then followed by letrozole for 3 
years. A bone sub-study is currently on-going. BMD has been collected in various cohorts at 2, 3, 4 
and 5 years but results have not been published yet. Fractures were reported as a serious adverse 
event at 28 months and 51 months follow-up. 
 
(Goss, PE 2007) reported the results conducted on the National Cancer Institute of Canada Clinical 
Trials Group (NCIC CTG MA.17). They enrolled 5187 postmenopausal women, with hormone 
receptor positive breast cancer, who had completed 5 years of adjuvant tamoxifen, and were then 
randomized to an additional 5 years of letrozole or placebo. The NCIC CTG MA.17B study 
evaluated bone mineral density in 122 women who were randomly chosen from the MA.17 trial. 
BMD of the L2-L4 region of the spine and hip through the DXA scan was measured at baseline and 
was then repeated at years 1, 2, 3, 4 and 5. To be eligible to join the study women were required to 
have a BMD T-score of at least 2.0 SD below the mean value of peak bone mass were only eligible 
to join the study. At baseline, women were asked for any past diagnosis of bone fractures and 
osteoporosis. Bisphosphonates were allowed after clinically significant bone loss.  Fracture rates 
were reported at a median follow-up of 30 months. The mean percentage change in BMD in LS and 
TH was reported at 1 and 2 years. 
 
(Hadji, P 2009) presented the first BMD results on the Tamoxifen Exemestane Adjuvant 
Multicenter (TEAM) trial. The TEAM is a Phase-III randomized trial designed to compare 5 years 
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of adjuvant exemestane versus 5 years of tamoxifen in 8000 postmenopausal women with early 
breast cancer. The bone sub-protocol was carried out on 538 patients. DXA measurements at LS 
and TH were conducted at baseline and 1 year (± 3 months). Patients with osteopenia and 
osteoporosis at baseline were not excluded unless they received bisphosphonates. At one year 
results were presented on 247 patients for whom baseline and one year measurements were 
collected. 
 
(Gonnelli, S 2007) studied the effect of exemestane on BMD in postmenopausal women aged less 
than 75 years. 70 patients with completely resected breast cancer and who were disease-free 
following 2-3 years on tamoxifen were randomly assigned to continue tamoxifen or switch to 
exemestane  for  a  total  of  5  years  of  endocrine  therapy.  The  patients’  BMD  were  measured by DXA 
scan at baseline, 6, 12, 18 and 24 months at LS, femoral neck and TH. Exclusion criteria included a 
T-score   ≤   -2.5, any fracture within the previous 6 months, and any other factors that may have 
affected the bone metabolism.  
 
(Coleman, RE 2007) reported results on the Intergroup Exemestane Study (IES). This was an 
international, intergroup, Phase III, randomized, double-blind study on 4742 postmenopausal 
women with HR-positive primary breast cancer. The study compared tamoxifen for 5 years to 
tamoxifen for 2 to 3 years followed by exemestane for a total of 5 years. Bone mineral density at 
LS and TH was measured by DXA scan at baseline, 6, 12 and 24 months. The fracture rate was 
reported after a median follow-up of 31 months. Exclusion criteria included the evidence of 
osteoporosis, current or in the last 6 months, or any use of bisphosphonate treatment, HRT, or 
calcium supplements for longer than 1 month in the previous 6 months. Patients with any fragility 
or non-fragility fractures in the previous six-months and other disease or concomitant drug 
treatment with expected effects on bone metabolism were also excluded. 
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(Geisler, J 2006) studied the effects of exemestane on 147 postmenopausal women who had been 
surgically treated for early breast cancer or ductal carcinoma-in-situ in a double-blind setting. 
Participants were randomly assigned to either exemestane 25 mg daily or placebo for 2 years, and 
subsequently followed for 1 year after cessation of treatment for the primary (BMD) and secondary 
(Bone biomarkers etc) study main end-points. BMD was measured on LS (L1-L4) and on the 
femoral neck by a DXA scan, at baseline, 6, 12, and 24 months of treatment. Patients were 
categorized as having normal BMD, osteopenia or osteoporosis according to the WHO definition, 
applied to either the spine or to the femoral neck. Exclusion criteria included prior or concurrent use 
of HRT, bisphosphonates and prior or concurrent history of any metabolic, bone or endocrine 
diseases within 6 months from study entry. 
 
The Letrozole, Exemestane Anastrozole Pharmacodynamics (LEAP) study by (McCloskey, EV 
2007), was an open, randomized, Phase I study to assess the differential effects of AIs on bone 
formation and resorption markers in healthy postmenopausal women. This is the only study that 
studied the effects of AIs on bone in healthy postmenopausal women, and also compared the 
potential differences between different AIs on bone. 102 healthy female volunteers were 
randomized to receive either anastrozole or exemestane or letrozole, once daily, for 24 weeks. 
These women were followed for a further 12 weeks after cessation of dosing. BMD was measured 
by DXA scanning at lumbar spine and hip at baseline and at 24 weeks. Volunteers were required to 
have hip and a lumbar spine T-score  of  ≥-1.0 prior to treatment to join the study.  
  
(Gnant, MF 2007; Bundred, NJ 2008) reported preliminary results from two Phase III, parallel-
designed, 5-year clinical trials, the Zometa-Femara Adjuvant Synergy Trials (Z-FAST) and (ZO-
FAST). The Z-FAST trial recruited patients form 94 North American sites and ZO-FAST trial from 
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132 other International sites. Both studies included postmenopausal women with stage I, II or IIIA 
HR-positive  breast  cancer  and  baseline  LS  and  TH  scores  of  ≥   -2 who had completed their initial 
breast cancer therapy. In this open-label, multicentre, randomized study, patients received letrozole 
orally, daily for 5 years, unless there was disease progression, in which case they were randomized 
to receive immediate or delayed 4 mg zoledronic acid intravenously for 15 minutes every 6 monthly 
for 5 years. The immediate group received zoledronic acid after randomization, whereas the 
delayed group received zoledronic acid when 1) post baseline LS or TH T-score decreased to below 
-2.0; 2) a non-traumatic clinical fracture occurred; or 3) asymptomatic fracture was discovered at 
the month-36 scheduled visit. Patients were also instructed to take an oral calcium tablet, and a 
multivitamin tablet containing vitamin D daily during the study. BMD was measured at LS and TH 
at baseline, 6 12, 24, 36 and 48 months, and at the final visit, using DXA.    
 
(Mamounas, EP 2008), reported results on the National Surgical Adjuvant Breast and Bowel 
Project B-33 (NSABP B-33) trial. This was a Phase III, randomized, double-blind, placebo-
controlled trial evaluating exemestane in early stage breast cancer patients who were disease-free 
after completing 5 years of adjuvant tamoxifen. The original protocol was designed to randomly 
assign patients to 2 years of exemestane versus 2 years of placebo. However, before any of the 
patients completed the 2 years of assigned therapy, the protocol was amended to stop the placebo 
group, and offered exemestane for a total of 5 years. The fractures were reported as a serious 
adverse event after 6 months of protocol amendment. 
2.2.5 Results 
2.2.5.1 Effect of letrozole and exemestane on bone mineral density 
 
The effect of letrozole on bone mineral density was only measured by the MA-17 trial. The rest of 
the studies looked at the effect of exemestane on BMD when compared either with tamoxifen or 
placebo (Table 2.2.2 & 2.2.4). 
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In the MA.17 trial, at a median follow-up of 24 months, women who received letrozole had a 
significantly greater BMD decrease at year 2 in TH (-3.60 % vs. –0.71 %, P=0.044), and significant 
loss in LS (-5.35 % vs. -0.70%; P= 0.008) (Perez, EA 2006).  
 
Seven trials studied the effect of exemestane on bone mineral density. Geisler et al observed a non-
significant mean annual rate of BMD loss in spine at year 1 (-2.17% vs. -1.84%; P=0.568) and at 
year 2 (-3.59 % vs. -2.12%) with exemestane compared to placebo. However, a significant increase 
in BMD loss was observed in the femoral neck at year 1 (-2.72% vs. -1.48%; P=0.024) and year 2 
(-4.42% vs. -2.50%). One year after terminating the treatment, BMD in the LS improved for 
patients in the exemestane arm (mean percentage bone loss changed from -3.59% at 24 months to -
2.16% at 36 months P=0.0003). However, BMD loss improved only slightly in the placebo group (-
2.12% at 24 months to -1.16% at 36 months; P=0.169). Importantly, the difference in BMD at the 
LS and femoral neck between the 2 treatment arms at 36 months remained non-significant (P= 
0.538). Similar results were seen in the IES study. In the Intergroup Exemestane Study, the 
withdrawal effects on BMD were assessed for 122 patients at 12 months and for 126 patients at 24 
months post exemestane treatment. Following treatment withdrawal, the decline in BMD seen 
earlier with exemestane was partially reversed. At 24 months spine, the BMD increased by 1.53% 
(P=0.001) after stopping exemestane. A similar pattern of changes was observed at the hip where 
the BMD stabilized with a change of 0.05% (P=0.92) (Coleman E R, 2010). 
Interestingly, no patients with normal BMD at baseline developed osteoporosis on exemestane. 
21% of patients in the exemestane group and 18% of patients in the placebo group with lumbar 
osteopenia at baseline became osteoporotic. 11% of patients on exemestane and 14% of patients on 
placebo with femoral neck osteopenia also became osteoporotic.  
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Other studies with exemestane showed a consistent negative effect on bone. In the IES study 
(Coombes, RC 2007), women who were switched to exemestane had a significantly greater BMD 
loss at 6 months at LS and TH (-2.7 % and -1.4 %, respectively; P<0.0001). Thereafter the decline 
in BMD progressively slowed in months 6-12 and 12-24, but continued to decline at year 2 at LS 
and TH (-1.0 %; p=0.002 and -0.8%; p=0.003, respectively). (Gonnelli, S 2007) also reported 
progressively decreased BMD at LS in the patients who were switched to exemestane (-2.37%, 
P<0.05 at month 12 and -2.99%, P <0.01 at month 24). BMD at femoral neck also significantly 
decreased by -1.24% at month 12 and -1.92% at month 24, whereas the tamoxifen group showed a 
modest and non-significant increase in BMD at both the sites. The difference between the two 
groups was also significant at both the sites (p= 0.05). In the TEAM trial the BMD loss was 
described with a change in T-score and no percentage change in BMD. Patients treated with 
exemestane experienced a decrease in BMD in the hip but not in the spine. No patient with a 
normal BMD became osteoporotic at 1 year (Hadji, P 2009). 
 
Evidence that bisphosphonates prevent bone loss in women receiving letrozole is confirmed in the 
Z-FAST and ZO-FAST trials. In the Z-FAST trial patients who received upfront zoledronic acid 
had an increase in BMD of 1.9% at the LS and 1.3 % at TH (P <0.001) at 12 months (Gnant, MF 
2007; Bundred, NJ 2008). Furthermore in the same trial, up-front zoledronic acid continued to 
prevent bone loss after 2 years of therapy. At 2 yrs patients who received up-front zoledronic acid 
had increased LS and TH BMD relative to baseline by 3.06% and 1.37% respectively, compared 
with the delayed group, in which LS and TH BMD decreased by 2.9% and 3.24%, respectively. 
The overall difference in BMD between the up-front and delayed groups was 6.0% at LS and 4.6% 
for TH (P<0.001 for both) after 24 months of therapy. In the ZO-FAST trial, patients who received 
up-front zoledronic acid had an increase in BMD of +2.1% at LS and 1.0% at TH, compared with 
 
 
103 
the delayed group, in which LS and TH BMD decreased by 3.5% and 2.2%, respectively (Table 
2.2.2).  
 
 
Among healthy postmenopausal women, results by (McCloskey, EV 2007) reported a decrease in 
T-score in most volunteers at 24 weeks with all three AIs. Interestingly, no significant difference 
was observed in the T-scores changes at lumbar spine and hip between anastrozole and exemestane 
or between anastrozole and letrozole. With regards to BMD, it is reported that retrospective non-
parametric analysis of change in BMD did not detect any significant difference between the 
treatment arms (McCloskey, EV 2007). No other details about the changes in BMD have been 
reported  for  any  AI’s. 
 
2.2.5.2 Effect of letrozole and exemestane on fracture rate (Table 2.2.3 & 2.2.5) 
In the BIG 1-98 study patients in the letrozole arm experienced significantly more bone fractures 
compared to tamoxifen (8.6 % vs. 5.8 %; respectively; P<0.001) after a median follow-up of 4.25 
years (Coates, AS 2007). However, at 24 months, when letrozole was compared to placebo in the 
MA.17 trial, there was no significant difference in the fracture rate (5.3% vs. 4.6 %; P=0.25, 
respectively). Long-term safety data, however, did report a significant difference in osteoporosis 
with a longer follow-up (8.1% vs. 6.0%; P=0.003). However, it should be noted that more women 
in the placebo group had received bisphosphonate treatments for osteoporosis prophylaxis than 
those taking letrozole (11 vs. 5), but the difference was not statistically significant (Goss, PE 2007).  
 
 
Coombes et al, reported fracture rate with exemestane when compared to tamoxifen in the IES 
study. They observed significantly increased fracture rate in the exemestane group than in the 
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tamoxifen group at 30 months in the main trial, (7.0% vs. 4.9 %, P=0.003). Also a significantly 
increased number of women developed osteoporosis in the study (9.2 % vs. 7.2 %; P=0.01). In the 
NSABP B-33 trial, 28 fractures were reported in the exemestane group as compared to 20 in the 
placebo group (P=0.33). 
 
2.2.6 Conclusion: 
 When compared to tamoxifen, both letrozole and exemestane reported a significant decrease in 
BMD at LS and TH in most of the trials. All the trials reported a significantly increased number of 
fracture rates with letrozole or exemestane after 26-31 months of treatment, when compared to 
tamoxifen. These results are similar to those seen with anastrozole in the ATAC and ABCSG/ 
ARNO 95 trial. However, when compared to placebo, letrozole did not show or lead to increased 
fracture rate at 24 months. In healthy postmenopausal women, no significant differences in T-score 
were found within the AI treatment groups. Results from Z-FAST and ZO-FAST trials showed the 
positive effect of zoledronic acid on BMD with letroozole (Z-FAST (Bundred, NJ 2006); ZO-FAST 
(Gnant, MF 2007), as seen in women receiving anastrozole in the ABCSG-12 trial.  
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Table 2.2.2: Effect of letrozole on bone mineral density 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L=letrozole; T=tamoxifen; P=placebo; LS=LS; TH=total hip; FN=femoral neck; MA.17 (Perez, EA 
2006); Z-FAST (Bundred, NJ 2006); ZO-FAST (Gnant, MF 2007) 
 
 
 
 
 
 
 
 
 
 
 
Trial 
Treatment arms F-up BMD 
(% change) 
 
LS TH FN 
MA.17 
 
Early 
breast 
cancer 
patients 
(122) 
 
 
T   
T  T 5yrs         
 
L vs. P for 5 yrs 
 
 
  24 months -5.35 vs. -0.70 
 
(P=0.008) 
-3.6 vs. -0.71 
 
(P=0.044) 
 
 
 
Z-FAST 
 
(Patients 
recruited 
from US 
and Canada) 
L  L + upfront  ZA vs.  
 L + delayed ZA 
 
12 months 
 
24months 
+1.9 vs. -2.4 
(<0.0001) 
+3.06 vs. -2.9 
 
+1.3 vs. -2.0 
(<0.0001) 
+1.37 vs. -3.24 
- 
 
- 
ZO-FAST  
 
(Patients 
recruited 
from 28 
countries 
other than 
US and 
Canada) 
L  L + upfront  ZA vs.  
 L + delayed ZA 
 
12 months   + 2.1 vs. -3.5 
(<0.0001) 
+1.0 vs. -2.2 
     (<0.0001) 
- 
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Table 2.2.3: Effect of letrozole on fracture rate 
 
Trial Treatment arms F-up 
 
Clinical fracture rate 
(%) 
BIG 1-98 T       L vs T 
 
4.25 yrs 8.6 vs. 5.8 
 
(P<0.001) 
 
MA.17 T  T   5yrs         
L vs. P for 2 yrs 
 
24 months 5.3 vs. 4.6% 
(P=0.25) 
 
L=letrozole; T=tamoxifen; P=placebo; LS=LS; TH=total hip; FN=femoral neck MA.17 (Perez, EA 
2006); BIG 1-98 (Coates, AS 2007) 
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Table 2.2.4: Effect of exemestane on bone mineral density 
 
 
 
A=anastrozole; L=letrozole; E=exemestane; ZA=zoledronic acid; P=placebo; IES (Coleman, RE 
2007); TEAM (Hadji, P 2009); (Geisler, J 2006) ; (Gonnelli, S 2007); LEAP (McCloskey, EV 
2007) 
 
 
 
 
 
 
 
 
Trial Treatment 
arms 
F-up BMD 
(% change) 
LS TH FN 
IES 
 
 (206 EBC 
patients) 
T   T 2-3yrs  then      
E for 5 yrs 
 
6 months 
 
 
 
12 months  
-2.7  
 
(P<0.0001) 
 
-1.0 
P=0.002 
-1.4 
     
    (P<0.0001) 
 
-0.8 
(P=0.003) 
 
NR 
TEAM 
 
(538 EBC 
patients) 
 E vs. T for 5 yrs 12 months 
 
 
24 months 
-2.8 vs. 1.2 
(P=0.008) 
 
-3 vs. -0.4 
(P=0.02) 
-1.1 vs. 1.6 
(P=0.09) 
 
-2.5 vs. -0.7 
(P=0.46) 
NR 
 
 
NR 
Geisler et al  
 
 (128 EBC 
patients) 
E vs. P for 2 yrs 12 months 
 
 
24 months 
-2.17 vs. -1.84 
(P=0.568) 
 
-3.59 vs. -2.12 
- -2.72 vs. -1.48 
(P=0.024) 
 
-4.42 vs -2.50 
 
Gonnelli et al  
 
 (70 EBC 
patients) 
T  T 2-3yrs         
E vs. T for 5 yrs 
 
12 months 
 
 
24 months 
-2.37 
(P<0.05) 
 
-2.99 
(P<0.01) 
NR 
 
 
-2 
 
 
-1.24 
 
 
-1.92 
 
 
LEAP 
 
  (90 healthy 
postmenopausal 
women ) 
A vs. L vs. E 24 weeks Change in T-score  
 
-0.1 
 
 
Change in T-
score  
-0.1 
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Table 2.2.5: Effect of exemestane on fracture rate 
Trial Treatment arms F-up 
 
Clinical fracture rate 
(%) 
IES T T 2-3yrs         
E vs. T for 5 yrs 
 
30 months 7.0 vs. 4.9 
 
(P=0.003) 
 
NSABP B-33 T  T   5yrs         
E vs. P for 2 yrs 
 
24 months 28 fractures vs. 20 
fractures 
 
(P=0.33) 
 
E=exemestane; T=tamoxifen; ZA=zoledronic acid; P=placebo; IES (Coleman, RE 2007); NSABP 
B-33 (Mamounas, EP 2008) 
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Section-III: Effect of Anastrozole and other AIs on lipid profile  
 
2.3.1 Introduction 
This purpose of this section of the review is to review the changes to lipid profile in 
postmenopausal women treated with anastrozole or letrozole or exemestane in an adjuvant setting 
or a chemoprevention setting. 
 
2.3.2 Criteria for considering studies for this review 
2.3.2.1 Type of studies/participants 
Randomised and non-randomised trials that recruited minimum 50 pre- or postmenopausal women 
who received anastrozole in an adjuvant or a neo adjuvant or a chemoprevention setting, are been 
considered for the review.  
2.3.2.2 Type of outcome measures 
To look at the changes in lipid profiles either at total cholesterol (TC) and/or high-density 
lipoprotein (HDL) and/or low density lipoprotein (LDL) levels. 
2.3.3 Search strategy for identification of studies 
Search databases including Web of Science, Pub Med and Embase were used to identify 
publications. The electronic search strategy through MEDLINE consisted of the following key text 
words 
#1 anastrozole 
# 2 aromatase inhibitors 
#3 (#1 AND # 2) 
#4 postmenopausal women 
#5 (#3 AND #4) 
# 6 premenopausal women  
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#7 (#5 AND #6) 
#8 early breast cancer or chemoprevention 
#9 Lipid profile 
#10 (#7 AND #8 OR #9)  
 Also searched  
(Anastrozole or aromatase inhibitors) AND (postmenopausal women) AND (early breast cancer) 
(chemoprevention) AND (lipid profile) or (cholesterol fractions) 
 Relevant review articles or related other articles located in the reference lists were searched 
for relevant trials.  
 Data from abstracts accepted at major conferences in the last two years are also included in 
the review as limited data is available from the published data in the journals. 
   
2.3.4 Review of randomised and non-randomised trials (Anastrozole) 
There has been insufficient evidence to determine the effects of AIs on cardiovascular (CV) disease 
and, in particular, on the risk of coronary heart disease. Preliminary data from adjuvant settings 
have shown some evidence and raised concern that long-term use of letrozole and exemestane may 
increase the risk of CV event. This section will review all available data on cholesterol fractions 
reported for anastrozole, letrozole and exemestane in different settings in order to evaluate the 
potential clinical impact of long-term use of AIs (Table 2.3.1). 
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Table 2.3.1: List of trials that reported the effect of anastrozole on lipid profiles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E=exemestane; A=anastrozole; L=letrozole;ITA trial (Boccardo, F 2005); Japanese study (Sawada, S 2005); IMPACT 
trial (Banerjee, S 2005) ; ATAC (Buzdar, A 2006); LEAP trial (McCloskey, EV 2007); BIG 1-98 trial (Thurlimann, B 
2005); MA.17 trial (Wasan, KM 2005); TEAM Greek (Markopoulos, C 2005); ATENA (Markopoulos, C 2005); 
(Lonning, PE 2005) 
Study/Authors Treatment  N Duration 
Anastrozole 
 ITA trial T 2-3yrs  
A vs. T for 2-3 yrs 
 
448  
 
Japanese women 
 
 
A  vs. T 
Upfront 
44 12 weeks  
 
IMPACT trial 
A vs. T 
 
Neoadjuvant  
Upfront 
 
176 12 weeks 
ATAC trial 
 
A vs. T 
 
Adjuvant  
Upfront 
 
9366 
 
 
 
 
LEAP trial 
 
A vs. L vs. E 90 12 weeks  
24 weeks 
36 weeks 
Letrozole 
 
 
BIG 1-98 trial 
L vs. T 
 
Adjuvant 
Upfront 
 
2463 
 
5 yrs 
 
 
MA.17 trial 
T  T 5yrs         
 
L vs. P for 5 yrs 
 
347 5 yrs 
 
 
LEAP trial 
A vs. L vs. E 90 12 weeks  
24 weeks 
36 weeks 
 Exemestane   
 Harper-Wynne et al 2002 HPMW 29 3 months 
 
 
TEAM Greek  
 
E   vs. T 
 
Adjuvant  
Upfront 
176 6 months 
 
 
12 months 
 
 
ATENA study 
E vs. 
Observation 
 
Switch trial 
340 12months 
Lonning et al 
2005 
E vs. T 64 24 months 
 
 
LEAP  
A vs. L vs. E 90 12 weeks 
24 weeks 
36 weeks 
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2.3.5 Description and results of studies 
In total, 13 studies have done an assessment of aromatase inhibitors on lipid profile, and 
inconsistent results have been observed. 
 
2.3.5.1 Anastrozole (Table 2.3.2) 
In the ATAC trial (Buzdar, A 2006), blood sample were not collected to report lipid profile levels. 
However, an exploratory analysis of non-predefined adverse events reported a higher incidence of 
hypercholesterolemia (9 vs. 3 %; P<0.001) in the anastrozole group as compared to tamoxifen. 
However, results from ATAC trial are difficult to interpret as TC data was collected irregularly, and 
65% of patients with hypercholesterolemia were started on a lipid-lowering medication while 
receiving treatment. Similar results were observed in the ITA trial (Boccardo, F 2005). At a 
median follow-up of 64 months, in 448 postmenopausal women with early stage breast cancer, 
higher levels of hypercholesterolemia were observed in the anastrozole group after 2-3 years of 
tamoxifen use than in women who continued on tamoxifen (18% vs. 6% respectively; P=0.01). In 
the adjuvant settings where anastrozole was prescribed as an upfront treatment, inconsistent results 
were observed in different trials. In another study, (Sawada, Sato et al. 2005) evaluated the effect 
on lipid metabolism of anastrozole, compared with tamoxifen, when used as adjuvant treatment in 
44 postmenopausal Japanese women with early breast cancer. Overnight fasting blood samples 
were collected at baseline and after 12 weeks of treatment. HDL-C levels significantly increased 
with anastrozole by 10.2% (P<0.001), and significant (P=0.029) difference between the two groups 
were observed after 12 weeks of treatment. Similar results were observed by (Banerjee, S 2005) 
(IMPACT trial). They randomised 176 postmenopausal women with anastrozole or tamoxifen 
alone, or a combination, in a neoadjuvant setting. Non-fasting blood samples were collected to 
measure TC and HDL-C at the baseline, 2 and 12 weeks prior to surgery. Non-HDL cholesterol 
levels were calculated by subtracting HDL-C from TC levels. This study showed a modest effect of 
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anastrozole on lipid profile, resulting in a non-significant 2.9% increase in TC (95% CI -0.9 to 6.6), 
3.4% non-significant increase in LDL and a significant 11.2% favourable increase in HDL-C levels. 
Whereas in the tamoxifen group, statistically significant 6.5% decrease in TC, significant 26.5% 
increase in HDL-C and significant 12.3% decrease in LDL levels. Interestingly, contrast to the 
previous study, the difference between two treatments was statistically significant for TC and LDL 
but not for HDL-C levels.  
 
In healthy postmenopausal women (McCloskey, EV 2007): In the LEAP trial 90 volunteers 
were randomised in an open, randomized Phase I study, comparing the effects of anastrozole, 
letrozole, and exemestane on lipid profiles.  Fasting blood samples were collected at baseline, 12, 
24 and 36 weeks. No significant differences were observed in lipid profiles with anastrozole as 
compared to letrozole and exemestane, except for decrease in triglycerides with anastrozole, 
compared to increase levels with letrozole (-2.9% vs. +9.6%, respectively, at 12wks; P<0.05) and a 
less marked reduction in HDL levels for anastrozole than exemestane after 24 weeks (0.3 % vs. -
13.9% respectively, at 24 weeks: P<0.001).  For TC, statistically significant decrease was observed 
in the exemestane group at 12 and 24 weeks, but there was no statistically significant difference 
between the three AI groups.                                                                                                                                                                                                                                                                                                                   
 
 
 2.3.5.2 Letrozole (Table 2.3.3) 
(Wasan, KM 2005) (MA.17 trial) did a randomised, placebo-controlled trial of letrozole in 
postmenopausal women with early breast cancer who had completed 5 years of tamoxifen, and 
studied the effects of letrozole on lipid profile in a sub-group of 347 women. Fasting blood samples 
were collected at baseline 6 months, 1, 2, and 3 years following the initiation of letrozole therapy. 
Recently reported results suggest that letrozole did not significantly alter TC, HDL, LDL and TG 
 
 
114 
levels (Wasan, KM 2005). These results are consistent with those from the MA. 17 core study, in 
which no evidence of detrimental effects on lipid profile was observed for letrozole compared with 
placebo in more than 5000 patients (hypercholesterolemia all grades: 16% vs. 16% letrozole and 
placebo group respectively, P=0.79). In contrast, (Thurlimann, B 2005) (BIG 1-98 trial), reported 
hypercholesterolemia with letrozole, as it was previously reported with anastrozole in the ATAC 
trial. Total cholesterol levels were measured at baseline, semi-annually for the first three years, 
yearly for the following two years, and one year after treatment ended. Early breast cancer patients, 
in an adjuvant setting, were either randomised to anastrozole or tamoxifen. After 5 years of 
treatment, anastrozole group had significantly increased total cholesterol levels (43.6% vs. 19.2%, 
respectively) compared with patients who received tamoxifen. It was noted that throughout 
treatment, serum cholesterol values remained stable under the letrozole arm but decreased in the 
tamoxifen arm by approximately 12%. The difference in hypercholesterolemia rates observed in 
above two trials could have been due to the lipid-lowering capacity of tamoxifen in the MA.17 trial 
rather than the real effect of letrozole on cholesterol fractions. 
 
In healthy postmenopausal women: LEAP trial (McCloskey, EV 2007), showed no significant 
difference in lipid profiles with letrozole, except for a 9.6% increase in triglycerides levels after 24 
weeks of treatment with letrozole. In yet another study on postmenopausal healthy women (Harper-
Wynne, C 2002), showed similar impact of letrozole on lipid levels. No Significant difference in 
TC, LDL and HDL were observed after 12 weeks of treatment on 27 healthy volunteers. However, 
both the above studies were done on a small sample population therefore additional information 
will be required to confirm the results.       
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2.3.5.3 Exemestane 
The lipid effects of exemestane have been more closely studied than those of the other aromatase 
inhibitors (Table 2.3.4). 
(Markopoulos, C 2005 (b)) (TEAM Greek study), studied the effect of exemestane on the lipid 
profile of postmenopausal women with early breast cancer in the adjuvant setting to that of 
tamoxifen. Assessments of TC, HDL, LDL and TG were performed at baseline and every 3 months 
for the first 12 months on 176 patients. No effect on TC, a slight non-significant unfavourable 
increase in LDL (with fluctuations over time), and a significant decrease in TG were seen in the 
exemestane group. Overall, HDL levels did not significantly changed over time, except only at 6 
months the exemestane arm presented with significantly lower levels compared to the tamoxifen 
arm, p=0.018. These results are quite similar to the EORTC study among metastatic breast cancer 
patients, especially in terms of no change in TC and HDL with time but contrast in TG levels, 
which favourably decreased with time. Almost similar results were observed by (Markopoulos, C 
2005 (a)) (ATENA study). This randomised multicentre trial was designed to compare 5 years of 
adjuvant exemestane versus 5 years of observation in 340 postmenopausal women with operable 
breast cancer who received 5-7 years of tamoxifen. Fasting blood samples for TC, HDL, LDL and 
TG were measured at baseline and then during 6 or 12 months. Overall, there was a trend of 
increase TC and LDL levels, and decrease TG and HDL levels. The changes in TC and LDL from 
baseline were statistically significant at 6 months, but maintained through to 12 months, with no 
significant difference between the two arms between the two treatments. With regards to HDL-C, 
no significant change was observed at 6 or 12 months. Interestingly, Lonning et al supported the 
results of other exemestane trials (Lonning P E 2005). They recruited 147 postmenopausal women 
with early breast cancer to either exemestane or placebo for 2 years and found no difference for TC, 
LDL and TG levels and a significant reduction in HDL levels (P<0.0001) with exemestane 
treatment.  
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In Healthy Postmenopausal women: In the LEAP trial (McCloskey, EV 2007), no significant 
differences in lipid profiles were observed with exemestane except for a marked reduction in HDL 
levels compared with anastrozole (P<0.001) after 24 weeks of treatment. 
 
Summary and conclusions  
Anastrozole significantly increased cholesterol levels when given upfront in the ATAC trial. 
However, 65% of patients in ATAC trial were on lipid-lowering medication. Anastrozole also 
reported to have caused hypercholestremia, when given to patients after 2-3 years of tamoxifen use, 
in the ITA trial. Significant increases in HDL-C were reported in the Japanese women and in the 
IMPACT study after 12 weeks of anastrozole use. Among healthy participants, no significant 
differences were observed in lipid profiles with anastrozole use for 24 weeks. Women receiving 
letrozole did not report any hypercholesterolemia in the MA.17 trial; however, in the BIG 1-98 trial 
significantly high total cholesterol levels were reported after 5 years of treatment. No significant 
changes in lipid levels were reported after 24 weeks in the LEAP and in the study by Hareper-
Wynne et al after 12 weeks of treatment. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
In the exemestane studies, low TG levels were reported in the TEAM Greek, ATENA and TEAM 
Japan study. A trend towards increase in TC and LDL levels was reported in the ATENA study but 
not in the TEAM Greek, TEAM Japan study and a study by Lonning et al.  
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Table 2.3.2: Effect of anastrozole on lipid profiles 
 
Study/Authors Treatment  N Duration                         Results 
TC LDL-
C 
HDL-C TG 
  
ITA trial 
T 2-3yrs  
A vs. T 
 
448  Hypercholesterolemia 
18 vs. 6 
(P= 0.01) 
 
 
Japanese 
women 
ESBC 
A  vs. T 
 
 
44 12 weeks  NC No 
change 
+10.2 
 
P<0.001 
Reduced 
P=0.003 
vs. 
baseline 
  
IMPACT trial 
A vs. T 
 
Neoadjuvant  
Upfront 
 
176 12 weeks + 2.9  (NS) + 3.4  
(NS) 
+ 11.2 
 
P<0.05 
NR 
 
LEAP trial 
A vs. L vs. E 
 
HPMW 
90 12 weeks  
24 weeks 
36 weeks 
-2.4 
+0.3 
-0.6 
-2.8 
+1.3 
-0.6 
-1.8 
-0.3 
0.5 
-2.9 
+0.2 
-6.7 
 
ATAC trial 
 
 
A vs. T 
 
ESBC 
Adjuvant  
Upfront 
 
 
9366 
 
 
 
 Hypercholesterolemia 
 
9.0 vs. 3.5 
 
 
 
 
ESBC = Early breast cancer patients; NR= not reported; NS= not significant; HPMW=Healthy 
postmenopausal women; E=exemestane; A=anastrozole; T=tamoxifene; ITA trial (Boccardo, F 
2005); Japanese study (Sawada, S 2005); IMPACT trial (Banerjee, S 2005) ; ATAC (Buzdar, A 
2006); LEAP trial (McCloskey, EV 2007). The changes in lipid profile are compared from baseline 
except in the ATAC trial where no blood samples were collected to assess lipid profiles. 
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Table 2.3.3: Effect of letrozole on lipid profiles 
 
Study/Authors Treatment  N Treatment Duration                         Results 
TC LDL-C HDL-C TG 
 
 
BIG 1-98 trial 
ESBC 
Adjuvant 
Upfront 
 
2463 
 
L vs. T 5 yrs +43.6 vs. 
+9.2  
ND 
Hypercholesterolemia 
51 vs. 25 
P<0.001 
 
 
MA.17 trial 
T  T 5yrs         
 
L vs. T for 5 
yrs 
 
 
347 L vs.  P 5 yrs Hypercholesterolemia 
16 vs. 16 
(P= 0.79) 
 
 
 
LEAP trial 
HPMW 90 A vs. L vs. E 12 weeks  
24 weeks 
36 weeks 
-3.7 
0.0 
    +2.3 
   -4.1 
+1.2 
  +2.3 
-3.5 
-2.9 
1.8 
9.6 
5.3 
10.7 
 
 Harper-Wynne et 
al 2002 
 
HPMW 29 L only 3 months NC 
 
NR 
E=exemestane; A=anastrozole; L=letrozole; BIG 1-98 trial (Thurlimann, B 2005); MA.17 trial (Wasan, 
KM 2005); TEAM Greek (Markopoulos, C 2005); LEAP trial (McCloskey, EV 2007); NC= no 
change; NR=not reported; ND=not done. 
Table 2.3.4: Effect of exemestane on lipid profiles (Rosen, CJ 2005) 
Authors/ Study Treatment  N Treatme
nt 
Duration                         Results 
TC LDL-C HDL-C TG 
 
 
TEAM Greek  
 
ESBC 
 
Adjuvant  
Upfront 
176 E   vs. T 6 months 
 
 
12 months 
NC 
 
 
NC 
Decreased 
 
 
Decreased 
(P=0.034) 
 
Decreased  
P= 0.018 
 
Decreased 
(P=0.008) 
 
NC 
 
 
 
ATENA study 
ESBC  
 
Switch trial 
340 E vs. 
Observation 
12months NS 
increase 
 
NS 
Increased 
 
NS decrease 
 
 
NS decrease 
 
 
(Lonning, P E 
2005) 
ESBC 64 E vs. T 24 months NC NC decreased 
P<0.001 
 
NC 
 
 
 
LEAP  
HPMW 90 A vs. L vs. 
E 
12 weeks 
24 weeks 
36 weeks 
-5.5 
-3.9 
1.8 
-3.5 
-0.5 
3.3 
-10.4 
-13.9 
-1.7 
 
-7.7 
2.3 
10.7 
ESBC = Early breast cancer patients; HPMW=Healthy postmenopausal women; NC=no change; NS=not 
significant 
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Section IV: Effect of risedronate on bone mineral density and fracture 
in postmenopausal women 
 
2.4.1 Introduction 
The purpose of this section is to review the effect of bisphosphonate (risedronate) treatment on 
bone mineral density (BMD), bone metabolism (bone biomarkers) and fracture risk in women who 
were found to be osteoporotic or moderately to severely osteopenic at baseline. 
 
 
The IBIS-II bone sub-study is unique as it will examine the impact of a weekly 35 mg risedronate 
dose on bone mineral density and bone metabolism in women taking anastrozole, and who are 
found to be osteoporotic or moderate to severely osteopenic at baseline. Anastrozole has never been 
studied in healthy high risk women before, but has been shown to reduce bone mass when taken by 
postmenopausal women with early or advanced breast cancer. For this reason, no published data 
were found on the effects of risedronate on bone mass in women receiving anastrozole. This review 
will study the effects of risedronate on bone mineral density and fracture rate in postmenopausal 
osteopenic and osteoporotic women. 
 
2.4.2 Criteria for selecting studies for this review 
2.4.2.1 Type of studies 
Randomised controlled trials of at least one year in duration, studying the effect of 5mg daily or 
35mg, once a week risedronate, in postmenopausal osteoporotic women have been included in the 
review. The studies include at least one of the primary outcomes: bone mineral density or fracture 
rate. 
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2.4.2.2 Types of participants 
The two major groups of women that are included are those with mild bone loss (prevention) or 
those with more severe bone loss as defined by a T score <-2 to <-2.5 SD. 
 
2.4.2.3 Type of Intervention 
Interventions included all doses of risedronate for the duration of at least one year. Calcium and/or 
vitamin D were allowed as concurrent therapy, if given to both the groups equally. 
 
2.4.2.4 Type of outcome measures 
1. Percept change in BMD as measured by DXA at baseline, 6-monthly or yearly intervals. 
2. Fracture rate 
 
2.4.3 Search strategy for identification of studies 
The data was searched in Jan 2008 and last updates in June 2008. The electronic search strategy 
through MEDLINE consisted of the following key text words 
#1 risedronate 
# 2 bisphophonates 
#3 (#1 AND # 2) 
#4 postmenopausal women 
#5 (#3 AND #4) 
# 6 osteoporosis 
#7 (#5 AND #6) 
#8 bone mineral density 
#9 (#7 AND #8)  
#10 fracture 
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# 11 (#9 AND #10) 
 Also searched  
((risedronate or bisphosphonates) AND (postmenopausal women) AND (osteoporosis) AND (bone 
mineral density or fracture)) 
* Relevant review articles or related other article located in the reference lists were searched for 
relevant trials.  
 
2.4.4 Description of studies 
Nine studies (randomized trials), studying the effects of risedronate on bone mineral density and/or 
fracture rate were found (Table 2.4.1 and 2.4.2). 
Table 2.4.1: List of trials that investigated the effect of risedronate on bone mineral density and/or 
fracture rate 
Author/Trial name Clinical fracture rate BMD change 
 
(Harris, ST 1999) 
(VERT-NA) 
 
R R 
(Reginster, J 2000) 
(VERT-MN) 
 
R R 
(Harris, ST 2004) 
 
R R 
(McClung, MR 2001) 
 
R R 
(Rosen, CJ 2005) 
 
R - 
(Reid, DM 2006) 
(FACTS-International) 
 
 - BMD 
(Fogelman, I 2000) 
 
- R 
(Sorensen, OH 2003) 
 
R R 
 (Valimaki, MJ 2007)  
 
- R 
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(Harris, ST 1999) conducted a randomized, double-blind, placebo-controlled trial called Vertebral 
Efficacy with Risedronate Therapy-North America (VERT-NA) on 2458 postmenopausal women at 
110 study centres in North America. Women were eligible for the study if they were not older than 
85 years, if 5 years had elapsed since natural or surgical menopause, and if they had either 2 or 
more radiographically identified vertebral fractures (T4-L4, inclusive) or 1 vertebral fracture and 
low BMD  (L1-L4) T-score of <-2. Subjects were randomly assigned to receive oral treatment for 3 
years with risedronate (2.5 or 5 mg/day) or placebo. Women were excluded if they had conditions 
that might interfere with the evaluation of spinal bone loss (such as oestrogens or calcitonin etc). 
Patients were stratified based on the number of baseline vertebral fractures (stratum 1, subjects with 
1 vertebral fractures   and   low   baseline   BMD;;   stratum   2,   subjects   with   ≥2   baseline   vertebral  
fractures). BMD was measured by DXA at baseline and at 6-month intervals throughout the study 
using Hologic or Lunar densitometers. Lateral thoracic and lumbar spine radiographs were taken at 
baseline and annually throughout the study.  
  
(Reginster, J 2000) conducted a randomized, double-masked, placebo-controlled trial called 
Vertebral Efficacy with Risedronate Therapy-Multinational (VERT-MN) on ambulatory women 
(n=1226) up to 85 years old and at least 5 years postmenopausal. All the women in the study 
received risedronate for 3 years, 2.5 mg/day for the first 2 years, and then moved to 5mg/day for 
one year. The eligibility criterion included at least two radiographically confirmed vertebral (T4-
L4) fractures. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, 
and BMD was measured by DXA at 6-month intervals. All patients received calcium 1000 mg/day 
in a single dose and up to 500 IU/day vitamin D if baseline 25-hydroxyvitamin D levels were below 
40 nmol/l. Exclusion criteria included conditions that could have interfered with evaluation of 
spinal osteoporosis, and the use of calcitonin, calcitriol or vitamin D supplements within 1month, 
oestrogen, oestrogen related drugs or progestogen within 3 months, or bisphosphonates.  
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(Harris, ST 2004) presented results from a large randomized, double-blind, active-controlled, trial 
among 1456 postmenopausal osteoporotic women, who received risedronate either 35mg once a 
week or 50 mg once a week or 5 mg/day for 2 years. Subjects were aged 50 years or older, 
postmenopausal for at least 5 years, and had either a BMD T-score of -2.5 or a T-score of -2 and at 
least one prevalent fracture. The primary endpoint was the percentage change from baseline in 
lumbar spine BMD at 12 months. BMD was measured by dual energy X-ray absorptiometry (DXA) 
at baseline and at 6 and 12 months using Hologic or Lunar densitometers. All the women received 
100 mg daily of elemental calcium and vitamin D if the baseline serum 25-hydroxyvitamin D3 was 
low. 
 
(McClung, MR 2001) studied 5445 women 70-79 years old who had osteoporosis (indicated by a 
T-score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak 
value in young adults (-4) or lower than -3 plus a non-skeletal risk factor for hip fracture, such as 
poor gait or a propensity to fall) and 3886 women at least 80 years old who had at least one 
nonskeletal risk factor for hip fracture or low bone mineral density at the femoral neck (T-score, 
lower than -4 or lower than -3 plus a hip-axis length of 11.1 cm or greater). The women in each of 
the two enrolment groups were randomly assigned to receive treatment with oral risedronate (2.5 or 
5.0 mg daily) or placebo for three years. All the women received supplemental calcium. Women 
also received vitamin D tablets if at baseline their serum 25-hydroxyvitamin D levels were below 
16ng/ml. The primary end point of the study was the incidence of radiologically confirmed hip 
fractures. A secondary end point was the incidence of non-vertebral osteoporotic fractures, defined 
as all radiologically confirmed fractures of the wrist, leg, humerus, hip, pelvis, or clavicle. 
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(Rosen, CJ 2005) presented results on the Fosamax Actonel Comparison Trial (FACT), which was 
a double-blind, randomized, active controlled, multicentre study conducted at 78 sites within the 
USA.  The  eligible  patients  were  postmenopausal  women  aged  ≥  40 years  with  a  BMD  ≥  2.0  SD  
below  young  normal  mean  BMD  (T  ≤   -2.0) in at least one of four sites; total hip, hip trochanter, 
femoral neck or postero-anterior (PA) lumbar spine (L1-L4). 1053 women were randomised to 
receive alendronate 70 mg/week or risedronate 35 mg/week for one year. Exclusion criteria 
included conditions that could have interfered with evaluation of spinal osteoporosis, and the use of 
calcitonin, calcitriol or vitamin D supplements within 1 month, oestrogen, and oestrogen related 
drugs or progestogen within 3 months, or bisphosphonates use within 1 year, or patients with 
hypocalcemia and hypovitaminosis etc. Patients were instructed to consume, for the duration of the 
study, 1000 mg of elemental calcium and 400 IU of vitamin D daily.  BMD was measured at 
baseline, 6 and 12 months using Hologic or Lunar DXA.  
 
(Reid, DM 2006) presented results from the Fosamax Actonel Comparison Trial-International 
(FACTS) Trial, which was similar in all terms as the FACT study but recruited women from 75 
international sites. FACT and FACTS studies were conducted over a 12-month period and both 
trials also conducted a 1-year extension to determine if the difference in BMD persisted over 2 
years and if tolerability remained similar. Here results are presented from the 1-year extension of 
the FACTS trial, encompassing 2 years of risedronate treatment.  
 
A randomized, double-blind, placebo controlled trial was conducted by (Fogelman, I 2000) They 
studied the effects of 2.5 or 5 mg/day risedronate versus placebo for 2 years on 543 postmenopausal 
women with a mean T-score of -2 or less. Bone mineral density was measured at the lumbar spine, 
femoral neck, and femoral trochanter by DXA machine at baseline and after 6, 12, 18 and 24 
months using Hologic or Lunar densitometers. Vertebral fractures were also assessed (T4- L4) at 
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baseline and at the end of the study. Patients were excluded from the study if they had a history of 
cancer, hyperparathyroidism, hyperthyroidism, osteomalacia etc, and if they had taken treatment 
affecting bone metabolism within the previous 6-12 months. 
 
Long-term efficacy of risedronate was studied by (Sorensen, OH 2003), in a small group of 
women. They studied the effects of 5mg risedronate vs. placebo on 265 osteoporotic women who 
were at least 5 years postmenopausal, 85 years of age or younger, and had two vertebral fractures at 
baseline. End points included vertebral and nonvertebral fracture assessments, bone mineral density 
measurements, and changes in biochemical markers of bone turnover. To determine the effects of 5 
years of risedronate, this study was the 2-year extension of a 3-year, placebo-controlled vertebral 
fracture study. BMD measurements of the lumbar spine and proximal femur obtained after 3 years 
were taken as the baseline value for this extension study and additional measurements were taken at 
year 4 and 5. Radiographs for the determination of vertebral fractures were obtained at 36, 48 and 
60 months. 
 
(Valimaki, MJ 2007) conducted a randomized, double-blind, placebo-controlled, parallel-group, 
Phase-III trial in 171 healthy, late-postmenopausal  women   (≥  5   years   from  menopause),   from  14  
centers in Europe who received 5 mg risedronate or an identical placebo for 2 years. The eligibility 
criteria included a BMD T-score between -2.5 and -1 SD and the presence of a greater or equal risk 
factor for osteoporosis (e.g. premature menopause, late menarche, maternal history of osteoporosis-
related  fracture,  BMI  ≤  22  kg/m2,  or  a  smoking  habit  of  ≥  10  cigarettes/day)  or  the  presence  of  hip  
osteopenia. Women were required to discontinue HRT, calcitriol, or calcitonin treatment 12, 4, and 
4 weeks prior to enrollment, respectively. Patients were excluded if they had any condition that 
could interfere with the evaluation of LS BMD (e.g., severe osteoarthritis, >2 fractured lumbar 
vertebrae (L1-L4), use of corticosteroids, bisphosphonates within 6 months of starting the study 
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medication or for more than 14 days within 1 year before start of the study. All women received a 
daily supplement of 1000mg of elemental calcium and 400 IU of vitamin D.  
 
(Leung, JY 2005) conducted a randomized, double blind, placebo controlled study on 65 
postmenopausal osteoporotic Chinese women, aged 67 ± 6 years, if postmenopausal for 5 years or 
more with spine BMD at L1-4 <2.5 SD of the local peak young mean value. Women were 
randomly assigned to receive either risedronate 5 mg daily or placebo for 12 months. All women 
received calcium carbonate 500 mg daily and vitamin D 400 IU daily. Women were excluded if 
they had a history of metabolic bone disease or other major disease or who had used oestrogen in 
last 12 months, and bisphosphonates or fluoride in the preceding 6 months etc. BMD was measured 
at baseline and at 3, 6 and 12 months by using Hologic or Lunar densitometers.  
 
2.4.5 Results 
2.4.5.1 Effect of risedronate on bone mineral density 
(Harris, ST 1999) reported significantly increased BMD with risedronate (5.4%, 1.6%, 3.3%, 
0.2%, respectively at LS, FN, HT and midshaft radius) when compared with placebo over 3 years. 
Reginster et al also reported significantly increased LS and TH BMD with risedronate after 6 
months. At 3 years, BMD in the risedronate group was significantly increased at the LS, FN and 
trochanter, and was maintained at the midshaft radius. In the control group at 3 years, BMD 
increased significantly at the femoral neck, and decreased significantly at the femoral trochanter 
and midshaft radius. In this trial all women received calcium 1000 mg/day and 400 IU vitamin D 
and that probably accounted for the increase in LS BMD in the control group and not at the 
trochanter and midshaft radius. (McClung, MR 2001) conducted the trial to look at occurrence of 
hip fractures also reported changes in BMD. At 3 years, the BMD at the FN was 2.1 and 3.4 percent 
higher among the women assigned to 2.5mg and 5.0 mg of risedronate, respectively, than among 
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those assigned to placebo and the BMD at the trochanter was 3.8 and 4.8 percent higher, 
respectively. 
 
The 2-year study data presented by (Harris, ST 2004) showed that the mean percentage change 
were 5.2%, 4.7% and 5.5% at lumbar spine, 3.4%, 3.0% and 3.8% at proximal femur, 2.5%, 1.9% 
and 2.5% at femoral neck and 4.7, 4.2 and 5.3%, for the 5, 35, and 50 mg groups, respectively. 
However, there was no placebo control group in this study to assess the difference. Fogelman et al 
reported that at 24 months the BMD percentage increase was 4% at LS and 1% at FN, with a 5mg 
dose of risedronate. However, BMD increased in patients treated with 5 mg risedronate but not in 
those receiving placebo, despite the fact that both groups received supplemental calcium. They also 
observed that the beneficial effect of risedronate on BMD was independent of the time since 
menopause. Significant increases were seen in women who had experienced menopause more than 
5 years before entry to the study and in women with a more recent menopause. (Leung, JY 2005) 
observed increase in BMD values at 12 months in LS by 6.6 % and at TH by 2.7%. It is likely that 
the greater BMD response noted in this study was attributed by the characteristics of the study 
population, as patients were more osteoporotic with lower T-score values. For example, the mean 
T-score at the spine was -3.2 for this study, whereas the mean T-score in other studies was -2 and -
2.5. BMD data in the Leung et al study showed that the increase in BMD with treatment was 
inversely related to the baseline values of BMD and bone markers, suggesting that those with more 
severe disease and higher rate of bone turnover responded better to risedronate treatment. The study 
by (Sorensen, OH 2003) is the only one to demonstrate the continuing beneficial effects of 
risedronate through 5 years of treatment. Over 5 years, risedronate treatment produced a significant 
increase from baseline in lumbar spine BMD of 9.3%. The placebo group continued to decline 
throughout the study.  
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In the FACT and FACTS trials, significant BMD increases from baseline at 6 and 12 and 24 
months were observed in the 35 mg risedronate group. In the FACT trial, the increases from 
baseline in BMD were significant at the TH, FN, and LS at 6 (P<0.001) and 12 months (P<0.001). 
The  percentage  of  patients  who  had  ≥3%  increase  in  hip  trochanter  BMD  at  12  months  was  51.1%  
for the risedronate group. In the alendronate group, a significantly larger increase in BMD (a 
difference of 1.5%) was observed at all the sites. In the FACTS trial, at 24 months, significant 
increases in BMD from baseline were observed at all time points for the risedronate group. In the 
FACTS trial, similar greater increases in BMD (as seen in the FACT trial) were observed at 24 
months. Results from FACT and this study show that risedronate promotes rapid increases in BMD.  
 
 
In osteopenic women, the study by (Valimaki, MJ 2007) reported that at 12 months, the mean 
percentage change from baseline in LS BMD was significantly greater with risedronate compared 
with placebo (P<0.001). FN BMD was increased significantly from baseline at all points, but FN 
BMD had decreased significantly in the placebo group by 24 months.  
 
2.4.5.2 Effect on Vertebral and Non-vertebral fractures (Table 2.4.3) 
Statistically significant reductions in vertebral and non-vertebral fractures were observed by 
risedronate in several studies. (Harris, ST 1999) observed that over 3 years, there was a statistically 
significant reduction of 41% (95% CI, 18-58%) in the risk of new vertebral fractures in the 5-mg 
risedronate group compared with placebo (P=0.003). The significant reduction of 65% in vertebral 
fractures was seen in the first year of treatment. The cumulative incidence of non-vertebral fractures 
over 3 years of treatment was lower by 39% (95% CI, 6%-61%) in the 5 mg risedronate group 
compared with placebo. (Reginster, J 2000) also reported that over 3 years the new vertebral 
fracture risk in the risedronate 5 mg/day was significantly reduced by 61% over 12 months and by 
49% over 3 years versus control (P<0.001) and the reduction of non-vertebral fracture was not 
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significant. The incidence over 3 years was 18% in the risedronate group and 29 % in the control 
group. There was also reduction in non-vertebral osteoporosis-related fracture in the risedronate 
group compared with control at 3 years, which resulted in 33% reduction in fracture risk (P=0.06). 
Significant reductions in hip fractures were also observed by (McClung, MR 2001). In the group of 
women with osteoporosis (those 70-79 yrs old) the incidence of hip fracture among those assigned 
to risedronate was 1.9 percent, as compared with 3.2 percent among those assigned to placebo. In 
the group of women selected primarily on the basis of non-skeletal risk factors (those at least 80 
years of age), the incidence of hip fracture was 4.2 percent among those assigned to risedronate and 
5.1 percent among those assigned to placebo (P=0.35). The risk of fractures in women <80 years 
old and who received risedronate was almost half compared to women in >80 yrs age group. 
 
(Harris, ST 2004) reported that out of 1456 women, only 25 subjects (1.7%) experienced one new 
vertebral fracture during 24 months. In this trial women received 5, 35 or 50 mg risedronate. Over 
the 2-years of treatment, the incidence of new vertebral fracture was (2.9%, 1.5% and 1.7% for the 
5, 35, and 50 mg groups, respectively; P=0.298). Osteoporosis-related non-vertebral fractures were 
reported as adverse events (5.0%, 4.9%, and 4.5% for the 5, 35, and 50mg groups, respectively; 
P=0.918). Over 5 years, risedronate treatment reduced the risk of new vertebral fractures by 59% 
(95 CI; P=0.01) in years 4 and 5, compared with a 49% reduction in the first 3 years (Sorensen, OH 
2003). Eleven women in the placebo group (8.5%) and 7 women in the 5 mg risedronate (5.2%) 
experienced an osteoporosis-related non-vertebral fracture during the 2-year extension study. The 
most common of these fractures was of the humerus, which occurred in 6 women (4.6%) in the 
placebo group and 3 women (2.2%) in the 5mg risedronate group. 
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2.4.6 Conclusions  
All the large studies that compared risedronate with placebo showed that risedronate significantly 
reduced the incidence of new vertebral fracture in postmenopausal women at high risk of fractures. 
Risedronate also demonstrated significant efficacy in reducing hip fracture among women with 
osteoporosis, when defined as a low bone mineral density at the femoral neck.  Significant 
reductions in fracture risk in response to treatment were evident within the first year, which is an 
important benefit in patients at high risk of fracture risk. 
 
All the studies reported the efficacy of risedronate in increasing BMD in postmenopausal 
osteoporotic women.  
 
In late-postmenopausal women with LS BMD T-score between -2.5 and -1.5  who  had  ≥  additional  
fracture risk factor or hip osteopenia, 24-month treatment with risedronate was associated with 
significant increase in BMD in the LS and FN. The increase in BMD was observed within 12 
months and sustained for the 24-month duration of therapy.  
 
In addition to sustained efficacy, all the studies showed favourable safety and tolerability profiles in 
terms of upper gastrointestinal tract adverse events, such as oesophagitis or oesophageal or gastric 
ulcers. These remained low and similar to placebo with continued treatment. 
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Table 2.4.2: Effect of Risedronate on BMD and fracture rate 
Author/ 
Study/Yr 
Treatment Participants 
Eligibility 
Effect on BMD Fracture rate 
 
 
VERT-NA 
 (1999) 
 
2458 
women 
 
 R (2.5 or 5 
mg/d) vs. P for 
3 years 
 All received Ca 
 All received 
vitamin D if 
baseline levels 
were low 
 
 < 85 years 
 
 5 years had 
elapsed since 
natural or surgical 
menopause 
 
 
 Either 2 or more 
radiographically 
identified vertebral 
fractures (T4-L4, 
inclusive) or 1 
vertebral fracture 
and low BMD (L1-
L4) T-score of <-2. 
Increased 
Significantly at  
 
 LS 
5.4 % vs. 1.1% 
 
 FN 
1.6 vs. -1.2% 
 
 HT 
3.3 vs. -0.7% 
 
 MSR 
0.2% vs. -1.4% 
 New vertebral fracture 
Reduced by 41% over  
3 years 
(11.3% vs. 16.3%; P=0.003) 
 
  Non-vertebral fracture 
Reduced by 39% over  
3 years 
(5.2% vs. 8.4%; P=0.02) 
 
 
VERT-MN 
 
(2000)  
 
1226 
women 
 
 Risedronat
e for 3 years, 
2.5 mg/day for 
the first 2 
years, and then 
moved to 
5mg/day for 
one year 
 
 All received 
Ca 
 
 All received 
vitamin D 
 85 years old and 
at least 5 years 
postmenopausal 
 
 At least two 
radiographically 
confirmed 
vertebral (T4-L4) 
fractures 
 
Treatment 
difference at 3 
yrs 
(P<0.001) 
 LS  
5.9 %  
 
 TH  
6.4% 
 
 FN 
3.1 
 
 MSR 
2.1% 
 
 
 
 New vertebral fracture 
Reduced by 49 % over 3 
years 
(P<0.001) 
 
 Non-vertebral fracture 
Reduced by 33% over 3 
years 
(P=0.06) 
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Author/ 
Study/Yr 
Treatment Participants 
Eligibility 
Effect on BMD Fracture rate 
Harris et 
al  
 
 (2004) 
 
1456 
women 
 
 Risedronate 
either 
5mg/day vs. 
35 mg /wk 
vs. 50 
mg/week for 
2 years 
 
 All 
received Ca 
 
 All 
received 
vitamin D 
if baseline 
levels were 
low 
 50 years or older, 
postmenopausal 
for at least 5 years 
 
 Had either a BMD 
T-score of -2.5 or 
a T-score of -2  
 
 And at least one 
prevalent fracture 
 
 LS (5, 35 and 
50 mg) 
5.2, 4.7%, and 
5.5 
 
 Proximal 
femur 
3.4%, 3.0% and 
3.8% 
 
 FN 
2.5%, 1.9% and 
2.5 
 
 Femoral 
trochanter 
4.7%, 4.2% and 
5.3% 
 
 
 
 Incidence of new vertebral 
fracture 
(2.9, 1.5, and 1.7%, 
respectively; P=0.0298) 
 
 Incidence of non-vertebral 
fracture reported as 
adverse events  
(5.0, 4.9, and 4.5%, 
respectively; P=0.918) 
 
McClung 
RM et al  
 
(2001)  
 
5445 
women 
3886 
women  
 Risedronate 
(2.5 vs. 5.0 
mg daily) vs. 
placebo for 
three years 
 
 All received 
Ca 
 
 All received 
vitamin D if 
baseline 
levels were 
low 
 
 
 70-79 years old 
who had 
osteoporosis (<-4 
or <-3 and non-
skeletal risk factor 
for hip fracture, 
such as poor gait 
or a propensity to 
fall) 
 80 years old who 
had at least one 
non-skeletal risk 
factor for hip 
fracture or low 
bone mineral 
density at the 
femoral neck 
At 3 years in 
1236 younger 
enrolment 
group 
  
 TH 
3.8% & 4.8% 
higher vs. P 
 
 FN 
2.1% % & 3.4% 
higher vs. P 
 
Hip Fracture  
 Overall incidence of hip 
fracture 
2.8% vs. 3.9% 
(difference in RRP=0.02) 
 70-79 yrs group 
Overall incidence of hip 
fracture 
1.9 % vs. 3.2% 
(difference in RRP=0.009) 
 >80 yrs group 
Overall incidence of hip 
fracture 
4.2 % vs. 5.12 (P=0.35 
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Author/ 
Study/Yr 
Treatment Participants 
Eligibility 
Effect on BMD Fracture rate 
Rosen et al  
 
    FACT 
 
    (2005) 
 
1053 
women 
from USA 
  Risedronate 
35mg/week  
vs. 
Alendronate 70 
mg/week for 
one year and 
one more 
extension 
period  
 
 All received 
Ca 
 
 All received 
vitamin D 
 
≥   40   years   with   a  
BMD   ≥   2.0   SD  
below young normal 
mean   BMD   (T   ≤   -
2.0) in at least one 
of four sites; TH, 
HT, FN or LS 
 
At 6 years   
  
 Trochanter  
2.1% vs. 3.4% 
 
At 12 months 
 
 BMD at TH, 
LS, & FN 
were 
statistically 
significant at 
6 and 12 
months 
 
- 
Reid DM 
et al 
 
 (2006) 
(2008) 
  
549 women 
FACTS-
Internation
al 
 Risedronate 
35mg/week  
vs. 
Alendronate 70 
mg/week for 
one year 
 
 All received 
Ca 
 
 All received 
vitamin D 
 
 
 
 
 
 
≥   60   and   <90   years  
with osteoporosis 
(BMD   ≤2.5,   at   LS  
or TH, or both LS 
and  TH    ≤ -2.0) 
 
 At 24 months, 
BMD at TH, 
LS,  & FN 
were 
statistically 
significant in 
both the 
groups 
 
 
 
 
 
 
 
 
 
- 
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Author/ 
Study/Yr 
Treatment Participants 
Eligibility 
Effect on BMD Fracture rate 
Fogelman 
et al.  
 
(2000) 
 
543 women 
 
 
 
Risedronate 2.5 
vs. 5 mg/day vs. 
placebo for 2 
years 
 T-score of -2 or 
less 
 At 24 
months 
LS 
4% increase 
 
FN 
1% increase 
 Month 12 and 24 
LS 
2.2% & 3.5% vs. no change 
in the placebo group and 
1.4% & 4.1% vs. no change 
in the P 
 
 FN 
0.7% & 1.2 vs. no change in 
P, 0.9% & 1.3 vs. -1.0  
Sorensen 
et al  
 
    (2003) 
 
   265 
women 
Risedronate 
5mg/wk vs. 
placebo for 5 
years 
 5 years 
postmenopau
sal 
 
  85 years of age or 
younger 
 
 Had two vertebral 
fractures at 
baseline 
Risedronate 
group 
 LS  
9.3 % increase 
 
 TH  
5.7% increase 
 
 FN 
2.2 % increase 
 
 TH 
Remained 
stable. 
In the placebo 
group, BMD 
continued to 
decline 
throughout the 
study. 
 
 
 Incidence of new vertebral 
fracture at 2 yr 
14% vs. 28% 
 
At 3 years 49% reduction 
At 5 years 59% reduction 
 
 Incidence of non-vertebral 
fracture 
   No hip fractures were 
observed. 
 
Difference were not 
significant between the 
groups 
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Author/ 
Study/Yr 
Treatment Participants 
Eligibility 
Effect on BMD Fracture rate 
Valimaki 
MJ et al  
 
(2007) 171 
healthy,  
 
5 mg 
risedronate vs. 
placebo for 2 
years 
 late-
postmenopaus
al (≥  5  years  
from 
menopause) 
 
 BMD T-score 
between -2.5 
and -1 SD 
 
 The presence 
of  a  ≥ greater 
risk factor for 
osteoporosis 
LS BMD 
4.49% increase 
vs. no increase 
(P=0.05) 
 At 12 
months 
LS 
3.07% vs. 0.44% 
P<0.001 
FN 
1.42 vs. -0.11 
P=0.002 
 At 24 
months 
LS 
4.58 % vs. 0.29% 
P<0.001 
 
FN 
2.34 vs. -0.44 
P<0.001     
- 
Leung et al 
(2005)  
 
65 women 
 Risedronate 5 
mg daily vs. 
placebo for 
12 months. 
 
 Ca and Vit D 
 
 Aged 67 ± 6 
years 
 LS BMD at 
L1-4 <2.5 SD 
 LS 
  6.6% vs. 0.4%; 
P<0.0001 
 TH 
  2.7% vs. 0.3%; 
P<0.0001 
 HT 
4% vs. 1.1%; 
P<0.0001       
- 
LS=lumbar spine; TH=total hip; MSR=mid shaft radius; FN=femoral neck. 
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Table 2.4.3: Effect of risedronate on GI symptoms 
 
Author/ Study/Yr GI Symptoms 
 
VERT-NA 
 Withdrawals 
36% vs. 42%  
 Most GI Symptoms in the risedronate group were mild 
to moderate 
 
Reginster JY et al  
(VERT-MN) 
Similar in both the groups and most were mild to 
moderate (R vs. P) 
Harris et al  
 
Similar in both the groups and most were mild (72%) to 
moderate in the 35mg group 
McClung RM et al  
5445 women 
3886 women  
Similar in both the groups (R vs. P) 
Rosen et al  
    FACT 
1053 women the US 
22% vs. 20% patients had GI symptoms (R vs. P)    
Reid DM et al 
549 women 
FACTS-International 
22.6% vs. 18.5% (R vs. P) 
Fogelman et al.  
543 women 
Similar in three groups (R 2.5mg vs. 5mg vs. P) 
Sorensen et al  
265 women 
The incidence was similar in both the groups 
Valimaki MJ et al  
 171 healthy women 
18.3% vs. 25.5% 
Leung et al  
65 women 
Equal in both the groups 
R=risedronate; P=placebo 
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Chapter 3: Methodology 
 
 
Section-I: Methodology of the bone sub-study, IBIS-II 
 
 
 
3.1 Introduction 
The bone sub-study of the International Breast Cancer Intervention Study-II (IBIS-II) was designed 
to examine the effect of anastrozole on bone mineral density (BMD) and the risk of developing 
osteoporosis. In addition, the study was designed to explore the effect of bisphosphonate treatment 
to reduce the risk of osteoporosis and fracture rate in women who had low bone mineral density at 
baseline. 
 
3.2 Study Design 
3.2.1 Study Outline 
The eligibility criteria to join the bone study were the same (will be discussed in the next section) as 
the IBIS-II prevention study except for a few additional exclusion criteria. All women joining the 
prevention study had their mammograms done to exclude breast cancer before randomisation; 
spinal x-ray to rule out low trauma vertebral fractures, and the DXA scan was conducted to evaluate 
lumbar spine, femoral neck and total hip T-scores. 
 
BMD measurements at the lumbar spine (LS), total hip (TH) and femoral neck (FN) were 
performed on 1326 women from the initial entrants of 3014 women who were enrolled in the IBIS-
II prevention study. It was planned to randomise women into one of the following strata depending 
upon their baseline LS and FN T-scores (Figure 3.1): 
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I. Initial plan was to recruit 300 women with T-scores greater or equal to minus one point 
five  (≥-1.5) at both LS and FN.  Later on it was decided to keep recruiting women into 
stratum-I until 400 women were recruited in stratum-II. These women did not receive 
risedronate. 
 
II. 400 moderately to severely osteopenic women with at least one T-score less than minus 
one point five and greater than or equal to minus two point five (-2.5≤T<-1.5) at LS and 
FN were randomised to risedronate or placebo. 
 
III. 300 osteoporotic women with at least one T-score less than minus two point five and 
greater than or equal to minus four (-4.0  ≤T- score<-2.5) at LS and FN or up to two low 
trauma vertebral fractures were provided with risedronate. 
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Figure 3.1: Randomisation chart of the IBIS-II bone study 
 
The initial study plan was to recruit 1000 women, 300 (30%) in stratum-I, 400 (40%) in stratum-II 
and 300 (30%) in stratum-III. It was later observed that about 70% women were getting recruited in 
stratum-I, only 20% in stratum-II and 10% in stratum-III. At that time 98% of women in the study 
had been recruited from within the UK. The analysis of these participants indicated that the mean 
Z-score was around 0.5 at the LS and FN, which showed higher population values of Z-scores in 
the  UK  than  in  the  USA,  where  the  NHANES  hip  and  Hologic  manufacture’s  spine  BMD  reference  
ranges were determined. This fully explained the lower percentage of recruitment in stratum-II and 
III. The bone committee (team of bone experts who met once a year to discuss the safety issues and 
 
* minimum score at Lumbar spine or femoral neck
Stratum - I
T- score*  >  - 1.5
(Normal)
Observation
Stratum - II
- 1.5  > T- score*  >  - 2.5
(Osteopenic)
Randomisation
Risedronate Placebo
N=300 N=200 N=200
Stratum - III
- 2.5 >  T-score * > - 4.0
(Osteoporotic)
Risedronate  for all
N=300
Women eligible to take 
part in the  IBIS-II 
Prevention  Study
IBIS-II Bone study (If met the 
inclusion and exclusion criteria)
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progress of the trial) met on March 2006 to discuss the slow recruitment in the bone study in 
general and improve the recruitment in stratum-II and III. Due to the difference in Z-score observed 
in the preliminary analysis it was then decided to change the limits of T-score in stratum-I and II. In 
stratum-I the lower limit  was  changed  from  ≥-1.5  to  ≥-1.0. In stratum-II, the upper limit of T-score 
were changed from <-1.5 to <-1.0. 
 
The change in limits of T-scores in stratum-I and II did improve the recruitment in stratum-II but 
not up to the expectations. Therefore, in November 2007 the committee again met and decided to 
continue recruiting women in the bone study until 400 women are recruited in stratum-II. 
 
Women were not suggested to take any particular dose of calcium and vitamin D tablets, but were 
instead advised to take regular dose prescribed by their local practitioner. 
 
 
3.3 Participating Centres 
A total of 51 international and the UK centres participated to recruit women in to the prevention 
trial. The recruitment into the bone study had started in Jan 2004 and accrual was dependent on the 
progress of the main trial. All centres randomised the participants through the central office in 
London, primarily by remote FTP (file transfer protocol, internet standard). A back-up system was 
provided for randomising by email, fax or telephone. 
 
For centres to participate in this study they had to have access to a DXA bone densitometry service 
using either Hologic or Lunar densitometers and had to be capable of performing BMD scans of the 
spine and hip.  
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3.4 Eligibility and Exclusion Criteria 
3.4.1Eligibility Criteria 
Women who met the entry criteria of the IBIS-II (Prevention) Study (chapter 3, section 3.8) were 
offered entry into the bone study.  Women who entered the bone study met the following additional 
criteria if they agreed to sign the informed consent form and if they met the exclusion criteria that 
are listed below.  
 
All women with T- scores < -2.5  and  ≤-4.0 or 1-2 low trauma vertebral fractures were treated with 
risedronate. Women who were already receiving oral bisphosphonate other than risedronate were 
allowed to continue taking them or changed to risedronate if wished to do so. 
 
 
3.4.2 Exclusion Criteria 
Women were not allowed to take part in the bone study if they had any of the following exclusion 
criteria: 
 
 Women with previous bilateral hip fractures or bilateral hip prostheses. This was because 
reliable DXA scans could not be performed. 
 
 Women   currently   with   any   type   of   metabolic   bone   disease   including:   Paget’s   disease,  
osteogenesis imperfecta, disorders of calcium or mineral metabolism, renal calculus, 
malabsorption, hyper- or hypocalcaemia, hyper- or hypoparathyroidism, hyper- or 
hypothyroidism (NB: women on stable thyroid replacement therapy can be included 
provided they were euthyroid as judged by the investigator).  Women with previous 
conditions that have been corrected were eligible. 
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 Women who had regularly taken any medication affecting bone metabolism within the past 
12 months including oestrogen, parathyroid hormone, calcitonin, oral or systemic 
glucocorticoid. However, women who had been diagnosed as osteoporotic and were 
currently taking oral bisphosphonate could join stratum-III of the bone sub-study providing 
their T-score was <-2.5 at the time of randomisation (DXA scan done within 3 months of 
joining the study). 
 
Women who had a T score less than –4 and/or more than 2 low trauma vertebral fractures. 
 
3.5 Investigations 
BMD was measured by DXA at LS, FN and TH at not more than 3 months before commencing the 
bone study and at 12 months. The T-scores for the femoral neck of the hip and lumbar spine were 
used to determine the stratum they joined. T-score results were calculated using either the Lunar 
(DPX  Series  Operators  manual  1998)  or  Hologic  (Kelly  1990)  manufacturer’s  reference  range  for  
the LS (L1-L4) and the NHANES III reference range for the hip region.  
 
A spinal radiograph was taken within 24 months prior to joining the bone sub study to rule out any 
spinal fractures or multiple wedges. 
Height, weight, hips and waist were measured at every DXA scan visit.   
 
3.6 Scan Analysis and Instrument Quality Control  
All the DXA scans were monitored and centrally analysed according to the study protocol. The 
quality control was conducted in two centres. The Hologic DXA scans were monitored by the 
quality control centres at the Division of Imaging Sciences, Kings College, London.  The Lunar 
DXA scans were monitored initially at the Academic unit of Physics, University of Leeds and then 
at Imperial College, London, UK. Throughout the study, instruments quality-control procedure (in 
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vivo cross-calibration) were undertaken by the different scanning centres, and included quality 
assurance  scans  defined  in  the  manufacturer’s  operating  manual  and  six-monthly summaries of the 
daily spine phantom scans were seen by the quality control centres. These were reviewed at regular 
basis to confirm that the equipment was working within specifications and no major fluctuations 
were occurring that might have affected the accuracy of the final DXA results. 
 
The investigators were informed at the beginning of the trial to use the same machine for the 
follow-up scans as used for the baseline scans and if possible to use the same machine throughout 
the study. Where this was not possible because of investigators upgrading or changing their 
densitometer, then the IBIS-II centre was informed in advance and a cross-calibration was 
performed.  
 
All the quality control data were reported as satisfactory. No problems were encountered at any of 
the centres except that one centre changed their DXA machine. At this centre, an in-vivo cross 
calibration was performed and the scans sent to the QC centre. 
 
3.7 Study End-points 
The subject ceased participation in this bone study when any of the following applied: 
 Withdrew from the main study 
 If they developed breast cancer  
 in case of death 
 If   rapid   bone   loss   occurred,   then   the   woman’s   treatment   was   unblinded   and   open   label 
risedronate was provided.  
 Severe adverse events 
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3.8 Follow-up DXA scans  
Baseline assessments for DXA were taken before the randomised therapy was commenced.  
Follow-up visits for DXA scans occurred within 1 month of the scheduled visit time for the 12 and 
36 month visit. Future follow-up scans are planned for 3, 5 and 7 years but are not described here. 
 
3.9 Bisphosphonate Supplies 
Risedronate was the bisphosphonate that was used in this sub-study. The dose was 35mg oral once 
a week. Careful instructions were given to all the participants who joined stratum-II or III of the 
study: 
 
 Women were asked to mark the date on the back of the packet when they started taking 
the first tablet so that they could keep a record of when to take the next tablet as they 
had to take only one tablet a week. 
 
 Women were advised to take the tablet in the morning. When they rose they were 
advised to swallow one tablet whole with a full glass of water on an empty stomach at 
least 30 minutes before the first food or other drink of the day or, if they took the tablet 
at any other time of the day, they were asked to avoid taking food and drink for at least 2 
hours before or after risedronate (particularly taking calcium-containing products e.g. 
milk, iron and mineral supplements and antacids). They were advised to stand or sit 
upright for at least 30 minutes after taking the tablet. They were advised not to take the 
tablet at bedtime or before rising. 
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Patients who were osteoporotic at entry and were currently taking oral bisphosphonate could 
remain on their treatment and could join stratum-III of the study if they still had an osteoporotic T-
score at the time of joining the bone study. 
 
3.10 Data Management  
3.10.1 Data Quality 
Local centres were advised to use DXA scanners that were regularly checked and met the QC 
standards as recommended by their manufacturers. Only BMD scans from centres that met these 
conditions were eligible for inclusion in the final data analysis.   
 
3.10.2 Bone Mineral Density (BMD) 
The BMD measurement at follow-up was expressed as a percentage of BMD at baseline i.e. 100= 
no change, <100 reduction, >100 increase. Wherever possible the lumbar spine DXA measurement 
was derived from the total of L1-L4. If a subsequent measurement of one of the vertebrae was not 
possible, e.g. due to vertebral fracture or artefact, then the BMD measurements were calculated 
using the remaining vertebrae. A minimum of two evaluable vertebrae were required. The TH site 
was used for the follow-up of hip BMD. 
 
 
3.10.3 Data Management 
All the data was treated as confidential and managed in accordance with the provisions of the Data 
Protection Act. 
 
 As  part  of  the  trial  program,  a  centre  randomised  remotely  by  simply  entering  the  woman’s  details  
and clicking randomise. A connection was made automatically to the Mercury, Cancer Research 
 
 
146 
UK ftp computer, and logged in to its own private space.  The program sent the encrypted details 
then checked every 5 seconds for a reply, up to 40 seconds, until an encrypted file appeared for it to 
download.  On  download  the  file  was  decrypted,  the  data  automatically  entered  onto  the  user’s  form  
and the database was updated. 
 
At Cancer Research UK the data file was decrypted, checked against Oracle, entered if a new 
recruit, and the study number was returned in an encrypted file for the centre to retrieve.  Requests 
for information from the centre were dealt with in the same way.  Everything was logged. 
 
3.11 Consent and Ethics Committee Approval 
Study sites taking part in the bone study required additional Ethics Committee approval for the 
BMD scanning.  In view of the very low radiation dose from DXA (typically 10 Sv for a spine and 
hip study) (Njeh, CF 1999) compared with a chest X-ray (typical dose 50 Sv) the BMD 
measurements did not create any ethical problems.  
 
3.12 Bone safety  
It was recommended that DXA scan should be repeated at 24 months, for all women who joined 
stratum I or stratum II of the bone study and had lost equal to or more than 6% bone mineral 
density, from either total hip or lumbar spine, at the 12 month DXA scan. 
 
3.13 Withdrawal of women from the bone study  
a) Women were withdrawn from their original stratum of the bone study only if: 
 In Stratum I participants developed osteoporosis (i.e. T-score of <-2.5), These 
women will be monitored by a DXA scan at a year 3, 5 and 7 and were provided 
with open label bisphosphonates from the IBIS Coordinating Centre. 
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 In Stratum-II participants developed osteoporosis and a drop in T-score of more than 
1 unit (i.e. equivalent to an approximately 10% drop of the baseline bone mineral 
density) or whose T-score dropped below -3.0 at either TH or LS (whichever 
happens first). These women will be monitored by a DXA scan at a year 3, 5 and 7 
and were provided with open label bisphosphonates from the IBIS Coordinating 
Centre.  
 
 In Stratum III, if the T-score fell <-4 (either lumbar spine or total hip) then 
Anastrozole/placebo was stopped immediately and women were referred to a bone 
specialist for further management. Centres were paid for an additional DXA scan to 
be performed at least a year later. Open label bisphosphonate was not provided in 
such cases as the participant remained under the care of a specialist. 
 
 
b. Women were also withdrawn from the bone study if: 
 They commenced any of the prohibited concomitant therapies as defined in Section 3.4.2 of 
this sub-protocol. 
 They wished to withdraw at any time (NB: This did not prejudice their remaining in the 
main IBIS-II trial). 
 They were in stratum II and started receiving open label bisphosphonate therapy. 
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3.14 Code Break 
3.14.1 Bone study Code Break 
If a woman developed osteoporosis in stratum-I then she was treated with open label risedronate, and 
if she was in Stratum II and developed osteoporosis and loss of 10% BMD then her blinded treatment 
(i.e. risedronate v placebo) was stopped.  The bone study treatment code (risedronate vs. placebo) 
could be broken at this stage, but the blinding for the main study (anastrozole vs. placebo) was kept 
intact.   
 
3.14.2 Main Study Code Break 
The IBIS-II (Prevention) Study is a double blind, placebo controlled randomised trial i.e. neither the 
doctor nor the woman will know who is on active treatment. 
The treatment code is only broken in the following circumstances: 
1) Where the woman develops breast cancer  
2) Where it is considered necessary by any clinician involved in her care. 
 
3.15 All Adverse Events 
 
3.15.1 Adverse Events (AE) 
 
An adverse event was defined as the development of a new, undesirable medical condition or the 
deterioration of a pre-existing condition following or during exposure to a medicine whether or not 
considered causally related to the product.  A medical condition could be a symptom (such as 
nausea or diarrhoea) a sign (such as rash or enlarged liver) or an abnormal result of an investigation 
(x-rays or scans or various types). An AE was recorded if an undesirable medical condition 
occurred at any time, even if no study treatment had been administered. 
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All adverse events were recorded and reported if they began at any time whilst the patient was 
receiving the randomised treatment and during 30 days after treatment withdrawal.  This was 
reported via the relevant follow-up CRF. 
 
3.15.2 Serious Adverse Events (SAE) 
A serious adverse event was an event that fulfilled one or more of the following criteria: 
  Was fatal 
 Was life-threatening  
  Required in-patient hospitalisation or prolonging hospitalisation 
 Resulted in disability or incapacity 
 Or was an important medical event that required medical intervention to prevent permanent 
impairment or damage. 
 
The causality of SAEs (i.e., their relationship to study treatment) was assessed by the investigator(s), 
who in completing the relevant CRF answered “yes”  or  “no”  to  the  question  “Do  you  consider  that  
there  is  a  reasonable  possibility  that  the  event  may  have  been  caused  by  the  drug?”    If  the  answer  to  
this question was yes, the SAE was classified as a Serious Adverse Reaction (SAR). All SAEs were 
reported to the IBIS Central Coordinating Centre within 24 hours. 
 
All SAEs, including those that were on going at the end of the follow-up period, were followed to 
resolution   unless,   in   the   investigator’s   opinion,   the   condition   was   unlikely   to   resolve   due to the 
patient’s  underlying  disease.   
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3.15.3 Recording of adverse events 
All adverse events were recorded in the electronic SAE CRF with the following information as 
appropriate: 
 
Complete description of events were recorded, which included; dates and times of onset and 
resolution, event intensity, seriousness, outcome, causality, any action taken (e.g. treatment, 
diagnostic tests).  It was important to distinguish between serious and severe AEs.  An AE of 
severe intensity needed not necessarily be considered serious.  For example, nausea, which 
persisted for several hours, was considered severe nausea, but not a SAE.   
 
 
3.15.4 Reporting of serious adverse events 
Investigators and other site personnel informed London IBIS Central Office of any SAE that 
occurred in the course of the study immediately (within 24 hours) of when he or she became aware 
of it. 
The  electronic  SAE  CRF’s  were  sent  to  the  IBIS  Central  Coordinating  Centre  within  24  hours  and  
by  selecting  the  “Talk-to-CR-UK”  option  on  the  IBIS-II program.  A hard copy of the SAE CRF 
were printed, signed by the local principal investigator and faxed to the IBIS Central Coordinating 
Centre as soon as he or she became available.  
 
3.16 Statistical Considerations  
The statistical plan for the study was based on a long-term precision for spine and total hip BMD of 
1.5% (Patel, R 2000) and a population standard of 3% for the biological variation in response for 
the women in each arm of the study. The assumption was made on type 1 error of p=0.05 and a 
90% power. 
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Stratum 1: In Stratum-I, women were randomised to either anastrozole or a placebo group. Hundred 
women in each arm completing the study was sufficient to identify a treatment effect of anastrozole 
of 1.4% with the stated p-value and power. Allowing for dropouts it was planned to enrol 150 
subjects in each arm. 
 
Stratum-II: With four groups (± anastrozole, ±risedronate) a total of 70 women in each group is 
sufficient to detect a difference of 1.65%. Allowing for dropouts it was planned to enrol 100 
subjects in each arm. 
 
Stratum-III: the plan for stratum-III was similar to Stratum-I. 
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Chapter 3 
Section-II: Brief study design of the IBIS-II Prevention Study 
 
3.17 Introduction 
IBIS-II (Prevention) was designed to continue the work started in IBIS-I in determining whether a 
chemopreventive strategy towards breast cancer is beneficial.  IBIS-I was set up to investigate the 
use of tamoxifen as a preventive agent for women with moderate to increased risk of getting breast 
cancer.  IBIS-II (Prevention) is a randomised double blind control trial but this time will compare 
anastrozole vs. placebo.  A companion protocol will compare anastrozole to tamoxifen for women 
with locally excised ER or PgR +ve DCIS.  
  
This study is running in accordance with the ICH GCP Guidelines, the principles of which have 
their origins in the Declaration of Helsinki 2000 (Christie, B 2000). 
 
Cancer Research UK is supporting this research study and Queen Mary, University of London are the 
sponsors. 
 
The primary aim of the study is to determine if anastrozole is effective in preventing breast 
cancer in postmenopausal women at increased risk of the disease. 
 
3.17 Study Design 
3.17.1 Outline 
A multicentre, randomised placebo-controlled clinical trial of 6,000 postmenopausal women aged 
between 40 and 70 years who are at increased risk of breast cancers is currently on going.  The 
specific categories for eligibility are shown in Section 3.18. In general terms increased risk is 
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determined from family history, previous benign disease with evidence of proliferation, 
mammographic dysplasia, and nulliparity.  All women have a mammogram to exclude breast 
cancer before randomisation and a blood sample is taken for analysis of biochemical and other risk 
factors for breast cancer and potential side effects. 
 
3.17.2 Dose and Duration 
Women are randomised in a 2-arm design to receive one of the following: 
 Anastrozole 1mg  
 Anastrozole placebo 
 
3.17.3 Participating Centres and Recruitment 
All centres are randomised through the central office in London, primarily by remote FTP (file 
transfer protocol, internet standard) and the randomisation ration is 1:1.  Back-up systems are 
provided for randomising by fax and failing that, by telephone or e-mail. The remote randomisation 
is part of the standard trial software distributed to all centres for the data management of the trial. 
 
3.17.4 UK and International centres 
Recruitment is based at regional centres.  Regional centres enter patients at their own hospital and 
also serve as a local co-ordinating centre (hub) for satellite centres in nearby hospitals throughout 
the region.   
 
Each centre is expected to recruit an agreed number of new participants per year to reach their 
target over 6-8 years. 
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3.18 Eligibility 
3.18.1 Inclusion Criteria 
a) All women must be postmenopausal and between the ages of 40-70.  Postmenopausal status is 
defined as meeting one or more of the following criteria:  
 Over the age of 60 
 Bilateral oophorectomy 
 Aged  60 with a uterus and amenorrhoea for at least 12 months 
Aged  60 without a uterus and with FSH >30 IU/L. 
b) Women must satisfy at least one of the entry criteria listed in section 3.18 below. 
c)  A mammogram must have been taken within the last year and must not show any evidence of 
breast cancer. 
d)  A baseline bone mineral density scan within the last two years (DXA either of hip, lumbar 
spine, femoral neck or forearm) will be required for all women. A spinal x-ray to assess low 
trauma vertebral fractures will also be required. 
e)  Fully informed signed consent must have been obtained. 
f)  Participants treated for Hodgkin's disease are eligible if they develop the disease before the age of 
30 and have been treated with mantle radiotherapy.  
g)  Participants who took part in IBIS-I but have been off trial therapy for at least 5 years. These 
women were eligible to take part in the prevention study. 
 
 
3.18.2 Entry Criteria 
Entry criteria are age-dependent to reflect increasing baseline risk with age.  
Women aged 45-70 
The entry criteria are based on a relative risk of at least two-fold and are similar to those in IBIS-I. 
At least one of the following must be satisfied: 
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1. First degree relative who developed breast cancer at age 50 or less 
2. First degree relative who developed bilateral breast cancer 
3. Two or more first or second-degree relatives who developed breast or                     
           ovarian cancer.  If both relatives are second degree and on opposite sides            
           of the family, then at least one must have been diagnosed at age 50 or less. 
4. Nulliparous (or first birth at age 30 or above) and a first degree relative      
            who developed breast cancer. 
5. Benign biopsy with proliferative disease and a first degree relative who developed breast 
cancer 
6. Mammographic opacity covering at least 50% of the breast in absence of HRT use 
within the last 3 months.  Films or digitised images must be supplied to the London 
IBIS central office or a designated national radiologist for confirmation before 
randomisation and will be returned promptly. 
 
Also women aged 60-70 
Because of their higher baseline risk, women aged 60-70 can enter the study with a smaller relative 
risk (approximately 1.5 or greater).  This corresponds to a similar 5-year absolute risk as that for a 
50-year old woman in the above group (approximately 3% at 5 years).  These women need only 
have one or more of the following risk factors: 
6) First degree relative with breast cancer at any age 
7) Age at menopause  55 years 
8) Nulliparous or age at first birth 30 years or above 
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Women aged 40-44 
Women aged 40-44 who are postmenopausal (usually because of a bilateral oophorectomy) are 
eligible if they satisfy one or more of the following criteria (approximately 4-fold risk or greater): 
9) Two or more first or second degree relatives who developed breast or ovarian cancer at 
age 50 or less 
10) First degree relative with bilateral breast cancer who developed the first breast cancer 
at age 50 or less 
11) Nulliparous (or first birth at age 30 or above) and a first degree relative who developed 
breast cancer at age 40 or less 
12) Benign biopsy with proliferative disease and a first degree relative who developed 
breast cancer at age 40 or less 
 
 
All Age Groups (40–70) – women who have had certain breast conditions will also be eligible. 
These are:  
14) Lobular carcinoma in situ (LCIS) 
15) Atypical ductal or lobular hyperplasia in a benign lesion 
16) Ductal carcinoma in-situ (DCIS), diagnosed within the last 6 months, and treated by 
mastectomy. Oestrogen Receptor or Progesterone Receptor status, (ER or PgR), of DCIS 
must be known, and must be greater than 5% positive cells. 
17) Women with a ten-year risk greater than 5%, who do not fit into the above categories 
(risk equivalent).  All risk equivalent women must be approved by the Steering 
Committee Co-Chairman (London IBIS central office). These women must have clearly 
apparent family history and/or other risk factors indicating appropriate increased risk of 
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breast cancer for their age. Particularly careful assessment of the risk-benefit for these 
women should be undertaken before a woman from this group is entered.  
In all cases, if desired, an individual clinician may enter only a subset of the eligible women.  
 
3.18.3 Exclusion Criteria 
a) Premenopausal women. 
b) Any previous diagnosis of breast cancer (including DCIS diagnosed >6 months ago) 
c) Any other previous cancer in the past 5 years (except non-melanoma skin cancer or in situ 
cancer of the cervix). 
d) Current or previous tamoxifen or raloxifene or other SERMs use for more than 6 months 
or participation in IBIS-I. However, women who took part in IBIS-I and have been off 
trial therapy for at least 5 years are eligible. 
e) Intention to continue to use oestrogen-based hormone replacement therapy (HRT). 
f) Women who have either had a prophylactic mastectomy or are planning to have this 
procedure.  
g) Evidence of osteoporosis or low trauma vertebral fractures within the spine.  However, 
these women may be eligible if their T-score is greater than minus four, and if they have 
no more than two low trauma vertebral fractures.  In either case they must take 
bisphosphonate treatment, have regular DXA scans and ideally join the bone sub study. 
Women with T-scores less than minus four, or with more than two low trauma vertebral 
fractures are not eligible. 
h) Any severe concomitant disease that would, in the opinion of the investigator, place the 
woman at unusual risk or confound the results of the study. 
i) Life expectancy of less than 10 years or other medical condition that would significantly 
interfere with the ability to accept the chemopreventive treatments. 
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j) Psychologically and physically unsuitable for five years anti-oestrogen therapy. 
k) Treatment with non-approved or experimental drug during the 6 months before 
randomisation. 
l) History of gluten intolerance. 
 
 
3.19 Study Procedures 
3.19.1 Investigations 
 
3.19.2 Mammography 
All women were required to have a physical examination and mammogram (and where necessary 
fine needle cytology or biopsy) to exclude pre-existing malignancy. A clear mammogram within 
the twelve months before entry was accepted.  
 
3.19.3 Bone Mineral Density (BMD) 
A baseline DXA scan within the last two years was required for all women prior to randomisation.  
 
3.19.4 Spinal Radiograph 
A baseline radiological assessment was needed within two years prior to randomisation to rule out 
low trauma vertebral fractures.  This required two x-rays in one lateral dimension to view the 
thoracic and the lumbar vertebrae.  These were reported by a qualified radiologist and the report 
were needed before randomisation took place.  If there were more than two low trauma vertebral 
fractures then the woman could not take part in any of the IBIS-II protocols (The European 
Prospective Osteoporosis Study (Epos) Group, 2002). 
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                                     Chapter IV: Results 
Section-I: Effect of Anastrozole on Bone Mineral Density:  1and 3 Year result 
from the Bone sub-study of the International Breast Cancer Intervention Study 
(IBIS-II) 
 
4.1.1: Introduction   
                                                                                                                                                                                                                                   
The third generation AIs have been shown to reduce bone mineral density when compared with 
tamoxifen in the advanced, adjuvant and neoadjuvant settings in women with early breast cancer 
((Buzdar, A 2006) (Thurlimann, B 2005) and (Coombes, RC 2004). Preliminary data from adjuvant 
trials also suggest that bisphosphonates can prevent AI-induced bone loss in postmenopausal 
women (Van Poznak, C 2010) (Lester, JE 2008). There is a hope that bisphosphonate therapy in 
combination with an AI will offer the potential to prevent AI-induced bone loss and fracture risk in 
postmenopausal women in a chemoprevention setting. 
 
The International Breast Cancer Intervention Study-II (IBIS-II) is the first trial on a large data set to 
report the effect of anastrozole on bone mineral density, compared with placebo, in healthy 
postmenopausal women with a high risk of breast cancer. It will also report the effect of 
bisphosphonate treatment on bone mineral density among women receiving anastrozole versus 
placebo who had an osteopenic or an osteoporotic T-score at the time of joining the trial. 
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4.1.2 Material and Methods  
IBIS-II is a randomised, double-blind study of the benefits of anastrozole in preventing breast 
cancer in postmenopausal women with at least double the average risk. The aim of the study is to 
recruit 6000 women so that half receive anastrozole 1mg/day and the other half receive a matching 
placebo for 5 years with follow-up for a further two years. 
 
The bone sub-protocol is a randomised, double-blind, multicentre study performed within the IBIS-
II main trial to examine the effect of anastrozole on bone mineral density (BMD), and the risk of 
developing osteoporosis and fractures. Additionally, it also aims to explore the ability of 
bisphosphonate treatment to reduce the risk of osteoporosis in women found to have low bone 
mineral density at baseline. 
 
Patients were randomised into different strata depending upon the baseline T-score. Women with T-
score greater or equal to minus one (≥-1.0) at both LS and FN joined stratum I of the study and 
received monitoring only without bisphosphonate treatment. Women with osteopenia with at least 
one T-score less than minus one and greater than or equal to minus two point five (-2.5 ≤ T score <-
1.0) at LS or FN were randomised to receive either risedronate or placebo. Osteoporotic women 
with at least one T-score less than minus two point five but greater than or equal to minus four (-4.0 
≥ T score <2.5) at LS or TH or up to two low trauma vertebral fractures received risedronate. 
Women with a T-score <-4.0 were not eligible to join the IBIS-II prevention study. 
 
A spinal radiograph was taken within 24 months prior to joining the bone sub study to rule out any 
fracture.  Height, weight, hips and waist were measured at every DXA scan visit. 
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4.1.3 Endpoint 
The primary endpoint of the study was mean annual change in BMD at LS and TH in patients who 
remained on the study at 12 and 36 months. 
 
4.1.4 Statistical Analysis  
Based on the number of scans available at 12 months, the power calculations were done again. It 
was calculated that in stratum-I with 500 subjects (250 in each arm) there is 90% power to detect a 
treatment effect (loss of BMD) of 0.9. In stratum-II, 264 subjects (66 in each arm) there is 90% 
power to detect a difference of 1.7% and in stratum-III, 45 subjects in each arm there is 90% power 
to detect a treatment effect of 2.0%.  
 
Based on scans available at 36 months, it was calculated that in stratum-I with 237 subjects 
(approx. 118 in each arm) there is 90% power to detect a treatment effect of 1.26%. In stratum-II, 
70 subjects (approx. in each arm) there is 90% power to detect a difference of 3%. Because of very 
few numbers, the power calculation was not done in stratum-III. 
 
Analysis was done on the BMD data sent by the quality control centres that were processed by 
using STATA (version 10). All patients who had DXA measurements at baseline and one and three 
year were included in the analysis. Results are expressed as mean percentage change from baseline 
to one year at lumbar spine and total hip. The distribution of mean percentage change was tested 
against the two treatment groups by Mann-Whitney U-test and Wilcoxon signed rank test. The 
mean percentage change within the treatment group (anastrozole and placebo) from baseline to 12 
and 36 months was tested by a simple paired t-test. Statistical significance was assessed based on a 
2-sided p-value of less than 0.05. The estimated mean percentage changes from baseline and 
associated 95% CIs are presented here. All patients who had DXA measurements at baseline and 
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one year were included in the analysis. Results are expressed as mean percentage change in BMD 
from baseline to one-year and three-year follow-up with corresponding 95% confidence intervals. 
The BMD changes in each treatment group in each stratum were evaluated to determine whether 
they followed a normal distribution. Data were normally distributed hence the P-value for the 
percentage changes from baseline to follow-up within treatment group was assessed using a paired 
t-test. A regression analysis was performed to investigate any interaction between anastrozole and 
risedronate treatment in stratum-II. Statistical significance was based on 2-sided p-values and a 5% 
significance level was used.  
 
Regression analysis (forward model) was also undertaken to identify important cofactors, such as 
age, smoking, and exercise, use of vitamin D, calcium and history of use of HRT. In the forward 
model, which involved starting with no variable and then the variable with most significance was 
added stepwise until the final model that included all the variables from the most significant to the 
least significant.  
Regression analysis in Stratum-II: A regression analysis was done to assess the percentage change 
at lumbar spine and total hip by creating 4 variables (a, b, c and d), where a represented data from 
only anastrozole group, b for data from only risedronate group, c for data from anastrozole and 
risedronate group and d for data from placebo and risedronate group. 
The equation used was: 
% BMD change= c + a*(Ana) + b*(Ris) + d*(Ana)*(Ris) 
Where: (Ana) = 1 in patients on anastrozole and 0 in patients on anastrozole placebo 
(Ris) = 1 in patients on risedronate on 0 in patients on risedronate placebo 
c= a constant giving the mean BMD change in patients on both placebos 
d= is the interaction term describing any additional effect of taking both active drugs 
a= the anastrozole main effect and b=the risedronate main effect 
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The analysis reduced the results for the four groups in Stratum 2 into 4 coefficients, a, b, c and d. 
 
4.1.5 Results at 12 months 
4.1.5.1 Participants 
Between March 2003 and May 2010, 3014 postmenopausal women took part in the IBIS-II 
prevention study, of which 1326 women from 31 centres in six countries took part in the bone sub-
study. Of these, 723 (55%) entered stratum-I, 463 (35%) entered stratum-II and 140 (11%) entered 
stratum-III of the study. Out of 1326 recruited in the bone sub-study, 1092 (82.4%) women 
potentially could have had 12-months of follow-up at the time of analysis (Figure 4.1.1 and Table 
4.1.1) 
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Figure 4.1.1: Recruitment into the IBIS-II prevention and bone sub-study at 12 months 
 
Of these 1092, 140 (12.8%) women dropped out of the study, 85 (7.8%) 12-months DXA scans 
were not received, 69 (6.3%) women were lost to follow-up or their follow-up forms were not 
received, 4 (0.4%) women were withdrawn from stratum-II as they had >10% bone loss and a 
developed a T-score of <-2.5, leaving 794 (72.7%) women for analysis. Of these, 457 (57.6%) were 
in stratum-I, 246 (31%) in stratum II, and 91 (11.5%) in stratum-III). Detailed information about 
dropouts is given in table 4.1.12. 
RisedronateObservation
Prevention Trial
n = 3014
Stratum-III
-4.0  ≤  T-score < -2.5
(Osteoporotic)
Stratum-I
T-score  ≥  -1.0
(Normal)
Bone Sub-Study
n = 1326
Randomisation
PlaceboRisedronate
n = 723
Numbers
enrolled n = 230 n = 233 n = 140
n = 615 n = 179 n = 178 n = 120
12 months follow-up 
data potentially 
available*
n = 457 n = 117 n = 129 n = 91
12 months follow-up 
data available
Stratum-II
-2.5  ≤  T-score < -1.0
(Osteopenic)
*Numbers who would have completed 1-year follow-up before allowing for drop-outs, subjects lost to follow-up and missing 
DXA scans
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Table 4.1.1: Distribution of women in different strata at 12- months of follow-up 
 Total 
(All strata) 
N (%) 
Stratum-I 
 
N (%) 
Stratum-II 
 
N (%) 
Stratum-III 
 
N (%) 
Randomised 12 months before 
data-cut date (2nd June 2010)  
1092 (100)  615 (100) 357 (100) 120 (100) 
Drop-outs (i)  140 (12.8) 
 
83 (13.5) 44 (12.3) 13 (10.8) 
DXA scans not received (ii)  85 (7.8) 
 
47 (7.6) 23 (6.4) 15 (12.5) 
Lost to follow-up/Follow-up 
forms not received (iii)  
69 (6.3) 28 (4.6) 40 (11.2) 1 (0.8) 
Women withdrawn from the 
study (iv) 
4 (0.4) - 4 (1.1) - 
Total (i + ii + iii + iv)  298 (27.3) 
 
158 (25.7) 111 (31.1) 29 (24.2) 
Scans available  794 (72.7) 457 (74.3) 246 (68.9) 91 (75.8) 
 
Women’s  baseline  demographics  and  bone  characteristics  are  shown  in  Table  4.1.2  
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Table 4.1.2: Baseline Characteristics - Mean or percentage (95% CI) 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
When baseline characteristics were observed in all strata, women in the two treatment groups  
  All Strata 
 Anastrozole 
(n=388) 
Placebo 
(n=406) 
p-value 
           Age (years) 59.3 
(58.8, 59.8) 
 
59.2 
(58.7, 59.8) 
0.77 
Weight (kg) 73.9 
(72.5, 75.4) 
 
75.2 
(73.7, 76.7) 
0.22 
Height (cm) 161.9 
(161.3, 162.5) 
 
162.2 
(162.6, 162.8) 
0.46 
BMI (kg/m2) 28.2 
(27.7, 28.7) 
 
28.6 
(28.0, 29.1) 
0.33 
Smoking (current and 
ex) status (%) 
46.9 
(41.9, 51.9) 
 
41.1 
(36.3, 45.9) 
0.10 
Past use of HRT (%) 50.0 
(45.0, 55.0) 
 
52.2 
(47.4, 57.1) 
0.53 
Hysterectomy (%) 32.2 
(27.6, 36.9) 
 
33.7 
(29.1, 38.3) 
0.65 
Use of calcium (%) 31.4 
 (26.6, 36.2) 
 
29.7 
(25.1, 34.3) 
0.61 
Use of Vitamin D (%) 29.1 
(24.4, 33.8) 
 
26.2 
(21.8, 30.7) 
0.38 
Lumbar spine T-score -0.66 
(-0.80, -0.53) 
 
-0.56 
 (-0.71, -0.42) 
0.32 
Total Hip T-score -0.33 
(-0.44, -0.22) 
 
-0.23 
(-0.34, -0.12) 
0.18 
Femoral neck T-score -0.71 
(-0.82, -0.60) 
-0.74 
(-0.85, -0.63) 
0.67 
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(anastrozole or placebo) were well matched in terms of age, height, weight, BMI, history of 
smoking, past use of HRT, hysterectomy, current use of calcium, current use of vitamin D, baseline 
lumbar spine, total hip and femoral neck T-scores.  
 
 
 
Table 4.1.3 (a): Baseline Characteristics in Stratum-I & II- Mean or percentage (95% CI) 
 
 
 
 
 Stratum-II Stratum-III 
 Anastrozole 
(n=224) 
Placebo 
(n-233) 
p-
value 
Anastrozole 
(n=127) 
Placebo 
(n=119) 
p-
value 
Age (years) 58.6 
(57.9, 59.7) 
 
58.2 
(57.5, 58.9) 
0.41 60.5 
(59.6, 61.3) 
59.8 
(58.8, 60.8) 
0.32 
Weight (kg) 77.7 
(75.8, 79.6) 
 
77.7 
(75.6, 79.8) 
0.99 69.39 
(67.2, 71.5) 
73.1 
(70.7, 75.5) 
0.02 
Height (cm) 162.8 
(161.9, 
163.6) 
 
162.8 
(162.1, 163.6) 
0.89 160.9 
(159.8, 162.1) 
161.9 
(160.8, 163.1) 
0.20 
BMI ( kg/m2) 29.2 
(28.5, 30.2) 
 
29.3 
(29.4, 30.2) 
0.77 26.7 
(25.9, 27.5) 
27.9 
(27.0, 28.9) 
0.06 
Smoking status 
(%) 
50.9 
(44.3, 57.5) 
 
42.5 
(36.1, 48.9) 
0.07 38.6 
(30.0, 47.2) 
40.3 
(31.4, 49.3) 
0.78 
Past use of 
HRT (%) 
49.1 
(42.5, 55.7) 
 
54.5 
(48.1, 60.9) 
0.25 52.8 
(40.5, 58.7) 
49.6 
(40.5, 58.7) 
0.62 
Hysterectomy 
(%) 
36.6 
(30.3, 43.1) 
 
34.3 
(28.2, 40.5) 
0.61 29.9 
(21.8, 38.1) 
30.3 
(21.9, 38.6) 
0.96 
Use of calcium 
(%) 
28.2 
(22.1, 34.3) 
 
30.1 
(23.9, 36.3) 
0.66 34.5 
(25.8, 43.1) 
28.6 
(20.1, 37.1) 
0.34 
Use of Vitamin 
D (%) 
25.4 
(19.5, 31.2) 
 
26.9 
(20.9, 32.8) 
0.72 34.5 
(25.8, 43.1) 
23 
(17.7, 34.1) 
0.16 
Lumbar spine 
 T-score 
0.12 
(-0.02, 0.26) 
 
0.22 
(0.06, 0.38) 
0.35 -1.47 
(-1.61, -1.34) 
-1.18 
(-1.33, -1.03) 
 
0.00 
Total Hip  
T-score 
0.22 
(0.97, 0.34) 
 
0.29 
(0.18, 0.42) 
0.35 -0.94 
(-1.06, -0.82) 
-0.74 
(-0.88, -0.59) 
0.03 
Femoral neck 
 T-score 
-0.11 
(-0.23, 0.01) 
-0.13 
(-0.24, -0.01) 
0.83 -1.30 
(-1.43, -1.18) 
-1.28 
(-1.42, -1.18) 
0.82 
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Table 4.1.3 (b): Baseline Characteristics in Stratum-III- Mean or percentage (95% CI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Stratum-III 
 Anastrozole 
(n=37) 
Placebo 
(n= 54) 
p-
value 
Age (years) 59.2 
(57.3, 61.0) 
62 
(60.7, 63.3) 
 
0.01 
Weight (kg) 66.9 
(62.7, 71.0) 
69.4 
(65.6, 73.1) 
 
0.38 
Height (cm) 160.1 
(158.2, 161.9) 
160.2 
(158.6, 161.8) 
 
0.91 
BMI ( kg/m2) 26.1 
(24.5, 27.8) 
27.0 
(25.6, 28.5) 
 
0.42 
Smoking status 
(%) 
51.4 
(34.5, 68.2) 
37.0 
(23.7, 50.30) 
 
0.18 
Past use of HRT 
(%) 
45.9 
(29.1, 62.8) 
48.2 
(34.4, 61.9) 
 
0.84 
Hysterectomy 
 (%) 
13.5 
(11.2, 25.1) 
38.9 
(25.4, 52.3) 
 
0.01 
Use of calcium 
(%) 
41.9 
(23.5, 60.3) 
30.2 
(17.4, 42.9) 
 
0.28 
Use of Vitamin D 
(%) 
34.4 
(17.1, 51.8) 
24.5 
(12.6, 36.5) 
 
0.33 
Lumbar spine  
T-score 
-2.62 
(-2.85, -2.40) 
-2.61 
(-2.81, -2.42) 
 
0.93 
Total Hip  
T-score 
-1.47 
(-1.74, -1.2) 
-1.35 
(-1.62, -1.74) 
 
0.55 
Femoral neck 
 T-score 
-1.89 
(-2.16, -1.61) 
-1.79 
(-2.08, -1.51) 
 
0.65 
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When baseline characteristics were examined separately in different stratum (table 4.1.3 (a)), 
women in stratum-I were well matched in terms of age, height, weight, BMI, history of smoking, 
past use of HRT, hysterectomy, current use of calcium, current use of vitamin D, baseline lumbar 
spine, total hip and femoral neck T-scores. 
 
 In stratum-II, a significant difference was observed for weight (p=0.02), baseline lumbar spine 
(p=0.004) and total hip T-scores (p=0.03). Women in the anastrozole group were lighter in weight 
than in the placebo group, and had lower lumbar spine & total hip T-scores.  
 
In stratum-III, women were well matched in terms of height, weight, BMI, history of smoking, past 
use of HRT, current use of calcium, current use of vitamin D, baseline lumbar spine, total hip and 
femoral neck T-scores, but there were significantly younger women in the anastrozole group 
compared to placebo (p=0.01). Similarly, a significantly lower number of women had undergone 
hysterectomy in the anastrozole group compared to placebo group (p=0.01). 
 
4.1.5.2 BMD Percentage Change in Stratum-I, II and III at 12 months  
The mean percentage changes at 12 months from baseline for lumbar spine and total hip BMD are 
shown graphically in Figures 4.1.2 & 4.1.3 and numerically in Tables 4.1.4 to 4.1.7.  
 
Stratum-I 
 
In stratum-I, a significant BMD loss at 12 months was observed at lumbar spine and total hip in 
both treatment arms, but the effect was significantly larger in the anastrozole group; lumbar spine (-
2.01% vs. -0.44%, p <0.0001) and total hip (-1.36% vs. -0.50%, p=0.0004) in the anastrozole and 
placebo groups, respectively (Table 4.1.4, Figure 4.1.2 & 4.1.3).  
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Table 4.1.4: Stratum-I: Mean percentage change in BMD from baseline to 12 months in the Lumbar 
spine and Total Hip according to treatment group 
* BMD values missing for 3 participants in the anastrozole group and 1 participant in the placebo group. 
** BMD values missing for 2 participants in the anastrozole group and 11 participants in the placebo group. 
 
 
 
Stratum-II 
 
In stratum-II, women randomised to risedronate had increases in BMD in both the anastrozole and 
placebo groups compared with BMD losses in those not receiving risedronate (Table 4.1.5 & 4.1.6, 
Figure 4.1.2 & 4.1.3).  
 
The BMD change was significant in the anastrozole group at lumbar spine (risedronate vs. non-
risedronate group (+1.46% vs. -0.48%, p=0.001), and highly significant in the placebo group 
(+2.05% vs. -0.42%, p <0.0001). At total hip, the BMD changes were not quite significant in the 
anastrozole group (+0.19% vs. -0.97%, p=0.07), but significant in the placebo group (+0.83 % vs. -
0.78% p=0.002).  
 
 Anastrozole 
(n=224)  
Placebo 
(n=233) 
Difference in mean values 
Between treatment groups 
 
Lumbar spine BMD* 
 (95% CI) 
-2.01 
(-2.50, -1.52) 
<0.0001 
-0.44 
(-0.86, -0.03) 
0.04 
 
-1.57 
(-2.21, -0.93) 
<0.0001 
 
Total Hip BMD** 
 (95% CI) 
 
-1.36 
(-1.68, -1.03) 
<0.0001 
-0.50 
(-0.84, -0.17) 
0.003 
-0.85 
(-1.32, -0.39) 
0.0004 
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Table 4.1.5: Stratum-II: mean percentage change in BMD from baseline to 12 months in the 
Lumbar Spine and Total Hip according to treatment group 
 
Site  Anastrozole 
with 
risedronate 
(n=64) 
 
Placebo 
with 
risedronate 
(n=53) 
 
Anastrozole 
without 
risedronate 
(n=63) 
 
Placebo  
without 
risedronate 
(n=66) 
 
Lumbar Spine (% change)* 
(95% CI) 
p-value 
 
1.46 
(0.51, 2.41) 
0.003 
2.05 
(1.30, 2.79) 
<0.0001 
-0.48 
(-1.17, 0.22) 
0.18 
-0.42 
(-1.27, 0.43) 
0.33 
 
Total Hip (% change)** 
(95% CI) 
p-value 
 
0.19 
(-0.41, 0.78) 
0.54 
0.83 
(0.11, 1.54) 
0.02 
-0.97 
(-2.05, 0.10) 
0.08 
-0.78 
(-1.49, -0.06) 
0.03 
* BMD values missing for 1 participant in the placebo with risedronate group and 1 participant from the placebo 
without risedronate group 
 **BMD values missing for 4 participants in the anastrozole with risedronate group, 1 participant in the placebo with 
risedronate group, 2 participants in the anastrozole without risedronate group and 2 participants from the placebo 
without risedronate group 
 
 
In stratum-II, the baseline T-score values were significantly different at lumbar spine (p=0.004) and 
total hip T-score (p=0.03) between the two chemoprevention treatment arms (Table 4.1.3 (a)). 
Therefore, a logistic regression analysis was conducted (adjusting for baseline T-score values at 
lumbar spine and total hip in the model) to look at the main effect of anastrozole and risedronate on 
BMD percentage change at 12 months. No effect of the difference in baseline T-score values 
between treatment groups on the percentage change was observed either at lumbar spine or at total 
hip either for anastrozole or risedronate treatment (Table 4.1.6). 
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Table 4.1.6: Stratum-II: Mean percentage change in BMD from baseline to 12 months in the 
Lumbar Spine and Total Hip according to treatment groups 
 
Stratum II 
(n=246) 
LS Difference in mean values 
between treatment groups 
(95% CI) 
p-value 
TH Difference in mean values 
between treatment groups 
(95% CI) 
p-value 
Anastrozole ± Risedronate 1.94 
(0.76, 3.12) 
0.001 
 
1.16 
(-0.07, 2.39) 
0.07 
Placebo ± Risedronate 2.47 
(1.31, 3.62) 
<0.0001 
1.60 
(0.58, 2.62) 
0.002 
 
Risedronate  ± Anastrozole 
 
-0.59 
(-1.83, 0.66) 
0.36 
 
-0.64 
(-1.56, 0.28) 
0.18 
 
No Risedronate  ± Anastrozole 
-0.06 
(-1.16, 1.04) 
0.92 
 
-0.20 
(-1.48, 1.08) 
0.76 
Anastrozole main effect* -0.32 
(-1.16, 0.53) 
0.46  
 
-0.50 
(-1.30, 0.31) 
0.25 
Risedronate main effect* 2.19 
(1.34, 3.02) 
<0.0001 
1.56 
(0.77, 2.36) 
<0.0001 
 
Anastrozole-Risedronate 
Interaction 
-0.52 
(-2.19, 1.14) 
0.54 
-0.37 
(-1.97, 1.13) 
0.65 
*main effect calculated using regression model (adjusting for baseline T-scores at lumbar spine and 
total hip) with no interaction 
 
A significant overall effect of risedronate was observed at lumbar spine (p<0.0001) and total hip 
(p=0.0004), however no significant main effect of anastrozole was observed at either of the sites 
(p=0.46 and 0.25) at lumbar spine and total hip, respectively. 
 
No significant evidence of an interaction was observed between anastrozole and risedronate either 
at lumbar spine (p=0.54) or total hip (p=0.65). 
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Stratum-III 
 
In stratum-III, statistically significant increases in BMD were observed at the lumbar spine in both 
arms of the study (anastrozole p=0.0006; Placebo p <0.0001), and also at the total hip for the 
placebo group (p=0.04). A marginally significant difference in mean values between the treatment 
groups was observed at lumbar spine (+2.27% vs. +3.85%, p=0.06), but not at total hip (+0.49 vs. 
0.96, p=0.47) in the anastrozole and placebo groups, respectively (Table 4.1.7, Figure 4.1.2 & 
4.1.3).  
 
Table 4.1.7: Stratum-III: Mean percentage change in BMD from baseline to 12 months in the 
Lumbar spine and Total Hip according to treatment group 
* BMD values missing for 1 participant in the placebo group. 
** BMD values missing for 2 participants in the placebo group. 
 
 
 
 
 
 
 
 
 
 
 
 Anastrozole 
(n=37)  
Placebo 
(n=54) 
Difference in mean values 
between treatment groups 
 
Lumbar spine BMD* 
 (95% CI) 
2.27 
(0.97, 3.58) 
0.0006 
3.85 
(2.81, 4.88) 
<0.0001 
-1.57 
(-3.22, 0.08) 
0.06 
 
Total Hip BMD** 
 (95% CI) 
 
0.49 
(-0.37, 1.35) 
0.27 
0.96 
(0.07, 1.86) 
0.04 
-0.47 
(-1.76, 0.81) 
0.47 
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Figure 4.1.2: Mean percentage change after 12 months at Lumbar Spine between two treatment 
arms (stratum-I, II and III) 
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Figure 4.1.3: Mean percentage change after 12 months at Total Hip between two treatment arms 
(stratum-I, II and III) 
 
 
 
 
 
 
 
176 
4.1.5.3 Substantial Bone Loss (Table 4.1.8) 
A total of 38 (8.3%) women in stratum-I  lost  ≥6%  BMD  at  lumbar  spine  and/or  total  hip  after  one  
year of treatment (28 in the anastrozole group and 10 in the placebo group), but none of them 
developed  osteoporosis.  Of  these  38  women,  30  (6.6%)  had  ≥6%  BMD  loss  at  lumbar  spine,  and  11  
(2. 4%) at total hip.  In stratum-II,  13  (5.3%)  women  lost  ≥6%  of  BMD  (8  in  the  anastrozole  group  
and  5  in  the  placebo  group).  Of  these  13  women,  7  (2.8%)  had  ≥6%  BMD  loss  at  lumbar  spine,  and  
6 (2.4%) at total hip.  In this group 8 (3.3%) women had developed osteoporosis. In accordance 
with the protocol, 4 women were withdrawn from the study as they had a BMD loss of more than 
10% and had become osteoporotic. These women were provided with open label risedronate and 
advised to continue follow-up DXA scans at 3, 5 and 7 years. In stratum-I, 20 (4.4%) women 
developed osteopenia, 9 (47%) in the anastrozole group and 11 (58%) in the placebo group. 
However, out of 20, 16 (80%) women had osteopenic T-score between -1.0 to -1.5 in both the 
groups.  
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Table  4.1.8:  BMD  loss  of  ≥  10  %  at  12  months  follow-up 
Stratum 
 
BMD  Loss  of  ≥  6  % Osteoporosis 
Total Spine Hip Total 
A P A P A P A P 
Stratum-I  
N=457 
38 (8.3 %) 30 (6.6 %) 11 (2.4 %) 0 
28 
(6.1 %) 
10 
(2.2 %) 
22 
(4.8%) 
8 
(1.8%) 
9 
(2.0%) 
2 
(0.4%) 
  
Stratum-II  
N=246 
13 (5.3 %) 7 (2.8 %) 6 (2.4 %) 8 (3.3%)* 
8 
(3.3%) 
5 
(2.0%) 
4 
(1.6%) 
3 
(1.2%) 
4 
(1.6%) 
2 
(0.8%) 
5 
(2%) 
3 
(1.2%) 
Stratum-III 
N=91 
5 (5.5 %) 
 
0 5 (5.5%) 48 (53%) ** 
0 5 
(5.5%) 
0 2 
(2.2%) 
0 
 
3 
(3.3%) 
16 
(17.6%) 
32 
(35.2%) 
*Out of 8 women, 4 women had <10% bone loss 
**48 women were no longer osteoporotic after 12 months  
 
In stratum-II, another 4 women with a baseline T-score between -2.0 to -2.5 had developed 
osteoporosis, but they were not withdrawn as they had not lost more than 10% BMD. 
 
In stratum-III,  only  5  women  (5.5  %)  had  a  BMD  loss  of  ≥6%.  Forty-eight women (53%) in this 
stratum were no longer osteoporotic (16 in the anastrozole group and 32 in the placebo group) after 
receiving bisphosphonate therapy for12 months. 
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4.1.5.4 BMD Percentage Change at LS and TH BMD changes at 12 months in 
women  ≤  4  years  and  >  4  years  since  menopause  (Stratum-I) (table 4.1.9) 
 
This analysis was done using the BMD data only from stratum-I to avoid the effect of 
risedronate on BMD change. In the anastrozole group, the BMD loss was not significantly 
different between the two groups; lumbar spine (-2.69 vs. -1.81, p=0.13) or total hip (-1.82 vs. 
-1.21,   p=0.12)   in   the   ≤4   years   and   >4   years   since   menopause   groups,   respectively.   In   the  
placebo group, a significant change was observed between the two treatment groups; lumbar 
spine (-1.41 vs. -0.20, p=0.02) and total hip (-1.30 vs. -0.30,  p=0.02)   in   the  ≤4  years  and  >4  
years   since   menopause   groups,   respectively.   There   were   fewer   women   who   were   ≤4   years  
since menopause in both the treatment groups. 
 
Table  4.1.9:  Percentage  LS  and  TH  BMD  changes  at  12  months  in  women  ≤  4  years  and  >  4 
years since menopause (Stratum-I only) 
 
 Anastrozole p-
value 
Placebo p-
value 
 ≤4  years 
 since 
menopause 
>4 years  
since 
menopause 
 ≤4 years 
 since 
menopause 
>4 years  
since 
menopause 
 
No. of 
participants 
Spine BMD 
95% CI 
 
51 
-2.69 
(-3.60, -1.78) 
170 
-1.81 
(-2.39, -1.23) 
0.13 47 
-1.41 
(-2.35, -0.46) 
185 
-0.20 
(-0.66, 0.27) 
0.02 
No. of 
participants 
Hip BMD 
95% CI 
 
52 
-1.82 
(-2.63, -1.01) 
 
170 
-1.21 
(-1.57, -0.86) 
0.12 44 
-1.30 
(-2.09, -0.51) 
178 
-0.30 
(-0.68, 0.07) 
0.02 
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4.1.5.5 Univariate and Multivariate analysis (BMD values at baseline) (Table 
4.1.10) 
In a univariate regression analysis, both at lumbar spine and total hip, a direct correlation was 
observed between higher baseline BMI and baseline BMD values, with women with higher 
BMI having higher BMD values (p=<0.0001), and in inverse correlation between use of 
calcium/vitamin D and BMD values at baseline was observed. At lumbar spine, no other 
predictive   factor   (age,   smoking,   ≤4   years   since   menopause   or   past   use   of   HRT)   had   any  
significant effect on baseline BMD values.  
 
At   total   hip,   an   inverse   correlation   was   also   observed   between   increasing   age   (p=0.01),   ≤4  
years since menopause (p=0.03) and baseline BMD values.  
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Table 4.1.10: Results from univariate and multivariate linear regression on a range of predictive 
factors and baseline BMD levels (coefficients give change in levels of BMD per unit change in 
variable) (Analysis done on data from all strata, n=790). 
 
 
 Spine Hip 
Coefficient 95% CI P-value  Coefficient 95% CI P -value 
Univariate analysis 
 
Age (years) -0.001 -0.003, 0.001 0.35 -0.002 -0.004, -0.001 0.01 
BMI 0.009 0.007, 0.011 <0.0001 0.011 0.009, 0.012 <0.0001 
Smoking 0.001 -0.024, 0.027 0.91 -0.002 -0.020, 0.017 0.87 
Menopause  ≤    4 years -0.012 -0.044, 0.021 0.49 -0.027 -0.051, -0.002 0.03 
Calcium & Vitamin D -0.043 -0.071, -0.015 0.003 -0.02 -0.043, -0.001 0.04 
Past use of HRT 0.004 -0.021, 0.029 0.75 -0.007 -0.026, 0.012 0.47 
 Anastrozole -0.009 -0.035, 0.16 0.45 -0.006 -0.024, 0.013 0.56 
Multivariate variable (stepwise forward model) 
 
BMI 0.009 0.007, 0.011 <0.0001 0.011 0.009, 0.012 <0.0001 
Vitamin D -0.037 -0.063, -0.010 0.01 -0.002 -0.004, -0.000 0.02 
 
In a multivariate analysis, both at lumbar spine and total hip, effect of BMI (p<0.0001) and use 
of calcium and vitamin D (p=0.01 at lumbar spine and p=0.02 at total hip) retained significance 
on baseline BMD value in a stepwise forward model. At total hip, no other covariates (age and 
≤4   years   since  menopause)   retained   significance   after other variables (past use of smoking, 
past use of HRT or treatment with anastrozole) were fitted in the model (Table 4.1.10). 
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4.1.5.6 Univariate and Multivariate analysis (BMD changes at 12 months) 
(Table 4.1.11) 
In a univariate analysis, at lumbar spine, a significant association was observed between BMD 
change  at  12  months  and  increasing  age  (p=0.001),  BMI  (p<0.0001),  ≤4  years  since  menopause 
(p=0.02), use of calcium and vitamin D (p=0.002), use of anastrozole (p=0.04) and baseline 
BMD (p=0.001). 
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Table 4.1.11: Results from univariate and multivariate linear regression on a range of 
predictive factors on BMD change at 12 months (coefficients give change in levels of BMD 
per unit change in variable) (Analysis done on data from Stratum-I, n=455). 
 
 
 
 Spine Hip 
Coefficient 95% CI P-value  Coefficient 95% CI P –value 
Univariate analysis 
 
Age (years) 0.005 0.002, 0.007 0.001 0.001 -0.006, 0.003 0.20 
BMI 0.007 0.005, 0.009 <0.0001 0.009 0.007, 0.010 <0.0001 
Smoking -0.004 -0.034, 0.025 0.76 -0.024 -0.044, -0.003 0.02 
Menopause  ≤    4 
years 
-0.041 0.006, 0.077 0.02 0.014 -0.010, 0.039 0.26 
Vitamin D -0.052 -0.085, -0.019 0.002 -0.011 -0.034, 0.012 0.34 
HRT -0.009 -0.039, 0.020 0.53 -0.008 -0.029, 0.013 0.44 
Anastrozole -0.031 -0.060, -0.002    0.04 -0.013 -0.034, 0.007 0.21 
Baseline BMD -0.98 0.959, 1.007 <0.0001 -0.977 0.955, 0.999 <0.0001 
Multivariate variable 
(stepwise forward model) 
 
Baseline BMD -0.96 0.939, 0.989 <0.0001 -0.955 0.931, 0.978 <0.0001 
Age 0.001 0.001, 0.002 <0.0001    
Anastrozole -0.018 -0.026, -0.011   <0.0001    
BMI 0.006 0.000, 0.001 0.04 0.001 0.001, 0.001 <0.0001 
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However at total hip, no correlation was observed between age and BMD change at 12 months 
and, a direct correlation was observed between BMD change at 12 months, and an inverse 
correlation with baseline BMD values. 
 
In a multivariate analysis at lumbar spine, baseline BMD (p<0.0001), age (p<0.0001) and 
treatment with anastrozole (p<0.0001) and BMI (p=0.04) retained significance after all other 
covariates were included in the model in a stepwise forward fashion. At total hip, baseline 
BMD (p<0.0001), and BMI (p<0.0001) remained significantly associated after all other 
covariates were included in the model. 
 
4.1.5.7 Use of Calcium and vitamin D 
The use of calcium supplementation increased from 30% at baseline to 74% during the first 
year of the follow-up, and vitamin D use increased from 28% to 71%, in accordance with study 
recommendations. 
 
4.1.5.8 Drop-outs 
Out of 1092 women who could potentially have completed 12 months follow-up before 
allowing for drop-outs, subjects lost to follow-up and missing DXA scans, 140 (12.8%) women 
withdrew from the bone study within 12-months of joining the trial. Out of the 140 
withdrawals, 83 (59.3%) were in stratum-I, 44 (31.4%) were in stratum-II and 13 (9.3%) 
women were in stratum-III. It is however important to note that out of the 140 withdrawals, 
117 (83.6%) women had withdrawn from the prevention trial and therefore had to be 
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withdrawn from the bone study as well. Only 23 (16.4%) women withdrew only from the bone 
study (6 from stratum-I, 16 from stratum-II and 1 from Stratum-III). Out of these 23 
withdrawals from the bone study, 10 women had moved residence to a place where DXA 
facility was not available, 2 woman commenced bisphosphonate therapy, 1 woman had a hip 
replacement surgery, 6 women withdrew consent for personal reason, and reason was not 
known for 4 withdrawals.  
 
Table 4.1.12: Reason of withdrawal from the bone study 
Total 140 (100%) Reason for withdrawal 
117 (83.6) Withdrew from the Prevention study 
23 (16.4) Withdrew from the bone study only 
10 women moved residence 
2 woman commenced bisphosphonate 
therapy 
1 had a hip replacement surgery for 
personal reason 
6 women withdrew consent 
4 reason not known 
 
4.1.5.9 Compliance   
The compliance for taking medication (risedronate or placebo) was more than 95% at 12 
months.  This   is  based  on  nurses’  interviews  at   the  12 months follow-up. No data is currently 
available on compliance for anastrozole to maintain the blinding of information on the main 
study. 
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4.1.5.10 Adverse and Severe Adverse Events  
Within 12 months of the study, 57 women reported a severe adverse event (SAE); only 17 were 
specifically related to bone study issues (12 fractures, 2 cases of severe bone loss, 1 atrial 
fibrillation and 2 cases of gastrointestinal symptoms).  
 
Within the first year of the study, within stratum-II, gastrointestinal related mild to moderate 
adverse events (bloating, nausea/ heartburn etc) were reported by 25 (21%) participants in the 
risedronate group and 20 (15.5%) participants in the non-risedronate group. In stratum-III, 12 
participants reported gastrointestinal related mild to moderate adverse events. 
 
 
4.1.6 Results at 36 months 
4.1.6.1 Participants 
Between March 2003 and May 2010, 3014 postmenopausal women took part in the IBIS-II 
prevention study, of which 1326 (44%) women took part in the bone sub-study. Out of 1326 
women, 604 (45.5%) women would have potentially completed 36 months at the time of 
analysis before allowing for drop-outs, subjects loss to follow-up and missing DXA scans 
(Figure 4.1.4 and Table 4.1.13). 
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Figure 4.1.4: Recruitment into the IBIS-II prevention and bone sub-study at 36 months follow-
up 
 
Of these 604, 140 women had dropped out of the study between baseline and 12 months 
follow-up, and another 38 women dropped out between 12 and 36 months.  
 
Of these 604, other than 38 (6%) drop-outs, 50 (8.3%) 36 month DXA scans were not received 
and 164 (27.2%) women were loss to follow-up or their follow-up forms were not received, 
RisedronateObservation
Prevention Trial
n = 3014
Stratum-III
-4.0  ≤  T-score < -2.5
(Osteoporotic)
Stratum-I
T-score  ≥  -1.0
(Normal)
Bone Sub-Study
n = 1326
Randomisation
PlaceboRisedronate
n = 723Numbersenrolled n = 230 n = 233 n = 140
n = 384 n =76 n =81 n = 63
36 months follow-up
data potentially
available*
Stratum-II
-2.5  ≤  T-score < -1.0
(Osteopenic)
*Numbers who would have completed 36 months follow-up before allowing for drop-outs, subjects lost to follow-up and missing DXA 
scans
n = 230 n = 38 n = 42 n = 4236 months follow-up data available
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which left 352 (58.3%) women for analysis. Of these, 230 (59.9%) were analysed in stratum-I, 
80 (24.8%) in stratum II, and 42 (13%) in stratum-III. Detailed information about dropouts is 
provided in table 4.1.12. 
 
Table 4.1.13: Distribution of women in different strata at 36 month of follow-up 
  (All strata) 
(%) 
Stratum-I 
(%) 
Stratum-II 
(%) 
Stratum-III 
(%) 
Randomised 3 years before data-cut 
date (2nd June 2010)  
604 
(100) 
384 
(100) 
157 
(100) 
63 
(100) 
Drop-outs (i)  38 
(6.3) 
29 
(7.6) 
6 
(3.8) 
3 
(4.8) 
DXA scans not received (ii)  50 
(8.3) 
27 
(7.03) 
19 
(12.1) 
4 
(6.3) 
Lost to follow-up/Follow-up forms 
not received (iii)  
164 
(27.2) 
98 
(25.5) 
52 
(33.1) 
14 
(22.2) 
Total (i + ii + iii)  252 
(41.7) 
154 
(40.1) 
77 
(49) 
21 
(33.3) 
Scans available  352 
(58.3) 
230 
(59.9) 
80 
(51) 
42 
(66.7) 
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4.1.6.2 BMD Percentage Change in Stratum-I, II and III 
The mean percentage changes at 36 month from baseline for lumbar spine and total hip BMD 
are shown graphically in Figures 4.1.4 & 4.1.5 and numerically in Tables 4.1.13 to 4.1.16.  
 
Stratum-I 
 
In stratum-I, a significant BMD loss at 36 month was observed at lumbar spine and total hip in 
both treatment arms, but the effect was significantly larger in the anastrozole group. The 
changes in the two groups (anastrozole vs. placebo) were: lumbar spine (-4.86% vs. -2.26%, p 
<0.0001) and total hip (-3.87% vs. -2.42%, p=0.001) (Table 4.1.14, Figure 4.1.5 & 4.1.6).  
 
Table 4.1.14: Stratum-I: Mean percentage change in BMD from baseline to 36 months in the 
Lumbar spine and Total Hip according to treatment group 
* BMD values missing for 1 participant in the anastrozole group and 1 participant in the placebo group. 
** BMD values missing for 4 participants in the placebo group. 
 
 
 
 
 Anastrozole 
(n=110)  
Placebo 
(n=120) 
Difference in mean values 
between treatment groups 
 
Lumbar spine BMD* 
 (95% CI) 
-4.86 
(-5.61, -4.11) 
<0.0001 
-2.26  
(-3.00, -1.53) 
<0.0001 
 
-2.60 
(-3.65, -1.54) 
<0.0001 
 
Total Hip BMD** 
 (95% CI) 
 
-3.87 
(-4.51, -3.23) 
<0.0001 
-2.42 
(-3.02, -1.82) 
<0.0001 
-1.45 
(-2.33, -0.58) 
0.001 
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Stratum-II 
 
In stratum-II, women randomised to risedronate had increases in BMD in both the anastrozole 
and placebo groups, except in the anastrozole group at total hip.  BMD losses were observed in 
the non-risedronate group in both the groups, except a BMD gain in the placebo group at 
lumbar spine (Table 4.1.15 & 4.1.16, Figure 4.1.5 & 4.1.6). The 36-month BMD results for 
stratum-II are summarised in Table 4.1.15. The results of the statistical analysis of these data 
are summarised in Table 4.1.16.  
 
 
The effect of risedronate on the BMD change was significant in the anastrozole group at 
lumbar spine (risedronate vs. non-risedronate group (+0.79% vs. -2.03%, p=0.02), but not 
significant in the placebo group (+1.97% vs. +0.33%, p=0.20) (please refer table 4.1.15 for p-
values showing BMD changes from baseline to 36 months within the treatment groups, and 
refer table 4.1.16 for p-values between two treatment groups). At total hip, the BMD changes 
were not significant in the anastrozole group (-0.71% vs. -1.98%, p=0.23), but significant in 
the placebo group (+0.96 % vs. -1.96%, p=0.02).  
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Table 4.1.15: Stratum-II: mean percentage change in BMD from baseline to 36 months in the 
Lumbar Spine and Total Hip according to treatment group 
 
Site  Anastrozole 
with 
risedronate 
(n=23) 
 
Placebo 
with 
risedronate 
(n=19) 
 
Anastrozole 
without 
risedronate 
(n=19) 
 
Placebo  
without 
risedronate 
(n=19) 
 
LS (% change) 
(95% CI) 
p-value 
 
 
+0.79 
(-1.04, 2.63) 
0.40 
+1.97 
(-0.12, 4.05) 
0.065 
 
-2.03 
(-3.25, -0.81) 
0.001 
+0.33 
(-1.08, 1.74) 
0.65 
TH (% change)* 
(95% CI) 
p-value 
 
-0.71 
(-2.24, 0.82) 
0.37 
+0.96 
(-0.63, 2.54) 
0.24 
-1.98 
(-3.31, -0.65) 
0.003 
-1.96 
(-3.85, -0.06) 
0.04 
*BMD values missing for 1 participant in the anastrozole without risedronate group, 1 participant in the placebo 
with risedronate group 
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Table 4.1.16: Stratum-II: Mean percentage change in BMD from baseline to 36 months in the 
Lumbar Spine and Total Hip according to treatment groups 
 
Stratum II 
(n=80) 
 
Difference in mean 
values between 
treatment groups at  
LS 
(95% CI) 
p-value 
Difference in mean 
values between 
treatment groups at  
TH 
 (95% CI) 
p-value 
Anastrozole ± Risedronate 2.83 
(0.52, 5.14) 
0.02 
 
1.27 
(-0.82, 3.37) 
0.23 
 
Placebo ± Risedronate 
1.64 
(-0.88, 4.15) 
0.20 
 
2.91 
(0.43, 5.40) 
0.02 
Risedronate  ± Anastrozole 
 
 
-1.17 
(3.94, 1.60) 
0.41 
-1.67 
(-3.90, 0.56) 
0.14 
 
 
No Risedronate/placebo  ± 
Anastrozole 
-2.36 
(-4.23, -0.50) 
0.01 
 
-0.03 
(-2.36, 2.31) 
0.98 
Anastrozole main effect* -2.02 
(-3.77, -0.28) 
0.02 
 
-0.86 
(-2.56, 0.84) 
0.31 
Risedronate main effect* 2.06 
(0.33, 3.79) 
0.02 
2.07 
(0.39, 3.74) 
0.02 
 
Anastrozole & Risedronate 
Interaction** 
1.07 
 (-2.36, 4.52) 
0.53 
-1.85 
(-5.26, 1.57) 
0.29 
              *main effect calculated using regression model (adjusting for baseline T-scores at      
               lumbar spine and total hip) with no interaction 
              ** Interaction model (adjusting for baseline T-scores at lumbar spine and total hip) 
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A regression model that adjusted for baseline T-scores at lumbar spine and total hip found no 
effect of the difference in baseline T-score values between treatment groups on the percentage 
change either at lumbar spine or at total hip for anastrozole or risedronate treatment. A 
significant overall effect of risedronate was observed at both, lumbar spine (p=0.02) and total 
hip (p=0.02), however the effect of anastrozole was only observed at lumbar spine (p=0.02), 
and not at total hip (p=0.31) (Table 4.1.16). 
 
No significant evidence of an interaction was observed between anastrozole and risedronate 
either at lumbar spine (p=0.53), or at total hip (p=0.29) (Table 4.1.16).  
 
Stratum-III 
 
In stratum-III, statistically significant increases in BMD were observed in the placebo arm of 
the study at the lumbar spine (p <0.0001) and total hip (p=0.002), but not in the anastrozole 
arm, either at lumbar spine (p=0.42) or at total hip (p=0.79). A significant difference in mean 
values between the treatment groups was observed at lumbar spine (+0.95% vs. +3.61%, 
p=0.05), and total hip (-0.30 vs. +2.23, p=0.05) in the anastrozole and placebo groups, 
respectively (Table 4.1.17, Figure 4.1.5 & 4.1.6).  
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Table 4.1.17: Stratum-III: Mean percentage change in BMD from baseline to 36 months in the 
Lumbar spine and Total Hip according to treatment group 
 
BMD values missing for 1 participant in the anastrozole group and 1 participant in the placebo group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Anastrozole 
(n=20) 
Placebo 
(n=22) 
Difference in mean 
values 
between treatment 
groups 
 
Lumbar spine BMD 
 (95% CI) 
0.95 
(-1.35, 3.25) 
0.42 
3.61 
(2.21, 5.01) 
<0.0001 
-2.66 
(-5.30, -0.02) 
0.05 
Total Hip BMD* 
 (95% CI) 
 
-0.30 
(-2.51, 1.92) 
0.79 
2.23 
(0.82, 3.64) 
0.002 
-2.53 
(-5.10, 0.04) 
0.05 
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Figure 4.1.5: Mean percentage change after 36 months at Lumbar Spine between two treatment 
arms (stratum-I, II and III) 
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Figure 4.1.6: Mean percentage change after 36 months at total hip between two treatment arms 
(Stratum-I, II and III) 
 
 
4.1.6.3 Time trend in BMD changes from baseline to 36 months 
This section examines the overall trends in bone loss from baseline to 36 months by plotting 
the 12 and 36-months changes on the same graph. The results are plotted separately for each 
stratum (Figures 4.1.7, 4.1.8 and 4.1.9). 
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Figure 4.1.7: Mean percentage change from baseline to 12 and 36 months at Lumbar Spine 
and Total Hip between two treatment arms for subjects in stratum-1  
In Stratum-I, the 36-months BMD data were available for only half the numbers (n=230) of 
participants as compared to 12-months (n=457). There is a consistent downward trend in BMD 
at both the lumbar spine and total hip in each treatment arm, but the effect was largest for the 
anastrozole group at lumbar spine (Figure 4.1.7).  
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Figure 4.1.8: Mean percentage change from baseline to 12 and 36 months at Lumbar Spine 
and Total Hip between two treatment arms for subjects in stratum 2 
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In stratum-II, the BMD changes seen at 36 months have large statistical errors due to the 
relatively small number of subjects who have presently completed their 36-month follow-up. 
Comparing the BMD trends in the stratum 2 subjects not taking risedronate (Figure 4.1.8 A, B) 
with the corresponding changes in stratum 1 there are apparent marked differences in the 
changes in spine BMD in particular which presumably reflect the statistical limitations of the 
smaller number of subjects.  
 
 
Figure 4.1.9: Mean percentage change from baseline to 12 and 36 months at Lumbar Spine 
and Total Hip between two treatment arms for subjects in stratum 3 
 
The interpretation of the time trends in BMD loss in the subjects in stratum 3 is limited by the 
small number of women who have so far completed their 36-month follow-up (Figure 4.1.9). 
The results are similar to the trends seen in the stratum 2 subjects who took risedronate (Figure 
4.1.8 C, D), with the early gains seen at 12-months apparently reaching a plateau or dropping 
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slightly by 36 months.  This may be an artefact of the limited number of subjects in both 
stratum 2 and stratum 3 completing 36-month follow-up.   
4.1.6.4 Substantial Bone Loss at 36 months 
A total of 16 (7.6%) women in stratum-I  lost  ≥10%  BMD  at  lumbar  spine  and/or  total  hip  after  
36 months of treatment, 14 (6.7%) in the anastrozole group and 2 (1%) in the placebo group), 
but none of them developed osteoporosis. Of these 16 women, 12 (5.7%) had  ≥10%  BMD  loss  
at lumbar spine, and 1 (0.5%) at total hip. In stratum-I, 8 (3.5%) women developed osteopenia, 
5 (62.5%) in the anastrozole group and 3 (37.5%) in the placebo group. However, all these 
women had developed osteopenic T-score between -1.0 to -1.5 in both the groups.  
 
In stratum-II,  no  participant  lost  ≥10%  of  BMD.    Five  (6.3%)  women  developed  osteoporosis  
as their T-score reduced <-2.5,  but  without  loosing  ≥10%  from  baseline.  None  of  these  women  
were withdrawn from the study (Table 4.1.18).  
Table  4.1.18:  BMD  loss  of  ≥  10  %  or  osteoporosis  at  36-month follow-up 
Stratum 
 
BMD  Loss  of  ≥  10  % Osteoporosis 
Total Spine Hip Total 
A P A P A P A P 
Stratum-I  
n= 210  
(%) 
16  
(7.6) 
13 
(6.2) 
7 
(3.3) 
0 
14  
(6.7) 
2 
 (1) 
12  
(5.7) 
1 
(0.5) 
5 
(2.4) 
2 
(1) 
  
Stratum-II  
n= 80  
(%) 
0 0 0 5* 
(6.3) 
      2 
(2.5) 
3  
(3.8) 
Stratum-III 
n= 42 
 (%) 
0 0 0 23** 
(54.8) 
      7 
(16.7) 
16  
(38) 
*Out of 5 women, no one had <10% bone loss 
**23 women were no longer osteoporotic after 36 months  
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In stratum-III, no   subject   had   a   BMD   loss   of   ≥10%.   Twenty-three (54.8%) women in this 
stratum were no longer osteoporotic, 7 (16.7%) in the anastrozole group and 16 (38%) in the 
placebo group, after receiving bisphosphonate therapy for 36 months. 
 
4.1.6.5 BMD Percentage Change  at  LS  and  TH  BMD  at  36  month  in  women  ≤  
4 years and > 4 years since menopause (Stratum-I) (table 4.1.19) 
 
This analysis was done using the BMD data only from stratum-I to avoid the effect of 
risedronate on the BMD change at 36 month in women from stratum-I. In the anastrozole 
group, a significant BMD loss was observed between two groups; lumbar spine (-6.3 vs. -4.2, 
p=0.01) or total hip (-5.6 vs. -3.04,  p=0.002)   in   the  ≤4   years   and  >4   years   since  menopause  
groups, respectively. In the placebo group, a significant change was observed between the two 
treatment groups; lumbar spine (-3.05 vs. -2.01, p=0.24) and total hip (-3.30 vs. -2.15, p=0.11) 
in  the  ≤4  years  and  >4  years  since  menopause  groups,  respectively.   
Table 4.1.19: Percentage LS and TH BMD changes  at  36  months  in  women  ≤  4  years  and  >  4 
years since menopause (Stratum-I only) 
 Anastrozole Placebo 
 ≤4  years  
since 
menopause 
>4 years 
since 
menopause 
p- 
value 
≤4  years  
since 
menopause 
>4 years  
since 
menopause 
p-
value 
No. of 
participants 
LS BMD 
95% CI 
 
35 
-6.3 
(-7.8, -4.8) 
74 
-4.2 
(-5.0, -3.3) 
0.01 29 
-3.05 
(-4.43, -1.67) 
90 
-2.01 
(-2.90, -1.12) 
0.24 
No. of 
participants 
TH BMD 
95% CI 
 
36 
-5.6 
(-6.7, -4.5) 
74 
-3.04 
(-3.78, -2.3) 
0.0002 27 
-3.30 
(-4.89, -1.12) 
89 
-2.15 
(-2.79, -1.51) 
0.11 
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4.1.6.6 Univariate and Multivariate analysis (BMD changes at 36 month) 
(Table 4.1.20) 
In a univariate analysis, at lumbar spine, a significant direct association was observed between 
BMD change at 36 months and increasing age (p=0.05), BMI (p=0.003), and an inverse 
correlation with use of calcium and vitamin D (p=0.02), use of anastrozole (p=0.03), baseline 
BMD values (<0.0001) (Table 4.1.20). 
 
However, at total hip no correlation was observed between age and BMD change at 36 month, 
but a direct correlation was observed with BMI and an inverse correlation with baseline BMD 
and a BMD change at 36 month. 
 
In a multivariate analysis, at lumbar spine, baseline BMD values (p<0.0001), treatment with 
anastrozole (p<0.0001) and age (p=<0.0001) retained significance after all other covariates 
were included in the model in a stepwise forward fashion. At total hip, baseline BMD values 
(p<0.0001), treatment with anastrozole (p=0.006) and BMI (p=0.02) retained significance after 
all other covariates were included in the model. 
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Table 4.1.20: Results from univariate and multivariate linear regression on a range of 
predictive factors and BMD change at 36 month (coefficients give change in value of BMD per 
unit change in variable) (Analysis done on data from stratum-I, n=230). 
 
 Spine Hip 
Coefficient 95% CI p-value  Coefficient 95% CI p-value 
Univariate analysis 
 
Age (years) 0.004 0.002, 0.007 0.05 0.000 -0.003, 0.003 0.799 
BMI (kg/m2) 0.005 0.002, 0.009 0.003 0.008 0.006, 0.011 <0.0001 
Smoking (Y/N) -0.001 -0.04, 0.038 0.94 -0.026 -0.057, -0.005 0.10 
Menopause  ≤  4 yrs 0.031 -0.013, 0.076 0.16 0.022 -0.012, 0.056 0.20 
Calcium/Vitamin D 
(Y/N) 
-0.051 -0.095, -0.007 0.02 -0.012 -0.048, 0.023 0.50 
HRT (Y/N) 0.006 -0.034, 0.045 0.78 0.211 -0.010, 0.052 0.18 
Anastrozole -0.045 -0.084, -0.005 0.03 -0.028 -0.059, 0.002 0.07 
Baseline BMD -0.992 0.949, 1.035 <0.0001 -0.482 0.396, 0.567 <0.0001 
Multivariate variable 
(stepwise forward model) 
 
Baseline BMD  -0.980 0.937, 1.024 <0.0001 -0.914 0.874, 0.955 <0.0001 
Anastrozole -0.030 -0.042, -0.017 <0.0001 -0.012 -0.021, -0.002 0.01 
Age 0.002 0.001, 0.003 0.002    
BMI    0.006 0.004, 0.002 0.006 
Menopause  ≤  4 yrs    0.015 0.003, 0.0273 0.01 
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However, at total hip no correlation was observed between age and BMD change at 36 month, 
but a direct correlation was observed with BMI and an inverse correlation with baseline BMD 
and a BMD change at 36 month. 
 
In a multivariate analysis, at lumbar spine, baseline BMD values (p<0.0001), treatment with 
anastrozole (p<0.0001) and age (p=<0.0001) retained significance after all other covariates 
were included in the model in a stepwise forward fashion. At total hip, baseline BMD values 
(p<0.0001), treatment with anastrozole (p=0.006) and BMI (p=0.02) retained significance after 
all other covariates were included in the model. 
 
4.1.6.7 Use of Calcium and vitamin D 
The use of calcium supplementation increased from 30% at baseline to 77% during the 36 
months of the follow-up, and vitamin D use increased from 28% to 77%. 
 
4.1.6.8 Drop-outs 
Overall, 38 (6%) women out of 604 withdrew from the bone study between 12 and 36 months. 
Out of the 38 withdrawals, 28 (74%) were in stratum-I, 6 (16%) were in stratum-II and 3 (8%) 
were in stratum-III. It is however important to note that out of 38 withdrawals, 34 women had 
withdrawn from the prevention trial therefore had to be withdrawn from the bone study also. 
Four women withdrew only from the bone study (2 from stratum-I and 2 from stratum-II). Out 
of these 4 withdrawals, 2 women had moved residence where DXA facility was not available, 
1 woman commenced bisphosphonate therapy and 1 woman withdrew consent. 
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4.1.6.9 Compliance   
In this study, compliance for taking medication (risedronate or placebo) was more than 94% at 
one and 3 year.  This  is  based  on  nurses’  interviews  at  the  follow-up appointments.  
 
4.1.6.10 Adverse and Severe Adverse Events  
Adverse and severe adverse event data up to 3rd June 2010 (until data-cut date) has been 
presented in the 12 months BMD results section. 
 
4.1.7 Discussion 
 Bone loss associated with use of an AI for chemoprevention is of particular concern in healthy 
postmenopausal women where side effects are of greater importance. No trials to date have 
studied the effect of aromatase inhibitors on BMD in this setting. Trials of anastrozole (Buzdar, 
A 2006), letrozole (Thurlimann, B 2005) and exemestane (Coombes, RC 2004) have all 
reported BMD loss in breast cancer patients, but these have usually been compared against 
tamoxifen and have been much smaller in size. The strength of the current study is that we 
performed a randomized comparison of the effect of anastrozole vs. placebo so that the 
additive effect of an AI beyond the natural effect of bone loss associated with ageing can be 
directly estimated. Thus our study directly establishes that women with normal BMD at the 
time of entry who are treated with anastrozole without bisphosphonate therapy have a 
significantly greater BMD loss after 1 year at lumbar spine and total hip than would be 
expected in the absence of treatment. The percentage of BMD loss experienced in stratum-I of 
our trial at 12 months is similar to BMD loss observed in the ATAC (Eastell, R 2006) and 
SABRE trials (Van Poznak, C 2010), and lower than ARIBON trial (Lester, JE 2008) among 
breast cancer patients. In the ATAC trial, patients who received anastrozole had significant 
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losses (P<0.001) in median BMD at the LS and TH at 1 year (n=81; -2.6% and -1.7%, 
respectively) and year 2 (n=65; -4.0% and -3.2%, respectively) when compared to tamoxifen. 
The BMD loss observed at 1 year in the ATAC trial is similar to 1 year BMD loss in our study, 
whereas BMD loss observed at 36-months are similar to 2 year BMD loss in the ATAC study 
(Eastell, R 2006). In the SABRE trial, women with breast cancer and T-score   of   ≥   -1.0 at 
baseline (N=35) had similar BMD loss at lumbar spine (-2.1%, p=0.0109), but not at total hip 
(-0.4%, p=0.5988) (Van Poznak, C 2010).   
 
In the ARIBON trial, after 2 years of treatment with anastrozole in breast cancer patients 
(N=59), the mean percentage change in lumbar spine and total hip was -4.79 and -3.72, 
respectively (Lester, JE 2008). These losses are similar to BMD loss observed in our trial at 36 
month. The BMD losses observed in the SABRE trial are much lower compared to the 
ARIBON study. This could be because all the breast cancer patients in SABRE trial were 
provided with vitamin D and calcium along with anastrozole.  
 
The effects on bone of two other 3rd generation AIs, letrozole (Hadji, P 2009) and exemestane 
(Coleman, RE 2007) have been studied in an adjuvant setting in women with breast cancer.  In 
the NCIC CTG MA.17 bone sub-study in 226 breast cancer patients, at a median follow-up 
interval of 24 months, women who received letrozole when compared to placebo had a greater 
BMD loss at 2 years at lumbar spine (-5.53% vs. -0.70%; P=0.08) and total hip (-3.60% vs. -
0.71%; P=0.04) (Perez, EA 2006). All patients in this study had received 5 years of tamoxifen 
previously. In the IES study, where exemestane was allocated after 2-3 years of tamoxifen 
therapy, a significant decrease in BMD at lumbar spine and total hip was reported, when 
compared to continuing with tamoxifen. The decreases were sustained for at least 24 months 
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after randomization (Coleman, RE 2007; Coombes, RC 2007). The results of both of these 
trials are difficult to interpret because AI use followed treatment with tamoxifen, which itself 
has a bone-protective effect. In the TEAM trial, 200 patients were randomised to receive 
exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. 
The percentage mean change in BMD from baseline for exemestane at 12 months was -2.8% at 
lumbar spine, and -2.2% at total hip (Hadji, P 2009). 
 
The main effect of analysis of anastrozole on BMD has never been reported in any trials 
before. At 12 months, it was surprising to observe no significant main effect of anastrozole on 
BMD (via the univariate analysis). This could be a chance finding. However, at 36 months, a 
significant effect of anastrozole was observed at LS, but not at TH. Most of the trials that have 
investigated the effects of anastrozole or other AIs (letrozole or exemestane) on BMD have 
compared the results with tamoxifen, which itself has a bone-protective effect through its 
oestrogen-agonist activity in bone. It is therefore difficult to know whether differences on 
effects on BMD observed between AIs and tamoxifen were due to oestrogen suppression by 
the AIs, the bone sparing effects of tamoxifen, or a combination of these factors. 
Unfortunately, most of the cross-trial comparisons are difficult to interpret due to many 
limitations. Many trials have not accounted for the confounding factors such as co-medications 
or co-morbid conditions. There are also differences in study designs, patient population and 
collection of safety data in the trials. For example, previous treatment with tamoxifen for 2-5 
years, as is the case for the extended adjuvant therapy and the switching trials, may minimize 
side-effects on bone density, while upfront trials, in which AIs were given for 5 years, tend to 
produce the highest levels of bone resorption. 
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The current analysis shows that women who had normal BMD at baseline, only 4.4% women 
developed osteopenia at 12 months, 2% at 36-months (with an osteopenic T-score between -0.1 
and -1.5) and none of the participants in stratum-I developed osteoporosis after 12months and 
36 months of treatment. Such an event is also unlikely because bone loss of more than 15% is 
necessary for transition from a healthy to osteoporotic state - a degree of change that was not 
seen in any patient. Even with 5 years of treatment with anastrozole, osteoporosis in a patient 
with baseline normal BMD has not been reported in the ATAC trial (Eastell, R 2008). It is 
known that BMD reduction in women accelerates around the menopause, averaging 1.5%, 
slowing to 0.2-1.4% per year thereafter over the subsequent 5 to 10 years (Rogers, A 2002; 
Eastell, R 2008). During this period, bone loss follows an exponential decline, with the most 
pronounced loss being in the immediate postmenopausal period. For this reason, the changes in 
BMD were evaluated against time since last menstrual period. One study with anastrozole has 
found that the rate of bone loss is at its most rapid during the first year of treatment, and the 
bone loss appears to decelerate after this initial period (Eastell, R 2008). However, in our 
study, the effect of anastrozole in the first 4 years after menopause when compared to women 
who had had their menopause more than 4 years, was not different at 12 months, but only at 
36-month. This shows that anastrozole reduces BMD during the first four years after 
menopause. These results are similar to the ATAC trial data published at 2 years and 5 years 
where greater BMD losses were observed in anastrozole-treated patients who had experienced 
the menopause in the previous 4 years (Eastell, R 2006). 
 
In a univariate analysis, we observed an expected significant correlation between BMI, age, 
baseline BMD and BMD values at 12 and 36 months. The unexpected finding was the inverse 
correlation between use of calcium/vitamin D at baseline and loss of BMD at 12 and 
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36months. This could either be a chance finding or there could be two reasons for this 
observation, one could be that women who had bone related symptoms and therefore low BMD 
values took calcium and vitamin D or secondly, improper reporting of use of calcium and 
vitamin D as participants were not asked about the doses and duration of calcium and vitamin 
D use. 
 
Stratum-II 
Results from clinical trials have already shown that the use of bisphosphonates with adjuvant 
AI therapy in breast cancer patients is a safe and effective way to prevent bone loss (Eidtmann, 
H ; Bertoldo, F 2009; Brufsky, AM 2009). In all these clinical trials IV zoledronic acid is the 
only compound that has been extensively studied and has proven efficacy in the context of AI-
associated bone loss. A few clinical trials have also indicated the effectiveness of oral 
bisphosphonates in maintaining BMD in breast cancer patients receiving hormonal therapy 
(Van Poznak, C ; Lester, JE 2008). 
 
The efficacy and safety of risedronate in osteopenic women has been reported in few studies 
(Valimaki, MJ 2007; Siris, ES 2008). The data from osteopenic women from four Phase III 
risedronate trials was analysed by Siris et al. Results showed that risedronate treatment 
significantly reduced the overall risk of fragility fractures by 73% over 3 years in patients with 
femoral neck T-score between -1 and -2.5 and no prevalent vertebral fractures. In another 
study, 5 mg/day risedronate was associated with significant increases in BMD in the LS and 
femoral neck within 12 months and sustained at 24-month treatment in late-postmenopausal 
women who had an LS BMD T-score between -2.5 and -1  SD  and  ≥1  additional  fracture  risk  
factor or hip osteopenia (Valimaki MJ 200). Results from two other smaller studies looking at 
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the effect of oral bisphosphonates on BMD when used concomitantly with AI therapy in an 
adjuvant setting have showed that oral bisphosphonates (risedronate/ ibandronate) increased 
BMD at LS and TH in osteopenic women (Van Poznak, C ; Rogers, A 2002; Lester, JE 2008). 
 
This is the first study to report on the use of an oral bisphosphonate for the treatment of AI-
induced bone loss in osteopenic, but otherwise normal women. We used a 2x2 factorial design 
to fully explore the joint effects of anastrozole and risedronate in this group. The baseline T-
score values were significantly different at lumbar spine (p=0.004) and total hip T-score 
(p=0.03) between the two treatment arms (Table 4.1.2), therefore a logistic regression analysis 
was conducted (adjusting for baseline T-score values at lumbar spine and total hip in the 
model) to look at the main effect of anastrozole and risedronate on BMD percentage change at 
1 year. No effects of the difference in baseline T-score values between treatment groups on the 
percentage change were observed either at lumbar spine or at total hip either for anastrozole or 
risedronate treatment. This shows that the difference in the two treatment groups was just by 
chance. 
 
In our study, women receiving anastrozole plus risedronate gained significant bone density at 
lumbar spine compared to women receiving anastrozole without risedronate but there was not 
significant gain at total hip. These differences reflect the greater amount of trabecular bone in 
the spine, which reacts more quickly to antiresorptive therapy, compared to the hip (Eastell, R 
2008). The finding of AI-induced bone loss and its prevention by bisphosphonates in our study 
agree with the results from the SABRE and ARIBON trial in breast cancer patients who 
received AIs along with oral bisphosphonate. In the SABRE trial, at 24 months, women in the 
osteopenic group (n=150), who received anastrozole and risedronate developed a significant 
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increase in BMD when compared to women who did not receive risedronate, at lumbar spine 
(2.2% v -1.8%; P< 0.001) and total hip (1.8% v -1.1%; P <0.001) (Van Poznak, C 2010). In the 
ARIBON study, osteopenic breast cancer patients (n=50) were randomized to receive 
ibandronate or placebo (Lester, JE 2008). After 2 years, patients treated with ibandronate 
gained 2.98% and 0.60% BMD at the lumbar spine and total hip, respectively.  
 
In stratum-II, although the effect of bisphosphonates was larger in women with low BMD at 
baseline, there was no evidence of an interaction with anastrozole, so these two effects appear 
additive. 
 
In postmenopausal women with osteoporosis, risedronate is an FDA approved drug for the 
prevention and treatment of osteoporosis. In these women, risedronate has been found to 
rapidly increase BMD (Reginster J 2000, Hooper MJ 2005) and significantly reduce the risk of 
fractures from 39% to 61% over 3-5 years (Reginster J 2000, Harris St 1999, Harris St 2004, 
Cranney A 2002, Hochberg MC 2002, McClung MR 2001). In stratum-III, osteoporotic 
women in the anastrozole group had a significant increase in BMD at lumbar spine at 12-
months, but not at total hip. At 36 months no significant increase was observed at any of the 
site at 36 months. However in the SABRE trial, a significant increase in BMD was reported in 
the osteoporotic breast cancer patients receiving risedronate at lumbar spine and total hip, both 
at year 1 (n=36, 3.4%; p=0.001 and 1.5%; p=0.00112, respectively) and year 2 (n=33, 3.0%; 
p=0.0006 and 2.0%; p=0.00112, respectively) (Van Poznak, C 2010).  
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In stratum-III, 2% women had a BMD loss of ≥6%  at  12  months,  and  none  had  ≥10%  BMD  
loss at 36-months. In the anastrozole group 17% women no longer remained osteoporotic after 
12 and 36 months of treatment.  
 
Treatment with risedronate was well tolerated and compliance was more than 94% at 12 and 36 
months. No cases of osteonecrosis of jaw were reported after one year of oral bisphosphonate 
use and there were no withdrawals due to gastrointestinal side effects.  
 
A few randomised studies have also suggested that bisphosphonates may also reduce the risk 
of recurrence in women with breast cancer (Gnant, M 2009), and these are now being explored 
in RCTs. Epidemiological evidence also suggest that they may actually lower the risk of 
developing breast cancer, but again this needs further confirmation (Mauri, D ; Newcomb, PA). 
 
4.1.8 Limitations 
This study has several limitations. Even though the 12 months analysis was done on a powered 
sample size, the power was compromised at 36 months due to few very participants had 
completed 36 months in stratum-II and III at the time of analysis. However, 36 months BMD 
changes can be confirmed by repeating the analysis on larger numbers at a later stage once 
enough 36 months scans are received from quality control centre. 
 
At the beginning of the study it was planned to measure BMD changes along with changes in 
blood  bone  marker  values  at  3,  6  and  12  months,  but  due  to  freezer  failure  at  the  St  Mary’s  lab  
in 2005 many IBIS-II bone study baseline and follow-up blood samples were lost. A thorough 
investigation was conducted at the time of incident and it was decided to change the collection 
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of samples for markers from blood to urine samples. This decision was taken on the basis of 
information from research nurses that healthy women had found it very difficult to reach 
hospital in morning hours when they could easily attend the afternoon IBIS-II clinics. The 
analysis of change in urine bone markers along with BMD change on powered data at 
36months will give strength to current results in future. 
 
Calcium and vitamin was not provided to the participants and the information collected on the 
use of calcium and vitamin D did not include doses and duration of intake.  
 
The comparison analysis conducted on participants from 12 to 36 months is not on the same set 
of women but all the subjects available for the analysis. Once enough scans are received, the 
comparison of BMD change at 12 and 36 months will be done on same set of women for 
whom we receive 12 and 36 months BMD data. 
  
4.1.9 Conclusions 
In women with a normal BMD at the time of entry, there was a consistent downward trend in 
BMD at both the lumbar spine and total hip in each treatment arm, but the effect was largest 
for the anastrozole group at lumbar spine. Osteopenic women, who received anastrozole plus 
risedronate, after 12-months of treatment gained significant bone density at lumbar spine 
compared to women receiving anastrozole without risedronate, but not at total hip. At 36 
months, there were no significant gains in bone density either at lumbar spine or total hip. In 
osteoporotic women, risedronate abrogated the detrimental effect of anastrozole, after 12 
months of treatment, significantly at lumbar spine but not at total hip. After 36 months of 
treatment, risedronate still abrogated the effect of anastrozole at lumbar spine, but not 
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significantly. These initial results from the IBIS-II bone study are reassuring, indicating that 
although women with a normal BMD at the time of entry had a significant BMD loss after 12 
and 36 months of anastrozole use, and no one became osteoporotic. The beneficial effect of a 
bisphosphonate abrogated the detrimental effect of anastrozole on BMD, indicating that these 
women could safely receive anastrozole if they also took a bisphosphonate. Further analysis of 
data at 36 months on a larger sample size will support the present results. 
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 Chapter 4, Section-II: Effect of anastrozole on lipid profiles 
 
4.2.1 Introduction 
The third generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, have 
been shown to be superior to tamoxifen in preventing breast cancer recurrence when given 
either as first-line adjuvant endocrine therapy or after 2-5 years of use of tamoxifen (Baum, M 
2002; Coombes, RC 2004; Howell, A 2005; Thurlimann, B 2005; Coombes, RC 2007)  
 
The impact of aromatase inhibitors (AIs) on cholesterol fractions is of concern in 
postmenopausal women receiving AIs in a prevention setting, especially as some adjuvant 
trials have reported an increased incidence of cardiovascular disease. There are no data 
available on the impact of AIs on lipid profile in well women in a chemoprevention setting. 
 
In the adjuvant setting, several studies with anastrozole (Thurlimann, B 2005; Buzdar, A 
2006), letrozole (Thurlimann, B 2005) and exemestane (Boccardo, F 2005; Coombes, RC 
2007) have shown that AIs do not have any negative impact on any of the cholesterol fractions. 
However a few trials have shown hypercholesterolemia with AIs but most of the trials had 
compared AIs with tamoxifen, which itself has a lipid lowering effect. 
 
Here, the results of a double-blind randomised study comparing 5 years of anastrozole with 
placebo in healthy postmenopausal women at a high risk of breast cancer are reported. 
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4.2.2 Patients and methods  
In the IBIS-II prevention study, 2184 women have already been randomised, and the 
recruitment of the remaining 3816 women is currently on-going, from patients all over the UK 
and from more than 20 international centres. Along with investigating anastrozole as a 
chemopreventive agent, the IBIS-II study also aims to examine the effect of anastrozole on 
lipid fractions. The effect of anastrozole on TC and HDL was examined in 380 women 
recruited within the UK for whom baseline and one-year blood sample were received. Non-
fasting blood samples were stored at -70 degrees until they were analysed. TC and HDL levels 
were measured by AU 2700 Automatic analyser at   the  St  Mary’s  Hospital, Imperial College 
London. Non-fasting blood samples were collected in the study for the convenience of 
participants. As IBIS-II  is  a  chemoprevention  study,  women  don’t  always  have  the  facility to 
go to their nearest health clinic and have to sometimes travel a long distance to take part in the 
study. Therefore, healthy postmenopausal women were not expected to visit the centre in the 
morning hours particularly for providing fasting blood samples. 
 
4.2.3 Statistical analysis 
Measurement of baseline characteristics including age, weight, height, prior use of HRT, 
smoking etc, and the study analysis, were conducted on participants for whom data was 
available both at baseline and one year. Summary statistics of all lipid variables were based on 
mean values, according to the treatment group. The differences in mean values from baseline 
to follow-up in the anastrozole and placebo group individually were tested by the Mann-
Whitney U-test. The difference in mean changes within the treatment group (from baseline to 
one year) was tested by the sample t-test. Any use of lipid-lowering agent at baseline was 
checked. The t-test was conducted with and without including participants who had taken 
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statins at baseline. Since no difference was found in the results, it was decided to include these 
participants in the analysis. 
 
4.2.4 Results 
Two thousand one hundred and eighty four women have been recruited into the prevention 
study so far. The baseline characteristics on 380 women with baseline and one-year data are 
presented in table 4.2.1. Groups were well balanced with respect to age, weight, height, use of 
HRT, baseline total cholesterol and baseline HDL levels.   
Table 4.2.1: Baseline characteristics 
 Anastrozole 
(n= 185) 
Placebo 
(n= 195) 
 Median age (years) 
(IQ range) 
 
58.7 
(57.8-59.5) 
58.3 
(57.559.1) 
Median Weight (kg) 
(IQ range) 
 
           72.1 
        (70.1-74.0) 
       74.6 
(72.6-76.7) 
Median height (cm) 
(IQ range) 
 
          161.6 
        (160.8-162.5) 
163 
 (162.2-163.9) 
Smoke (%) 
 
          48%   51% 
HRT (%) 
 
   49%   51% 
Mean TC, mmol/L 
 
5.9 
   (5.7-6.03) 
 
5.9 
(5.8-6.0) 
Mean HDL, mmol/l 
 
1.5 
   (1.4 – 1.5) 
 
1.5 
(1.4 -1.6) 
 
38 participants were taking statins at baseline, 17 in the anastrozole group and 21 in the 
placebo group. 
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Changes in the mean absolute values for each lipid parameter from baseline to one year are 
shown in table 4.2.2.  
 
The absolute mean changes and 95% CIs for TC and HDL are (-0.07mmol/l [-0.17, 0.03] 
P=0.18 and 0.05 (0.02, 0.08) P=0.0009) for the anastrozole arm and (-0.003 mmol/l [-0.12, 
0.11] P=0.96 and 0.06 (0.03, 0.09) for the placebo arm, respectively (table 4.2.2.). 
 
After one year, there was a significant increase in HDL levels in both the treatment arms, with 
a non-significant reduction in TC levels in the anastrozole arm. However, there was no 
significant difference in TC and HDL levels between the two treatment arms after one year of 
treatment. 
 
 
Table 4.2.2: Mean changes for total cholesterol and HDL (mmol/ml) levels according to 
treatment arms 
 
 
 
Lipid  Anastrozole 
(n=180) 
Placebo 
(n=188) 
Difference in mean 
changes between the  
treatment arms 
TC 
(95% CI) 
P-value 
-0.07 
(-0.17, 0.03) 
0.18 
-0.003 
(-.12, 0.11) 
0.96 
-0.067 
(-0.22, 0.09) 
0.40 
HDL 
(95% CI) 
P-value 
0.05 
(0.02,  0.08) 
<0.0001 
0.06 
(0.03, 0.09) 
<0.0001 
-0.01 
(-0.05, 0.03) 
0.61 
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Figure 4.2.1: Mean percentage change in TC and HDL levels at one year 
 
4.2.5 Discussion  
Alterations in lipid profile, including increase in total cholesterol, triglycerides, low-density 
lipoprotein and a decrease in high-density lipoprotein levels are known high risk factors for the 
development of cardiovascular disease (CVD) (Knopp, RH 2002). Results from this study have 
indicated that anastrozole does not have any negative impact on HDL and total cholesterol 
within one year of treatment. 
 
In healthy postmenopausal women with a high risk of breast cancer, IBIS-II is the only trial 
currently evaluating the effect of anastrozole on lipid profiles in a chemoprevention setting. 
There are hardly any data available on the impact of any of the AIs on lipid profile in healthy 
women in a chemoprevention setting, and conflicting data is available in an adjuvant setting.  
 
In the adjuvant setting, several studies on AIs including anastrozole (Banerjee, S 2005; 
Markopoulos, C 2005; Markopoulos, C 2005; Sawada, S 2005) have shown that they do not 
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have any significant negative impact on any of the cholesterol fractions. However, a few trials 
have reported significant hypercholesterolemia with AIs (Boccardo, F 2005; Thurlimann, B 
2005; Wasan, KM 2005; Buzdar, A 2006). Most of these trials studied the effect of AIs on 
lipid levels from 12 weeks to 2 years after starting the trial medication. 
 
In an upfront adjuvant setting, when compared with tamoxifen, hypercholesterolemia was 
reported with anastrozole in the ATAC trial (9 vs. 3%; P<0.0001), and with letrozole in the 
BIG 1-98 trial (43.6 vs. 19.2%) (Thurlimann, B 2005). However, results from the ATAC trial 
are difficult to interpret as TC data was collected irregularly, and 65% of patients with 
hypercholesterolemia were started on a lipid-lowering medication while receiving treatment. In 
the BIG 1-98 trial, the majority of cases had grade I hypercholesterolemia, and median TC 
values remained stable under the letrozole arm but decreased in the tamoxifen arm by 
approximately 12%.  
 
The same increase was seen if AIs were given in the switch setting after 2-3 years of tamoxifen 
use. In the ITA trial, significant lipid disorders were reported in the anastrozole group (9.3 % 
vs. 4.0; P=0.04) when compared to the tamoxifen group (Boccardo, F 2005). In the IES study, 
the incidence of hypercholesterolemia reported with exemestane was not significant (8.8% vs. 
7.6%; P=0.14) when compared to tamoxifen. In the same setting, however another randomized 
study reported significantly increased LDL levels (P < 0.01), and significantly decreased HDL 
and triglycerides levels (P<0.01). However, in this study the analysis was done on a very small 
sample size (55 postmenopausal women). 
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When compared with tamoxifen, it seems that AIs lack the lipid-lowering effect, but they do 
not seem to have detrimental effect on lipid profile. When compared with placebo, 
hypercholesterolemia was not observed in the MA.17 trial (Wasan, KM 2005). In this study, 
hypercholesterolemia occurred at similar rates in both the letrozole and placebo group (16% vs. 
16%; P=0.79). These results were further confirmed in the lipid sub-study, which found that 
letrozole did not significantly alter lipid parameters in postmenopausal women who had 
completed 5 years of adjuvant tamoxifen therapy. Likewise, another study found that 
exemestane had no major effects on lipids, with the exception of a small decrease from 
baseline HDL and apolipoprotein (Lonning, PE 2005), which showed a marginally significant 
percentage, increase in LDL at 12 months.  
 
In the Tamoxifen and Exemestane Adjuvant Multicentre (TEAM) sub-study, the lipid profiles 
remained unchanged in the anastrozole group after one year of treatment (Markopoulos, C 
2005). In the Adjuvant post-Tamoxifen Exemestane versus Nothing Applied (ATENA) study, 
when compared with placebo, no significant differences were observed for any lipid 
parameters (Markopoulos, C 2005). In a neoadjuvant setting, after 3 months of treatment in the 
Immediate Preoperative Arimidex, Tamoxifen, or combination with Tamoxifen (IMPACT) 
trial, anastrozole resulted in a significant positive increase in HDL levels but no significant 
increase in non-HDL and TC levels (Banerjee, S 2005).  
 
In the LEAP study of healthy postmenopausal women, no difference was found in lipid profiles 
for either letrozole or exemestane, compared to anastrozole, except for an increase in 
triglycerides with letrozole than anastrozole at 12 weeks (+9.6% vs -2.9%; P <0.001) 
(McCloskey, EV 2007).  
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To rule out the increase in HDL levels in both the treatment group due to sample storage 
failure, it was investigated if serum samples were handled in proper temperature while they 
were transported  from  the  site  to  St  Mary’s  lab  and  if samples were stored at -70 degree at the 
lab throughout until they were taken out for measurements. It was confirmed from the records 
and various checks made at the trial sites that the samples were handled, transported and stored 
according to the standard operating procedure provided to the research nurses at the sites and to 
the laboratory staff. 
 
It is difficult to compare the effect of AIs on lipid profile observed in this trial on healthy 
postmenopausal women at a high risk of breast cancer, with the results of the trials where 
anastrozole  or  AI’s  were  prescribed  to  breast  cancer  patients  as  a  first  line  treatment  in  an  neo-
adjuvant, adjuvant or postadjuvant setting, or given after 2-5 years of tamoxifen. Further 
clinical trials comparing the effect of anastrozole versus placebo in healthy postmenopausal 
women with a high risk of breast cancer are needed to confirm the results of this study. 
 
4.2.6 Limitations 
As explained before, non-fasting blood samples were collected in the study; therefore, serum 
levels of LDL and triglycerides could not be performed to support the effect of anastrozole on 
all lipid levels. HDL levels rose significantly in both the treatment arms, it was an unexpected 
finding to see such a significant rise in HDL levels and no conclusive reason could be found 
out from the literature. It was planned to conduct the Apo-A and Apo-B levels to confirm the 
results of our findings, but due to logistic reason (delay in getting the required material at the 
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Wolfson institute laboratory where the  measurements  were  planned)  it  couldn’t  be  performed 
at the time of analysis.  
 
4.2.7 Conclusion  
These data are reassuring about the effects of anastrozole on cholesterol fractions. No 
significant difference was seen between anastrozole and placebo for any fraction. If anastrozole 
has any effect on cardiovascular disease, it is likely to be mediated by mechanisms not related 
to cholesterol levels. These data support the lack of impact of anastrozole on cholesterol 
fractions in a chemoprevention setting, similar to reports in the adjuvant setting in women with 
breast cancer. The randomisation in the IBIS-II prevention study is still on going, and no other 
planned measurements on available serum levels are sent to the lab. It is planned that along 
with other measurements (e.g. serum oestradiol levels etc), a complete lipid profile (along with 
Apo-A and Apo-B) on a different set of participants will be conducted at a later stage to 
confirm the findings of these results. 
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Chapter 4, Section-III: Risk factors for fractures: 5-year data from 
the ATAC trial 
 
4.3.1 Introduction  
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial was a randomized, 
double/blind designed study to evaluate the safety and efficacy of 5 years of anastrozole versus 
5 years of tamoxifen or the combination in postmenopausal women with hormone/receptor 
positive breast cancer (ATAC 2005). The aim of this study was to assess possible risk factors 
for fractures in patients from the ATAC trial. 
 
The risk of fracture is multi-factorial and many independent risk factors have been identified 
that contribute to risk over and above reflected by BMD (Paganini-Hill, A 1981; Cooper, C 
1988; Farmer, ME 1989; Grisso, JA 1991; Paganini-Hill, A 1991). Menopause and a lower 
body mass index (BMI) have been associated with decreased serum oestradiol levels, which in 
turn may reduce BMD (Pinheiro, MM ; Johnell, O 1995). An additional complication is that 
lower weight is regarded as a factor for increased risk of hip/vertebral fracture, whereas higher 
weight is also regarded as a factor for increased risk of ankle/most lower limb fractures 
(Greenfield, DM 2001). In a study, patients treated for hypercholesterolemia with statins for 15 
months had significant increase in BMD at the femoral neck (Chung, YS 2000). Cigarette 
smoking is also often considered a risk factor for hip fracture, but several studies (Baron, JA 
2001) have found no or a modest association between cigarette smoking and hip fracture. In 
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addition, postmenopausal women with breast cancer who receive hormonal therapy could have 
a higher rate of fractures due to low oestradiol levels (Boccardo, F 2005; Howell, A 2005; 
Perez, EA 2006; Coombes, RC 2007; Jakesz, R 2007). 
 
In the ATAC trial, after 33 months the combination arm was discontinued as no efficacy or 
tolerability benefit over tamoxifen alone was observed (Baum, M 2002). The completed 
treatment analysis, with a median follow-up of 68 months, revealed that anastrozole 
significantly improved the primary endpoint, disease-free survival, compared with tamoxifen 
(P=0.01) (Howell, A 2005). Fracture and arthralgia were recorded as predefined adverse 
events. Overall, patients on anastrozole experienced more fractures than on tamoxifen (11.0% 
vs. 7.7%; P<0.0001). This may be explained, at least in part, by the results from the bone sub-
protocol after 2 and 5 years of treatment, which showed that anastrozole was associated with 
significant BMD loss and a small increase in bone turnover, whereas tamoxifen was associated 
with increased BMD and decreased bone modelling (Baum, M 2002; Eastell, R 2006; Eastell, 
R 2008).  
 
In women, not receiving AIs, the lifetime risk of osteoporotic fractures worldwide is 
approximately 40-50%, and because of the ageing of the population, the overall prevalence of 
osteoporotic fractures is expected to rise considerably (Johnell, O 2005). In 1990, there were 
1.7 million hip fractures worldwide (Johnell, O 2006) and this could increase to 6.3 million by 
2050 (Cooper, C 1992; Kannus, P 1996).  
 
Several researchers have addressed the subject of identifying the risk factors for the primary 
and secondary fractures in postmenopausal women (Cummings, SR 1995; Burger, HG 1999; 
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Black, DM 2000; Siris, ES 2001).  WHO has recently developed a FRAXTM tool to assess 10-
year clinical fracture risk of patients diagnosed with osteoporosis (Kanis, JA 2008; Watts, NB 
2008). The risk assessment is based on the assessment of up to 6 clinical risk factors, BMI and 
with or without femoral neck BMD. The FRAXTM model has been developed from studying 
population-based cohorts and it gives the 10-year probability of fracture at spine, forearm, hip 
or shoulder, but cannot be used on patients who have already initiated therapy. 
 
In women on AIs, identification of additional factors that increase the likelihood of fracture 
would help target prophylactic measures, such as bisphosphonate therapy, to those patients 
most at risk.  
 
4.3.2 Methods 
Eligible patients were postmenopausal women with breast cancer who had completed primary 
surgery and chemotherapy, and were candidates to receive hormonal adjuvant therapy. The 
trial was designed to test two hypotheses: that anastrozole was non-inferior or superior to 
tamoxifen and that the combination of anastrozole and tamoxifen was superior to tamoxifen 
alone as adjuvant therapy in postmenopausal patients with early breast cancer. The primary 
objectives of the trial were efficacy against breast cancer and safety. The primary endpoint was 
disease-free survival. Secondary endpoints were time to a recurrence, and incidence of new 
contralateral primary breast tumours. Distant recurrence and overall survival were also 
secondary endpoints.  
 
All women enrolled in the ATAC trial and receiving anastrozole or tamoxifen monotherapy 
were included in the present analysis. In general there are three types of models used for 
 226 
analyzing time-to-event data: parametric, nonparametric, and semiparametric. For a parametric 
model, the distribution of the times to events given a set of risk factors and covariates is 
completely specified except for a (finite) set of unknown parameters, which are estimated from 
the data. For a nonparametric analysis, these distributions are estimated from the data with 
essentially no model assumption, e.g. by using Kaplan-Meier plots for each combination of 
risk factors and covariate values. For a semiparametric analysis, these distributions are 
modelled as a function of an unspecified baseline distribution and a set of unknown 
parameters. In this study, time to event modelling using both, parametric and non-parametric 
analysis, to assess possible risk factors for fractures. Patients who had not experienced a 
fracture event were censored at the last recorded visit. 
The following risk factors were considered in the time or event model:  
1. Age (<60- >70 years). 
2. Weight/height/BMI. 
3. Medications use at baseline (vitamin D supplements, calcium, 
thiazides, statins, corticosteroids, thyroid hormones, bisphosphonates, 
antiepileptics, anxiolytic/hypnotic benzodiaxepine derivatives). 
4. Geographical regions (very high risk: USA and Sweden; high risk: 
Canada, Germany, Holland, Hungary, Italy, UK, Australia, Spain, 
Belgium, Czech Republic/Slovakia, New Zealand, Ireland and Poland; 
moderate and low risk: France, Spain, Argentina, South Africa and 
Turkey). 
5.  Smoking; previous chemotherapy; previous radiotherapy and trial 
therapy.  
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The risk of fracture by geographical region was based on the work of Kanis and colleagues 
(Kanis, JA 2002), who studied the probability of hip fractures worldwide over a 10-year 
period.  
 
BMI, height and weight are correlated; therefore, a stepwise procedure was used to assess these 
risk factors. First the effect of BMI was investigated and then whether height or weight added 
any benefit in statistical modelling was observed. 
 
Cox proportional-hazards regression allows analyzing the effect of several risk factors on a 
given outcome. In this study we did multivariate Cox proportional hazard analysis using a 
‘forward   selection’   type   procedure,   with   a   5%   significance   level,   to   ascertain   whether   any  
particular risk factors should be included in the time to event model. A series of significance 
tests were performed to assess the order of inclusion of risk factors in the model. This test was 
conducted by assessing the difference in the log likelihoods between the present model (null 
model initially) and the new model containing an additional risk factor. The difference was 
multiplied by -2 and this statistic has a chi-squared distribution with degrees of freedom equal 
to the difference in the number of parameters between the two models. The risk factor that 
produced the most significant reduction in the log likelihood was the next risk factor included 
in the model, and subsequent  risk  factors  were  included  using  a  ‘forward  selection’  procedure  
using the same principles. 
 
For the final model, hazard ratios, together with 95% confidence intervals were calculated for 
all the risk factors included, and tabulated in the order they were included in the model. 
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4.3.3 Results 
Of the 9366 patients who participated in the ATAC trial, 6186 received either anastrozole or 
tamoxifen monotherapy and were included in the safety population. Of 6186 patients who 
received monotherapy with either anastrozole (n=3092) or tamoxifen (n=3094) as part of the 
ATAC trial and were included in this analysis, 732 (12 %) had a fracture. Table 4.3.1 shows 
the distribution of first fractures reported in the tamoxifen and the anastrozole group. 
 
Table 4.3.1: Fractures at different sites in the tamoxifen and anastrozole group 
 
 
 
 
 
 
 
 
 
 
 
 
 
A tabular summary of each risk factor giving the number and percentage of fractures observed 
is presented (table 4.3.2). The data are also summarized using Kaplan-Meier plots for the 
First fracture site Tamoxifen Anastrozole Total 
 
Clavicle/sternum 12 15 27 
Elbow 3 5 8 
Femoral neck of 
the hip 
7 4 11 
Foot 18 42 60 
Hand 11 14 25 
Total Hip 30 39 69 
Humerus/Arm 23 44 67 
Leg /Knee/Patella 11 14 25 
Pelvis 9 8 17 
Radius/ulna other 8 18 26 
Rib 26 35 61 
Skull 6 3 9 
Spine 32 49 81 
Tibia/fibula/ankle 46 50 96 
Wrist/colles 69 81 150 
Total 311 421 732 
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significant   risk  factors.   In  order  of   importance,   the  ‘forward  selection’  procedure  defined   the  
following risk factors for inclusion in the final modelling process: age, region and trial therapy 
(table 4.3.3). No other risk factors were significant in the modelling process.  
 
Some of the risk factors appear to be confounded. For example, smoking was a significant 
factor when age alone or age and treatment were fitted to the model but not when geographical 
regions were fitted. Prior chemotherapy was not a significant risk factor. HRT was a highly 
significant risk factor, when age alone was fitted to the model. When the very high-risk region 
or treatment was added to the model HRT lost significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 230 
 
Table 4.3.2: Final Model of defined risk factors associated with increased fracture risk in the 
ATAC trial, with stratified age variable fitted 
 
 No of patients  Patients with 
fractures (%) 
Hazard ratio 
(95 % CI) 
p-value 
Age, years 
<60 2195 193 (8.79)  - 
≥  60  to  <70 2329 266 (11.42) 1.36 (1.13, 1.63) 0.002 
>/=70 1662 273 (16.43) 2.18 (1.81, 2.63) <0.0001 
     
Age (10 yr increase) 6186 732 (12) 1.48 (1.34, 1.63) <0.0001 
     
Geographical regions 
Low or moderate risk 714 63 (8.82)   
High risk 3818 395 (10.35) 1.15 (0.88, 1.50) 0.296 
V high risk 1654 274 (16.57) 1.97 (1.50, 2.59) <0.0001 
     
Trial therapy 
Tamoxifen 3094 311 (10.05)   
Anastrozole 3092 421 (13.62) 1.38 (1.19, 1.60) <0.0001 
     
Statin use 
No 5369  613 (8.95)   
Yes 817  119 (14.57) 1.24 (1.02, 1.51) 0.028 
     
Smoking 
No 3665 421 (11.49)   
Yes 2514 310 (12.33) 1.09 (0.94, 1.26) 0.264 
     
Trial chemotherapy     
No  4848 590 (12.17)   
Yes 1338 142 (10.61) 0.89 (0.74, 1.06) 0.199 
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Table 4.3.3: Final Model of defined risk factors associated with increased fracture risk in the 
ATAC trial, with stratified age variable fitted 
 
Model-building variable  Chi-sq Chi-sq test p-value 
 
  Age (alone)    
(continuous variable) 
90.73 
 
<0.0001 
 
Age + Geog. Regions   42.24 
 
<0.0001 
 
Age + Geog. Regions + Treat. (ANA or TAM) 20.76 
 
<0.0001 
 
 
 
Statistically significant predictors of fractures, calculated from the final model, were age, 
geographical region and trial therapy (table 4.3.3, figure 4.3.1 to 4.3.3).  
 
In addition, statin use was significant when treatment alone was fitted to the model but lost 
significance when geographical region or age were fitted to the model. When the final model 
was fitted with a continuous age variable, chemotherapy (P=0.199), and smoking (P=0.264) 
became insignificant. 
 
No alteration in fracture risk was observed in association with any of the other factors studied, 
including BMI, radiotherapy, previous HRT or other concomitant medications (vitamin D, 
thiazide, thyroid hormone, bisphosphonates or anxiolytic treatments). Only three hundred and 
fifty patients had received vitamin D. 
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4.3.4 Discussion 
The identification of risks for fractures is important in the management of osteoporosis. This 
analysis of fracture risk factors in this trial revealed that women aged either 60 to 70 years 
(P=0.002) or aged 70 years or older (p< 0.0001) (Table 4.3.2 and figure 4.3.1), living in very 
high geographical risk regions (p<0.0001, or taking anastrozole (P<0.0001) (Table 4.3.2 and 
figure 4.3.2 and 4.3.3) rather than tamoxifen, are significantly more likely to experience a 
fracture. These positively associated risk factors for fracture were expected and are consistent 
with previously published data on fractures risks (Chapurlat, RD 2000; Kanis, JA 2002). 
 
The increased risk of fracture in postmenopausal women has been well documented 
(Chapurlat, RD 2000). Low oestradiol levels after menopause could be contributing to a 
decreased BMD and sometimes osteoporosis in later years. The results from the present study 
confirm that older patients are at greater risk of fracture than younger patients, with the 
incidence of fracture increasing significantly compared with those aged 60 years by 
approximately 36% increase in the hazard for those aged 60 to 70 years and an approximately 
2 fold increase for those aged 70 years and over.  
 
The incidence of fractures was also shown to be region specific, with patients living in very 
high-risk countries (USA and Sweden) being significantly more vulnerable to fracture than 
those living in high-and moderate/lower-risk countries. The reason for this variation in regional 
incidence of fractures observed could be due to change in lifestyle and dietary characteristics, 
although the definitive reasons for these differences have not been determined. 
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Fracture rates reported here were significantly more in patients receiving anastrozole, which 
shows that women on anastrozole are more likely to be at risk of fracture than those receiving 
tamoxifen. Similar significant increases in fracture rate with AIs have been reported by four 
other trials (Boccardo, F 2005; Howell, A 2005; Perez, EA 2006; Coombes, RC 2007; Jakesz, 
R 2007). 
 
However, all these trials compared the AIs with tamoxifen, which has a protective effect on 
bone (Fisher et al 2005, Grey et al 1995). When the use of letrozole was compared with 
placebo after 5 years of tamoxifen, the fracture rate was not found significantly different 
between the two groups (Perez, EA 2006).  
 
Patients in this study who received statins did not have reduce risk of fracture, although 
previous studies have noted an association between statins, increased BMD and decreased 
fracture rates (Chan, KA 2000; LaCroix, AZ 2003)). The exact mechanism for the protective 
effect of statins is not known although it has been suggested that this could be due to activation 
of vitamin D receptors (Grimes, DS 2006) ). No association between fracture risk and patient 
on concomitant vitamin D treatment was seen in the present trial. This could possibly due to 
the low number of patients receiving vitamin D supplements in the ATAC trial.  
 
Similarly, the absence of a significant association between fracture risk and other risk factors 
such as radiotherapy, bisphosphonates and other concomitant medications during the ATAC 
trial could be because the number of patients in these particular sub-groups was lower. Also, 
the effect of these risk factors could have masked as certain medications were only given to 
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patients with the highest risk of fractures and hence the least positive outcomes were seen with 
these risk factors. 
 
Although anastrozole therapy has shown an increased risk in the incidence of fracture 
compared with tamoxifen in postmenopausal women with breast cancer, overall anastrozole 
therapy has a more favourable risk: benefit profile compared with tamoxifen (Howell, A 2005; 
Howell, A 2006). Anastrozole offers significant benefits over tamoxifen in terms of efficacy 
and key adverse events, such as lower incidence of endometrial cancer, gynaecological 
problems, thromboembolic events and stroke. In addition, anastrozole is currently the only AI 
with a detailed safety profile from over 5 years of follow-up, and the only AI to show 
significant lower rates of drug-related adverse events, serious adverse events and events 
leading to withdrawals compared with tamoxifen. 
 
When considering these fracture-risk findings from the ATAC trial, patients at risk of 
experiencing a loss in BMD and increased fracture rate can be identified prior to anastrozole 
treatment and can be protected against fracture through the use of appropriate therapies, such 
as bisphosphonates, calcium and vitamin D supplements. Results from the 1-yr analysis of the 
study of Anastrozole with the Bisphosphonate Risedronate (SABRE) trial has shown that the 
addition of risedronate to adjuvant anastrozole therapy, for postmenopausal women with 
hormone receptor-positive early-stage breast cancer at a moderate or higher risk of fracture, 
resulted in smaller BMD losses at LS and TH and favourable reductions in markers of bone 
turnover (Van Poznak, C 2010). Evidence from other clinical trials (ABCSG-12, Z-FAST and 
ZO-FAST trials) has shown an increase in BMD when AIs were used along with IV 
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bisphosphonate, zoledronic acid in pre- and postmenopausal women with breast cancer 
(Confavreux, CB 2007; Gnant, MF 2007; Bundred, NJ 2008). 
 
4.3.5 Conclusion 
This analysis of risk factors for fracture has shown anastrozole treatment to be a significant 
predictor of fracture risk. Risk factors such as age and geographical region were also strong 
predictive factors for fracture risk in this study, which means the risk of fracture in women 
receiving anastrozole could increase further as age increases and for women living in very high 
risk countries. Despite the increase risk of fracture with anastrozole, the overall risk: benefit 
profile remains in favour of anastrozole compared with tamoxifen therapy. This would ensure 
that fracture events associated with anastrozole could be predicted and managed. 
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Figure 4.3.1: Kaplan-Meier showing probability of time to first fracture according to age 
group 
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Figure 4.3.2: Kaplan-Meier showing probability of time to first fracture according to 
geographical region 
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Tam=tamoxifen; Ans= Anastrozole 
Figure 4.3.3: Kaplan-Meier showing probability of time to first fracture according to 
randomized trial treatment 
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Chapter 4, Section IV: Effect of baseline serum vitamin D levels on aromatase 
inhibitors induced musculoskeletal symptoms 
 
4.4.1. Introduction 
 
It has been reported that severe deficiency of vitamin D in adults can cause severe 
musculoskeletal pain, stiffness and joint discomfort (Pfeifer, M 2002; Bischoff-Ferrari, HA 
2004; Waltman, NL 2009). In the general population, postmenopausal status and low oestrogen 
concentrations are associated with the development of joint pain and joint symptoms. These 
symptoms are reported mostly around the ages of 50-59 years (Croft, P 1993; Wolfe, F 1995), 
and often improve during use of hormone replacement therapy (HRT). These symptoms are 
also frequently seen in breast cancer patients receiving adjuvant aromatase inhibitors (AIs). A 
number of clinical trials of AIs have reported musculoskeletal symptoms that include joint 
pain, joint stiffness (arthralgia), bone pain, muscle pain (myalgia), and muscle weakness, with 
incidences ranging from 5% to 36% (Goss, PE 2003; Coombes, RC 2004; Felson, DT 2005; 
Howell, A 2005; Jakesz, R 2005; Thurlimann, B 2005; Burstein, HJ 2007; Coombes, RC 2007; 
Crew, KD 2007; Mouridsen, H 2009). 
 
Arthralgia is considered a class effect of AIs, with an incidence 2-8% higher in patients treated 
with AIs than among those treated with tamoxifen in blinded controlled randomised trials 
(Cella, D 2008). The exact mechanism of AI-related arthralgia is unclear, but is believed to be 
related to oestrogen deprivation (Donnellan, PP 2001; Holick, MF 2006). It has been suggested 
that arthralgia/musculoskeletal symptoms in breast cancer patients on AIs could be a result of 
low levels of vitamin D (Heaney, RP 2005; Holick, MF 2005). Several studies have shown that 
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a serum vitamin D level of at least 20ng/ml   is   necessary   to   minimally   satisfy   the   body’s  
vitamin D requirement (Plotnikoff, GA 2003), and maintenance of serum vitamin D levels in 
the 30-50ng/ml range is recommended (Malabanan, A 1998; Heaney, RP 2003; Holick, MF 
2003; Bischoff-Ferrari, HA 2009). In breast cancer patients receiving AIs, four studies have 
reported a high incidence of serum vitamin D insufficiency (<30ng/ml) (Prieto-Alhambra, D ; 
Khan, QJ 2009; Waltman, NL 2009) and one study (Taylor M, RA, Civitelli R, Ellis M 2004) 
has reported a significant inverse correlation between musculoskeletal pain intensity and serum 
vitamin D levels (Waltman, NL 2009). Among breast cancer patients, one study has recently 
reported the association of AI-induced arthralgia and low plasma concentration of vitamin D 
levels.  
 
In this study it was examined whether baseline serum vitamin D levels predict arthralgia within 
the first year of follow-up in the overall group and separately in anastrozole and placebo 
treated participants. It was also studied whether anastrozole influenced serum vitamin D levels 
after 12 months of treatment.  
 
4.4.2 Methods  
IBIS-II is a multicentre, randomised, double blind trial aimed at preventing breast cancer in 
postmenopausal women aged 40-70 years receiving either anastrozole (1mg) or placebo for 
five years. Women are followed-up at 6 and 12 months, and then annually for the 5 years of 
active treatment. Details of the trial design and primary objectives have been published 
elsewhere (Cuzick, J 2008). Written informed consent was obtained from all participants 
before trial entry. Regulatory and ethics authorities for all participating centres approved the 
protocol before enrolment of participants. The trial was done in accordance with the 
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Declaration of Helsinki (2000) (Christie, B 2000) and under the principles of good clinical 
practice. 
 
This sub-study was performed to investigate if serum vitamin D influences musculoskeletal 
symptoms in women receiving AIs. The primary aim of the study was to determine if low 
levels (10ng/ml difference) of baseline serum vitamin D levels predicts arthralgia (any degree) 
within the first year of follow-up (at 6 and 12 month) in the overall group, and separately in the 
anastrozole and placebo treated participants. The secondary goal was to study the extent of 
serum vitamin D deficiency at baseline, to look for risk factors for arthralgia and risk factors 
for baseline serum vitamin D levels, and to investigate whether anastrozole influenced the 
levels of serum vitamin D at 12 months.  
 
Women who had an indication of arthralgia at entry (women who were taking medication for 
pain; paracetamol, non-steroidal anti-inflammatory (NSAIDs), other pain medications 
[ibuprofen, rheumox, celebrex etc] and glucosamine, were excluded from the regression 
analysis, as no direct question regarding arthralgia was asked at entry. Investigators of the 
study were asked to make an assessment of the degree of arthralgia as mild, moderate and 
severe using subjective criteria and no standard questionnaire or a scale was used to assess 
arthralgia. All women were recommended to take calcium and Vitamin D.  Four cut points 
were   used   to   define   serum   vitamin   D   levels;;   adequate   (≥30ng/mL),   inadequate   (>20-
<30ng/mL),   deficient   (≥10-<20ng/mL) and severely deficient (<10ng/mL). We measured 
serum vitamin D samples on 416 participants. The samples were sent for assays in three 
batches (batch1, n=149; batch2, n=101 and batch 3, n=166) (table 4.4.1).  In the first two 
batches paired serum samples were sent to the laboratory. Subsequently, a third batch was 
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identified from later recruits into the trial. This was enriched with women who had arthralgia 
within the first year of follow-up (n=121). A further 414 women were present at 1 year, but 
were not included due to assay costs. Out of 416 participants, one year follow-up samples were 
measured for 294 participants (batch 1=134, batch 2=98 and batch 3=62). In the third batch, 
only 62 follow-up samples were sent for measurements due to assay costs.  
 
 
Table 4.4.1: Numbers of serum Vitamin D samples sent to the laboratory.  
Batch-1 Baseline 
samples 
Follow-up 
samples 
Baseline done  
but no follow-up 
Arthralgia 
(within 1st year) 
I 149 134 15 59 (41%) 
II 101 98 3 43 (43%) 
III 166* 62 104 121** 
Total assays 
performed  
416 294 122 223 (54%) 
* 62 paired and 104 only baseline samples 
** Biased samples were representing women who reported arthralgia within 1st year of follow-up 
 
 
Seasons were defined as follows: winter (Dec-Feb); spring (March-May); summer (June-Aug) 
and autumn (Sep-Nov). The non-fasting blood samples were stored at -70°. The serum samples 
were obtained by using a manual radio immunodiagnostic assay at the department of Clinical 
Chemistry, Imperial College, London (Hollis, BW 1985). Baseline characteristics including 
age, BMI, use of vitamin D supplements, median serum 25 (OH) vitamin D levels, use of 
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glucosamine, paracetamol and medications used for pain were tabulated. Serum vitamin D 
levels were tabulated for an initial comparison of data between the treatment groups.  
 
4.4.3 Statistical analysis 
Logistic regression was performed to compare the occurrence of arthralgia within the first year 
of follow-up (at 6 month and 1-year) according to baseline serum vitamin D levels. Univariate 
analysis was initially performed followed by multivariable model adjusting for risk factors 
where appropriate. A final model adjusting for season of randomisation, BMI and use of HRT 
was performed in the overall group and in the anastrozole and placebo groups, separately. A 
test of homogeneity was performed to compare odds ratio in the two treatment groups. Mean 
change of vitamin D levels between baseline and 1 year were compared between two treatment 
groups using a paired t-test. A test for interaction between vitamin D and randomisation groups 
was performed but no significant interaction was found so this was not included in the final 
model. Statistical significance was assessed using 2-sided p-values and a 5% significance level, 
and all confidence intervals are at the 95% level. All calculations were done using STATA 
(version 10). 
 
4.4.4 Results 
A total of 416 women were included in the analysis. The two treatment groups were well 
matched in terms of age, BMI, median serum vitamin D levels, past use of HRT, use of 
glucosamine, paracetamol and other medications for pain at baseline (Table 4.4.2).  
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Table 4.4.2: Baseline characteristics; mean or percentage (95% CI) 
Baseline characteristics Anastrozole 
(n=206) 
Placebo 
(n=210) 
P-value 
Mean age (years) 
 
58.5 
(57.7, 59.3) 
57.8 
(57.1, 58.6) 
0.24 
Weight (kg) 72.7 
(71.1, 74.4) 
74.6 
(72.6, 76.6) 
0.16 
Height (cm) 
 
161.8 
(161.1, 162.6) 
163 
(162.2, 163.9) 
0.03 
BMI (kg/m2) 
 
27.8 
(27.2, 28.4) 
28.1 
(27.4, 28.8) 
0.54 
HRT use (%)         54.4 
 
59.8 0.26 
Mean serum vitamin D 
levels (ng/mL) 
21 
 
21.6 
 
0.59 
Use of Vitamin D 
supplements (%) 
2.9 2.9 0.97 
Glucosamine Use (%)           5.8 
 
6.2 0.88 
Paracetamol Use (%)           1.9 
 
1.4 0.69 
Any medications used for 
pain (%) 
         14.6 15.2 0.85 
 
 
 245 
 Of   416   participants,   only   56   (13%)   had   adequate   serum   vitamin   D   levels   (≥30ng/mL)   at  
baseline. Of the remaining 360 (87%) participants, 172 (41%) had inadequate  (≥20-≤30ng/ml),  
40%  (165)  had  deficient  (≥10-<20ng/ml) and 23 (6%) had severely deficient (<10ng/ml) serum 
vitamin D levels (Table 4.4.3). The mean baseline serum vitamin D levels were 21.2ng/ml in 
the anastrozole group and 21.6ng/ml in the placebo group.  
 
Table 4.4.3: Levels of 25(OH) vitamin D levels at baseline 
25 (OH) vitamin Levels at baseline (%) 
<10 23 (6) 
>=10 & <20 165 (40) 
>=20 <=30 172 (41) 
>30 56 (13) 
Total 416 (100) 
 
Twenty-one (5%) participants reported taking vitamin D from a vitamin D supplement and/or 
from a multivitamin. The doses of vitamin D taken were not clearly reported.  
 
Women who had evidence of arthralgia at baseline (receiving medication for pain) were not 
included in the analysis for investigating a change in serum vitamin D levels predicting 
arthralgia within the first year of follow-up. Sixty-two (15%) women were receiving 
medication for pain at the time of randomisation. The univariate analysis revealed that a 
10ng/ml difference in baseline serum vitamin D levels did not significantly predict arthralgia 
within the first year, either in the overall group (OR 0.87 (95% CI: 0.67, 1.13; p=0.30) or 
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separately in the anastrozole (OR 0.90 (95% CI: 0.62, 1.3; p=0.60) or placebo groups (OR 0.85 
(95% CI: 0.59, 1.2; p=0.38) (Table 4.4.4). The p-value for the test of homogeneity to compare 
odds ratio in the two treatment groups was 0.82. Similar results were seen in a multivariate 
model, when adjusted for BMI, HRT and season of randomisation (OR 0.91 (95% CI: 0.69, 
1.21; P=0.52). No interaction was observed between treatment received and baseline serum 
vitamin D levels (p=0.60). 
 
Table 4.4.4: Odds ratio for arthralgia in the 1st year for a 10ng/ml increased in baseline serum 
vitamin D levels in women who did not take medication for pain and inflammation at baseline 
         Total Odds ratio 95% CI P-value 
Both  groups  (N=354) 0.87 0.67, 1.13 0.17 
Anastrozole  (N=176) 0.90 0.62, 1.3  
*0.82 
 
Placebo         (N=178) 0.85 0.59, 1.2 
 Regression analysis was performed on 354 women out of 416 as 62 women had taken 
medication for pain at baseline and were taken out of analysis 
* P-value for homogeneity for the anastrozole and placebo group 
 
Absolute serum levels of vitamin D increased significantly at one year in the anastrozole group 
(2.88ng/ml, [1.71, 4.06; p <0.0001]) but not in the placebo group (0.75ng/ml [-0.35, 1.85; 
p=0.18]). Significant difference in mean serum vitamin D change between baseline and one-
year (2.13 ng/ml [95% CI, 0.53, 3.74; P= 0.01]) was observed between the two groups after 
one year of treatment (Table 4.4.5). 
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Table 4.4.5: Mean change in serum vitamin D levels at one year in two treatment arms (and 
95% CI); women for whom both baseline and follow-up samples were available 
 
4.4.5 Discussion 
This study revealed that about 87% participants in the anastrozole and placebo group had 
serum vitamin D levels below normal limits (<30ng/ml), which is inadequate to maintain 
calcium homeostasis. This reflects a general vitamin D deficiency in postmenopausal women 
from within the UK. These deficiencies are consistent with the results reported in general 
population (Plotnikoff, GA 2003; Warner, AE 2008) and among breast cancer patients (Taylor 
M, RA, Civitelli R, Ellis M 2004; Waltman, NL 2009). Joint pain and stiffness, bone pain, and 
musculoskeletal pain have been associated with low serum vitamin D levels in number of 
studies, and also been linked to low adherence rate among patients during the first year of AI 
therapy (Fontaine, C 2008; Partridge, AH 2008). 
 
Serum vitamin D 
levels (n=294) 
Anastrozole 
(n= 151) 
Placebo 
(n=143) 
Difference between the 
treatment arms 
Mean change 
(95% CI) 
P-value 
2.88 
(1.71, 4.06) 
< 0.0001 
           0.75 
(-0.35, 1.85) 
0.18 
                   2.13 
(0.53, 3.74) 
0.01 
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In this study of 830 postmenopausal women living in the UK and receiving anastrozole for 
chemoprevention of breast cancer, we found that low baseline serum vitamin D levels did not 
predict musculoskeletal pain/ arthralgia in the first year of follow-up in the overall group or 
when assessed separately in the anastrozole or placebo groups. Several studies have reported 
varied results on the levels of serum vitamin D among patients with musculoskeletal pain and 
its effect on musculoskeletal symptoms. Taylor et al examined serum vitamin D level in 233 
breast cancer survivors (BCSs) with musculoskeletal symptoms. Fifty nine of the 233 BCSs 
were on AI therapy, and 65% of these 59 women had low levels of vitamin D (Taylor M, RA, 
Civitelli R, Ellis M 2004). Waltman at al reported serum vitamin D levels from 29 BCSs, and 
86% women had levels below 30 ng/ml. In this study patients reported muscle pain in the neck 
and back, and a significant inverse correlation was observed between pain intensity and serum 
vitamin D levels (r=-0.422; p<0.05) (Waltman, NL 2009). Also, data from Plotnikoff AG on 
150 patients, including those using non-steroidal inflammatory drugs and not receiving AIs 
showed that 93% outpatients with persistent, nonspecific musculoskeletal pain had deficient 
serum vitamin D levels (Plotnikoff, GA 2003). However, Block SR reported that 25-
hydroxyvitamin D insufficiency (20ng/ml) was not common in these patients with chronic, 
widespread musculoskeletal pain. Although this study lacked a control arm and treatment was 
not blinded (Block, SR 2004). Similar results were reported by Warner et al in 288 patients 
with diffuse pain or osteoarthritis, and found that vitamin D treatment had no effect on pain 
when compared with the placebo group (Warner, AE 2008).  It is reported that even in patients 
with osteomalacia the best characterized consequence of vitamin deficiency has been shown to 
be present in patients with circulating levels of up to 30ng/ml (Prieto-Alhambra, D 2010; 
Sanders, KM 2010). Overall, it was felt that the genesis of pain in postmenopausal women 
might not necessarily be related to vitamin D insufficiency. 
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It was observed that anastrozole lead to increased serum vitamin D levels. This was an 
unexpected finding and a new observation that is not been reported in the literature before.  
There is no explanations available at this point for this finding and needs further confirmation. 
In order to rule out that the increase in 25(OH) vitamin D levels could be due to any other bias 
or due to an error in a way samples were stored, transferred or handled during measurements, 
thorough checks were done. It was confirmed that the samples were handled in an appropriate 
temperature throughout the process.  
 
Low levels of vitamin D levels are associated with high-risk of bone loss and osteoporosis in 
postmenopausal women (Utiger, RD 1998; Aguado, P 2000). In the bone study of the IBIS-II 
(thesis results section I), anastrozole significantly reduced BMD in women who had normal 
BMD at baseline. However, in this sub-group of women from the prevention study of IBIS-II, 
25 (OH) vitamin levels were significantly raised in the anastrozole group. To look for an 
association between serum 25(OH) D levels and BMD, a future study can be planned to 
measure 25(OH) D levels in participants from the bone sub-study. 
4.4.6 Limitations 
This study has several limitations. A standard questionnaire or visual analogue scale was not 
used to score the intensity of joint pain. The history of arthralgia was not recorded at entry 
hence women who were taking medication for pain at baseline were excluded from the 
analysis. The details of vitamin D (doses) taken within the trial were not recorded at baseline or 
at the follow-up visit.  
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4.4.7 Conclusions 
No significant effect of baseline vitamin D levels were seen on the risk of musculoskeletal 
symptoms in healthy postmenopausal women at a high risk of breast cancer. Serum vitamin D 
levels had significantly risen in the anastrozole arm of the study. Further studies measuring 
serum levels of vitamin D in a chemoprevention setting among AI users are needed to confirm 
these findings. 
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Chapter V: Conclusions of the Thesis 
 
 
The data from the bone sub-study of the IBIS-II suggests that in women with a normal BMD at 
the time of entry, there was a consistent downward trend in BMD at both the lumbar spine and 
total hip in each treatment arm, but the effect was largest for the anastrozole group at lumbar 
spine. Osteopenic women, who received anastrozole plus risedronate, after 12-months of 
treatment gained significant bone density at lumbar spine compared to women receiving 
anastrozole without risedronate, but not at total hip. At 36 months, there were no significant 
gains in bone density either at lumbar spine or total hip. In osteoporotic women, risedronate 
abrogated the detrimental effect of anastrozole, after 12 months of treatment, significantly at 
lumbar spine but not at total hip. After 36 months of treatment, risedronate still abrogated the 
effect of anastrozole at lumbar spine, but not significantly. These initial results from the IBIS-
II bone study are reassuring, indicating that although women with a normal BMD at the time of 
entry had a significant BMD loss after 12 and 36 months of anastrozole use, but no one became 
osteoporotic. The beneficial effect of a bisphosphonate abrogated the detrimental effect of 
anastrozole on BMD, indicating that these women could safely receive anastrozole if they also 
took a bisphosphonate. Further analysis of data at 36 months on a larger sample size will 
support the present results. 
 
Overall, the data suggests that bone loss associated with anastrozole may be manageable with 
DXA monitoring and use of concomitant bisphosphonate. The recruitment into the bone study 
will continue until a total of 1500 women are recruited and the DXA scan will be performed 
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further at 3, 5 and 7 years. Analysis of 12 and 36 months BMD data on a bigger sample size 
and the analysis of BMD results at 5 and 7 years, at a later point would be able to confirm the 
BMD losses observed with anastrozole at LS and TH in women with normal baseline BMD 
and the beneficial effect of concomitant risedronate in osteopenic and osteoporotic women 
observed in the current analysis. 
 
The results from the prevention arm of the IBIS-II study were positive for both the lipid 
profile. Considering that cardiovascular disease is the leading cause of morbidity and mortality 
among postmenopausal women due to the effect of reduced oestrogen levels and other risk 
factors, anastrozole led to only marginal decrease in TC levels. LDL levels were not measured 
in the study as only non-fasting blood samples were collected due to logistic reasons. However, 
since increase in the LDL levels is considered the major predictor of the cardiovascular 
disease, it is planned to send the sample for apo-A and apo-B measurements. The apo-A and 
apo-B measurements detect lipid-related risk more accurately than LDL and can be conducted 
on non-fasting blood samples. This was not planned at the time of sending the samples 
previously. However, the IBIS-II prevention study is still recruiting women on to the study and 
it is planned that Apo-A and Apo-B samples will be conducted in near future once all the 
logistics are placed in order. 
                                                                                                                                                                                                                             
In the ATAC trial, amongst breast cancer patients, treatment with anastrozole, increasing age 
and high-risk countries were observed to be the significant risk factors associated with fracture 
risk. This analysis of risk factors for fracture has shown anastrozole treatment to be a 
significant predictor of fracture risk. Risk factors such as age and geographical regions were 
also strong predictive factors, which mean the risk of fracture in women receiving anastrozole 
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could increase further as age increases and for women living in very high-risk countries. 
Despite the increase risk of fracture with anastrozole, the overall risk: benefit profile remains in 
favour of anastrozole compared with tamoxifen therapy. This would ensure that fracture events 
associated with anastrozole could be predicted and managed. 
 
In the prevention arm of the IBIS-II study, the 25(OH) vitamin D levels were measured to see 
if baseline levels predict arthralgia/musculoskeletal symptoms within one year of joining the 
study. No significant effect of baseline vitamin D levels were seen on the risk of 
musculoskeletal symptoms in healthy postmenopausal women at a high risk of breast cancer. 
Interestingly, it was observed that serum vitamin D levels significantly rose in the anastrozole 
arm of the study. There is no published data in the literature to confirm these findings. Further 
studies measuring serum levels of vitamin D in a chemoprevention setting among AI users are 
needed to confirm these findings. 
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